


NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS

Field of the invention

The present invention relates to new benzylamino substituted pyridopyrimidinones and
5 derivatives of formula (I)



wherein the groups R^1 to R^4 , **A** and **p** have the meanings given in the claims and
specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain
compounds of this kind and their use as medicaments/medical uses, especially as agents
10 for treatment and/or prevention of oncological diseases.

Background of the invention

RAS-family proteins including KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog), NRAS (neuroblastoma RAS viral oncogene homolog) and HRAS (Harvey
murine sarcoma virus oncogene) and any mutants thereof are small GTPases that exist in
15 cells in either GTP-bound or GDP-bound states (McCormick *et al.*, J. Mol. Med. (Berl),
2016, 94(3):253-8; Nimnual *et al.*, Sci. STKE., 2002, 2002(145):pe36). The RAS-family
proteins have a weak intrinsic GTPase activity and slow nucleotide exchange rates
(Hunter *et al.*, Mol. Cancer Res., 2015, 13(9):1325-35). Binding of GTPase activating
proteins (GAPs) such as NF1 increases the GTPase activity of RAS-family proteins. The
20 binding of guanine nucleotide exchange factors (GEFs) such as SOS1 (Son of Sevenless
1) promote release GDP from RAS-family proteins, enabling GTP binding (Chardin *et al.*,
Science, 1993, 260(5112):1338-43). When in the GTP-bound state, RAS-family proteins
are active and engage effector proteins including C-RAF and phosphoinositide 3-kinase
(PI3K) to promote the RAF/mitogen or extracellular signal-regulated kinases (MEK/ERK)
25 pathway, PI3K/AKT/mammalian target of rapamycin (mTOR) pathway and RalGDS (Ral

guanine nucleotide dissociation stimulator) pathway (McCormick *et al.*, J. Mol. Med. (Berl.), 2016, 94(3):253-8; Rodriguez-Viciana *et al.*, Cancer Cell. 2005, 7(3):205-6). These pathways affect diverse cellular processes such as proliferation, survival, metabolism, motility, angiogenesis, immunity and growth (Young *et al.*, Adv. Cancer Res., 2009, 102:1-17; Rodriguez-Viciana *et al.*, Cancer Cell. 2005, 7(3):205-6).

Cancer-associated mutations in RAS-family proteins suppress their intrinsic and GAP-induced GTPase activity leading to an increased population of GTP-bound/active RAS-family proteins (McCormick *et al.*, Expert Opin. Ther. Targets., 2015, 19(4):451-4; Hunter *et al.*, Mol. Cancer Res., 2015, 13(9):1325-35). This in turn leads to persistent activation of effector pathways (*e.g.* MEK/ERK, PI3K/AKT/mTOR, RalGDS pathways) downstream of RAS-family proteins. KRAS mutations (*e.g.* amino acids G12, G13, Q61, A146) are found in a variety of human cancers including lung cancer, colorectal cancer and pancreatic cancer (Cox *et al.*, Nat. Rev. Drug Discov., 2014, 13(11):828-51). Mutations in HRAS (*e.g.* amino acids G12, G13, Q61) and NRAS (*e.g.* amino acids G12, G13, Q61, A146) are also found in a variety of human cancer types however typically at a lower frequency compared to KRAS mutations (Cox *et al.*, Nat. Rev. Drug Discov., 2014, 13(11):828-51). Alterations (*e.g.* mutation, over-expression, gene amplification) in RAS-family proteins have also been described as a resistance mechanism against cancer drugs such as the EGFR antibodies cetuximab and panitumumab (Leto *et al.*, J. Mol. Med. (Berl). 2014 Jul;92(7):709-22) and the EGFR tyrosine kinase inhibitor osimertinib/AZD9291 (Ortiz-Cuaran *et al.*, Clin. Cancer Res., 2016, 22(19):4837-47; Eberlein *et al.*, Cancer Res., 2015, 75(12):2489-500).

Son of Sevenless 1 (SOS1) is a human homologue of the originally identified Drosophila protein Son of Sevenless (Pierre *et al.*, Biochem. Pharmacol., 2011, 82(9):1049-56; Chardin *et al.*, Cytogenet. Cell. Genet., 1994, 66(1):68-9). The SOS1 protein consists of 1333 amino acids (150 kDa). SOS1 is a multi-domain protein with two tandem N-terminal histone domains (HD) followed by the Dbl homology domain (DH), a Pleckstrin homology domain (PH), a helical linker (HL), RAS exchanger motif (REM), CDC25 homology domain and a C-terminal proline rich domain (PR). SOS1 has two binding sites for RAS-family proteins; a catalytic site that binds GDP-bound RAS-family proteins to promote guanine nucleotide exchange and an allosteric site that binds GTP-bound RAS-family proteins which causes a further increase in the catalytic GEF function of SOS1 (Freedman *et al.*, Proc. Natl. Acad. Sci. U S A., 2006, 103(45):16692-7; Pierre *et al.*, Biochem. Pharmacol., 2011, 82(9):1049-56). Published data indicate a critical involvement of SOS1 in mutant

KRAS activation and oncogenic signaling in cancer (Jeng *et al.*, Nat. Commun., 2012, 3:1168). Depleting SOS1 levels decreased the proliferation rate and survival of tumor cells carrying a KRAS mutation whereas no effect was observed in KRAS wild type cell lines. The effect of loss of SOS1 could not be rescued by introduction of a catalytic site mutated SOS1, demonstrating the essential role of SOS1 GEF activity in KRAS mutant cancer cells.

SOS1 is critically involved in the activation of RAS-family protein signaling in cancer via mechanisms other than mutations in RAS-family proteins. SOS1 interacts with the adaptor protein Grb2 and the resulting SOS1/Grb2 complex binds to activated/phosphorylated Receptor Tyrosine Kinases (e.g. EGFR, ErbB2, ErbB3, ErbB4, PDGFR-A/B, FGFR1/2/3, IGF1R, INSR, ALK, ROS, TrkA, TrkB, TrkC, RET, c-MET, VEGFR1/2/3, AXL) (Pierre *et al.*, Biochem. Pharmacol., 2011, 82(9):1049-56). SOS1 is also recruited to other phosphorylated cell surface receptors such as the T cell Receptor (TCR), B cell Receptor (BCR) and monocyte colony-stimulating factor receptor (Salojin *et al.*, J. Biol. Chem. 2000, 275(8):5966-75). This localization of SOS1 to the plasma membrane, proximal to RAS-family proteins, enables SOS1 to promote RAS-family protein activation. SOS1-activation of RAS-family proteins can also be mediated by the interaction of SOS1/Grb2 with the BCR-ABL oncoprotein commonly found in chronic myelogenous leukemia (Kardinal *et al.*, 2001, Blood, 98:1773–81; Sini *et al.*, Nat. Cell Biol., 2004, 6(3):268-74).

Furthermore, alterations in SOS1 have been implicated in cancer. SOS1 mutations are found in embryonal rhabdomyosarcomas, sertoli cell testis tumors, granular cell tumors of the skin (Denayer *et al.*, Genes Chromosomes Cancer, 2010, 49(3):242-52) and lung adenocarcinoma (Cancer Genome Atlas Research Network., Nature. 2014, 511(7511):543-50). Meanwhile over-expression of SOS1 has been described in bladder cancer (Watanabe *et al.*, IUBMB Life., 2000, 49(4):317-20) and prostate cancer (Timofeeva *et al.*, Int. J. Oncol., 2009, 35(4):751-60). In addition to cancer, hereditary SOS1 mutations are implicated in the pathogenesis of RASopathies like e.g. Noonan syndrome (NS), cardio-facio-cutaneous syndrome (CFC) and hereditary gingival fibromatosis type 1 (Pierre *et al.*, Biochem. Pharmacol., 2011, 82(9):1049-56).

SOS1 is also a GEF for the activation of the GTPases RAC1 (Ras-related C3 botulinum toxin substrate 1) (Innocenti *et al.*, J. Cell Biol., 2002, 156(1):125-36). RAC1, like RAS-family proteins, is implicated in the pathogenesis of a variety of human cancers and other diseases (Bid *et al.*, Mol. Cancer Ther. 2013, 12(10):1925-34).

Son of Sevenless 2 (SOS2), a homolog of SOS1 in mammalian cells, also acts as a GEF

for the activation of RAS-family proteins (Pierre *et al.*, Biochem. Pharmacol., 2011, 82(9):1049-56; Buday *et al.*, Biochim. Biophys. Acta., 2008, 1786(2):178-87). Published data from mouse knockout models suggests a redundant role for SOS1 and SOS2 in homeostasis in the adult mouse. Whilst germline knockout of SOS1 in mice results in lethality during mid-embryonic gestation (Qian *et al.*, EMBO J., 2000, 19(4):642-54),
5 systemic conditional SOS1 knockout adult mice are viable (Baltanás *et al.*, Mol. Cell. Biol., 2013, 33(22):4562-78). SOS2 gene targeting did not result in any overt phenotype in mice (Esteban *et al.*, Mol. Cell. Biol., 2000, 20(17):6410-3). In contrast, double SOS1 and SOS2 knockout leads to rapid lethality in adult mice (Baltanás *et al.*, Mol. Cell. Biol., 2013,
10 33(22):4562-78). These published data suggest that selective targeting of individual SOS isoforms (e.g. selective SOS1 targeting) may be adequately tolerated to achieve a therapeutic index between SOS1/RAS-family protein driven cancers (or other SOS1/RAS-family protein pathologies) and normal cells and tissues.

Selective pharmacological inhibition of the binding of the catalytic site of SOS1 to RAS-family proteins is expected to prevent SOS1-mediated activation of RAS-family proteins to the GTP-bound form. Such SOS1 inhibitor compounds are expected to consequently inhibit signaling in cells downstream of RAS-family proteins (e.g. ERK phosphorylation). In cancer cells associated with dependence on RAS-family proteins (e.g. KRAS mutant cancer cell lines), SOS1 inhibitor compounds are expected to deliver anti-cancer efficacy
20 (e.g. inhibition of proliferation, survival, metastasis *etc.*). High potency towards inhibition of SOS1:RAS-family protein binding (nanomolar level IC₅₀ values) and ERK phosphorylation in cells (nanomolar level IC₅₀ values) are desirable characteristics for a SOS1 inhibitor compound. Furthermore, a desirable characteristic of SOS1 inhibitor compound would be the selective inhibition of SOS1 over SOS2. This conclusion is based on the viable
25 phenotype of SOS1 knockout mice and lethality of SOS1/SOS2 double knockout mice, as described above.

These characteristics have not been fully achieved in previously described SOS1 inhibitor compounds. In the last decades the RAS family proteins-SOS1 protein interaction has gained increasing recognition. Until today several efforts to identify and optimize binders,
30 which target either the effector binding site of RAS or the catalytic binding site of SOS1 (for a selected review see: Lu *et al.*, ChemMedChem. 2016, 11(8):814-21), have been made with limited success.

Recently, small activating molecules have been identified, which bind to a lipophilic pocket

of SOS1 in close proximity to the RAS binding site (Burns *et al.*, Proc. Natl. Acad. Sci. 2014, 111(9):3401-6). However, binding of these molecules seems to lead to increased nucleotide exchange and thereby activation of RAS instead of deactivation.

In an effort to stabilize the protein-protein-interaction of RAS-family proteins with SOS1 and to prevent reloading of RAS-family proteins with GTP, several different fragments
5 were subsequently identified (Winter *et al.*, J. Med. Chem. 2015, 58(5):2265-74). However, reversible binding of fragments to SOS1 did not translate into a measurable effect on the nucleotide exchange and only a weak effect was observed for fragments covalently bound to RAS.

Also recently, studies have been conducted to combine rational design and screening
10 platforms to identify small molecule inhibitors of SOS1 (Evelyn *et al.*, Chem. Biol. 2014, 21(12):1618-28; Evelyn *et al.*, J. Biol. Chem. 2015, 290(20):12879-98; Zheng *et al.*, WO 2016/077793), *i.e.* compounds which bind to SOS1 and inhibit protein-protein interaction with RAS-family proteins. Although compounds with a slight inhibitory effect on SOS1
15 have been identified, the effects on guanine nucleotide exchange and cellular signal transduction modulation (*e.g.* ERK phosphorylation) are weak.

WO 2018/115380 and WO 2018/172250 disclose quinazoline-based SOS inhibitors.

Herein we describe novel SOS1 inhibitor compounds, which bind to the SOS1 catalytic site (confirmed by means of crystallography) and simultaneously prevent interactions with
20 and activation of RAS-family proteins. This results in a pronounced inhibitory effect on the interaction of SOS1 with RAS-family proteins, in particular KRAS (with low single digit nanomolar IC₅₀ activity) and consequently a significant reduction of ERK phosphorylation in KRAS mutant cancer cell lines.

The selective SOS1 inhibitor compounds described herein are expected to deliver a
25 pharmacological benefit to patients with cancers that are associated with dependence on RAS-family protein signaling. Such cancers expected to be targeted by a SOS1 inhibitor compound include those exhibiting alterations (mutations, gene amplification, over-expression) of components (proteins, genes) in the RAS-family protein pathway such as KRAS, NRAS, HRAS, receptor tyrosine kinases (*e.g.* EGFR, ErbB2, ErbB3, ErbB4,
30 PDGFR-A/B, FGFR1/2/3, IGF1R, INSR, ALK, ROS, TrkA, TrkB, TrkC, RET, c-MET, VEGFR1/2/3, AXL), GAPs (*e.g.* NF1) and SOS1. Additionally, given the role of SOS1 in RAC1 activation, cancers demonstrating dependence on RAC1 are expected to be targeted by SOS1 inhibitor compounds. Furthermore, in other diseases associated with RAS-family protein pathway dysregulation such as the neurofibromatosis, Noonan

syndrome (NS), cardio-facio-cutaneous syndrome (CFC) and hereditary gingival fibromatosis type 1, SOS1 inhibitor compounds would also be expected to deliver a pharmacological benefit.


In addition to the inhibitory effect and potency, compounds disclosed herein show good solubility, fine-tuned DMPK properties and good selectivity over kinases of the human kinome. Furthermore, these structurally and synthetically novel pyridopyrimidinone based compounds show a good metabolic stability, a decreased risk of time dependent inhibition of cytochromes and, presumably, a decreased general off target liability.

Detailed description of the invention

Compounds

It has now been found that, surprisingly, compounds of formula (I) wherein the groups R^1 to R^4 , **A** and **p** have the meanings given hereinafter act as inhibitors of the interaction of the catalytic site of SOS1 with RAS-family proteins which is involved in controlling cell proliferation. Thus, the compounds according to the invention may be used for example for the treatment of diseases characterised by excessive or abnormal cell proliferation.

The present invention therefore relates to a compound of formula (I)



wherein

[A0]

R^1 is R^{a1} ;

R^{a1} is selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, 3-10 membered heterocyclyl, C_{6-10} aryl and 5-10 membered heteroaryl, wherein the C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, 3-10 membered heterocyclyl, C_{6-10} aryl and 5-10 membered heteroaryl are all optionally substituted by one or more, identical or different R^{b1} and/or R^{c1} ;

each R^{b1} is independently selected from the group consisting of $-OR^{c1}$, $-NR^{c1}R^{c1}$, halogen, $-CN$, $-C(O)R^{c1}$, $-C(O)OR^{c1}$, $-C(O)NR^{c1}R^{c1}$, $-S(O)_2R^{c1}$, $-S(O)_2NR^{c1}R^{c1}$, $-NHC(O)R^{c1}$, $-N(C_{1-4}alkyl)C(O)R^{c1}$, $-NHC(O)OR^{c1}$ and $-N(C_{1-4}alkyl)C(O)OR^{c1}$;

each R^{c1} is independently selected from the group consisting of hydrogen, $C_{1-6}alkyl$, $C_{1-6}haloalkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{3-10}cycloalkyl$, $C_{4-10}cycloalkenyl$, 3-10 membered heterocyclyl, $C_{6-10}aryl$ and 5-10 membered heteroaryl, wherein the $C_{1-6}alkyl$, $C_{1-6}haloalkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{3-10}cycloalkyl$, $C_{4-10}cycloalkenyl$, 3-10 membered heterocyclyl, $C_{6-10}aryl$ and 5-10 membered heteroaryl are all optionally substituted by one or more, identical or different R^{d1} and/or R^{e1} ;

each R^{d1} is independently selected from the group consisting of $-OR^{e1}$, $-NR^{e1}R^{e1}$, halogen, $-CN$, $-C(O)R^{e1}$, $-C(O)OR^{e1}$, $-C(O)NR^{e1}R^{e1}$, $-S(O)_2R^{e1}$, $-S(O)_2NR^{e1}R^{e1}$, $-NHC(O)R^{e1}$, $-N(C_{1-4}alkyl)C(O)R^{e1}$, $-NHC(O)OR^{e1}$ and $-N(C_{1-4}alkyl)C(O)OR^{e1}$;

each R^{e1} is independently selected from the group consisting of hydrogen, $C_{1-6}alkyl$, $C_{1-6}haloalkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{3-10}cycloalkyl$, $C_{4-10}cycloalkenyl$, 3-10 membered heterocyclyl, $C_{6-10}aryl$ and 5-10 membered heteroaryl;

[B0]

R^2 is selected from the group consisting of hydrogen, $C_{1-4}alkyl$, $C_{3-6}cycloalkyl$, 3-6 membered heterocyclyl and halogen;

[C0]

R^3 is selected from the group consisting of hydrogen, $C_{1-4}alkyl$ and $C_{1-4}haloalkyl$;

[D0]

ring system **A** is selected from the group consisting of $C_{6-10}aryl$, 5-10 membered heteroaryl and 9-10 membered bicyclic heterocyclyl;

p denotes 1, 2 or 3;

each R^4 is independently selected from the group consisting of $C_{1-4}alkyl$, $C_{2-4}alkenyl$, $C_{2-4}alkynyl$, $C_{1-4}haloalkyl$, hydroxy- $C_{1-4}alkyl$, hydroxy- $C_{1-4}haloalkyl$, $C_{3-6}cycloalkyl$, 3-6 membered heterocyclyl, hydroxy- $C_{3-6}cycloalkyl$, $C_{1-4}haloalkyl$ substituted with a 3-6 membered heterocyclyl, 3-6 membered heterocyclyl substituted with hydroxy, halogen, $-NH_2$, $-SO_2-C_{1-4}alkyl$ and the bivalent substituent $=O$, while $=O$ may only be a substituent in a non-aromatic ring;

or a salt thereof.

In one aspect **[A1]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

R¹ is **R^{a1}**;

R^{a1} is selected from the group consisting of C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₀cycloalkenyl, 3-10 membered heterocyclyl, C₆₋₁₀aryl and 5-10 membered heteroaryl, wherein the C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₀cycloalkenyl, 3-10 membered heterocyclyl, C₆₋₁₀aryl and 5-10 membered heteroaryl are all optionally substituted by one or more, identical or different **R^{b1}** and/or **R^{c1}**;

each **R^{b1}** is independently selected from the group consisting of -OR^{c1}, -NR^{c1}R^{c1}, halogen, -CN, -C(O)R^{c1}, -C(O)OR^{c1} and -C(O)NR^{c1}R^{c1};

each **R^{c1}** is independently selected from the group consisting of hydrogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₀cycloalkenyl, 3-10 membered heterocyclyl, C₆₋₁₀aryl and 5-10 membered heteroaryl, wherein the C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₀cycloalkenyl, 3-10 membered heterocyclyl, C₆₋₁₀aryl and 5-10 membered heteroaryl are all optionally substituted by one or more, identical or different **R^{d1}** and/or **R^{e1}**;

each **R^{d1}** is independently selected from the group consisting of -OR^{e1}, -NR^{e1}R^{e1}, halogen, -CN, -C(O)R^{e1}, -C(O)OR^{e1} and -C(O)NR^{e1}R^{e1};

each **R^{e1}** is independently selected from the group consisting of hydrogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₀cycloalkenyl, 3-10 membered heterocyclyl, C₆₋₁₀aryl and 5-10 membered heteroaryl.

In another aspect **[A2]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

R¹ is **R^{a1}**;

R^{a1} is selected from the group consisting of C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₀cycloalkenyl, 3-10 membered heterocyclyl and 5-10 membered heteroaryl, wherein the C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₀cycloalkenyl, 3-10 membered heterocyclyl and 5-10 membered heteroaryl are all optionally substituted by one or more, identical or different **R^{b1}** and/or **R^{c1}**;

each **R^{b1}** is independently selected from the group consisting of -OR^{c1}, halogen and -C(O)NR^{c1}R^{c1};

each R^{c1} is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, 3-10 membered heterocyclyl, C_{6-10} aryl and 5-10 membered heteroaryl, wherein the C_{1-6} alkyl, C_{1-6} haloalkyl, 3-10 membered heterocyclyl, C_{6-10} aryl and 5-10 membered heteroaryl are all optionally substituted by one or more, identical or different R^{d1} and/or R^{e1} ;

each R^{d1} is independently selected from the group consisting of $-OR^{e1}$ and halogen;

each R^{e1} is independently selected from the group consisting of hydrogen and C_{1-6} alkyl.

In another aspect [A3] the invention relates to a compound of formula (I) or a salt thereof, wherein

10 R^1 is R^{a1} ;

R^{a1} is selected from the group consisting of C_{3-10} cycloalkyl and C_{4-10} cycloalkenyl, wherein the C_{3-10} cycloalkyl and C_{4-10} cycloalkenyl are both optionally substituted by one or more, identical or different R^{b1} and/or R^{c1} ;

15 each R^{b1} is independently selected from the group consisting of $-OR^{c1}$, $-NR^{c1}R^{c1}$, halogen, $-CN$, $-C(O)R^{c1}$, $-C(O)OR^{c1}$ and $-C(O)NR^{c1}R^{c1}$;

20 each R^{c1} is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, 3-10 membered heterocyclyl, C_{6-10} aryl and 5-10 membered heteroaryl, wherein the C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, 3-10 membered heterocyclyl, C_{6-10} aryl and 5-10 membered heteroaryl are all optionally substituted by one or more, identical or different R^{d1} and/or R^{e1} ;

each R^{d1} is independently selected from the group consisting of $-OR^{e1}$, $-NR^{e1}R^{e1}$, halogen, $-CN$, $-C(O)R^{e1}$, $-C(O)OR^{e1}$, $-C(O)NR^{e1}R^{e1}$;

25 each R^{e1} is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, 3-10 membered heterocyclyl, C_{6-10} aryl and 5-10 membered heteroaryl.

In another aspect [A4] the invention relates to a compound of formula (I) or a salt thereof, wherein

R^1 is C_{3-8} cycloalkyl optionally substituted by one or more, identical or different R^{b1} and/or R^{c1} ;

each R^{b1} is independently selected from the group consisting of $-OR^{c1}$, halogen and $-C(O)NR^{c1}R^{c1}$;

each R^{c1} is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, 3-8 membered heterocyclyl, phenyl and 5-6 membered heteroaryl, wherein
 5 the C_{1-6} alkyl, C_{1-6} haloalkyl, 3-8 membered heterocyclyl, phenyl and 5-6 membered heteroaryl are all optionally substituted by one or more, identical or different R^{d1} and/or R^{e1} ;

each R^{d1} is independently selected from the group consisting of $-OR^{e1}$ and halogen;


each R^{e1} is independently selected from the group consisting of hydrogen and C_{1-6} alkyl.


10 In another aspect [A5] the invention relates to a compound of formula (I) or a salt thereof, wherein

R^1 is C_{3-8} cycloalkyl optionally substituted by one or more, identical or different substituent(s) selected from the group consisting of C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy- C_{1-4} alkyl, 5-6 membered heteroaryl, phenyl, halophenyl, halogen, 3-6
 15 membered heterocyclyl, $-C(O)N(C_{1-4}alkyl)_2$ and hydroxy.

In another aspect [A6] the invention relates to a compound of formula (I) or a salt thereof, wherein

R^1 is selected from among





In another aspect **[A7]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

R¹ is selected from the group consisting of C₁₋₆alkyl and C₁₋₆haloalkyl.

5 In another aspect **[A8]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

R¹ is selected from the group consisting of C₁₋₄alkyl and C₁₋₄haloalkyl.

In another aspect **[A9]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

10 **R¹** is 3-10 membered heterocyclyl optionally substituted by one or more, identical or different **R^{b1}** and/or **R^{c1}**;

each **R^{b1}** is independently selected from the group consisting of -OR^{c1}, -NR^{c1}R^{c1}, halogen, -CN, -C(O)R^{c1}, -C(O)OR^{c1} and -C(O)NR^{c1}R^{c1};

each **R^{c1}** is independently selected from the group consisting of hydrogen, C₁₋₆alkyl, 15 C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₀cycloalkenyl, 3-10 membered heterocyclyl, C₆₋₁₀aryl and 5-10 membered heteroaryl, wherein the C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl,

C₄₋₁₀cycloalkenyl, 3-10 membered heterocyclyl, C₆₋₁₀aryl and 5-10 membered heteroaryl are all optionally substituted by one or more, identical or different **R^{d1}** and/or **R^{e1}**;

each **R^{d1}** is independently selected from the group consisting of -OR^{e1}, -NR^{e1}R^{e1}, halogen, -CN, -C(O)R^{e1}, -C(O)OR^{e1} and -C(O)NR^{e1}R^{e1};

- 5 each **R^{e1}** is independently selected from the group consisting of hydrogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₀cycloalkenyl, 3-10 membered heterocyclyl, C₆₋₁₀aryl and 5-10 membered heteroaryl.

In another aspect **[A10]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein


- 10 **R¹** is 3-10 membered heterocyclyl optionally substituted by one or more, identical or different substituent(s) selected from the group consisting of C₁₋₆alkyl, C₁₋₆haloalkyl and C₆₋₁₀aryl.


In another aspect **[A11]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

- 15 **R¹** is 3-8 membered heterocyclyl optionally substituted by one substituent selected from the group consisting of C₁₋₆alkyl, C₁₋₆haloalkyl and C₆₋₁₀aryl.

In another aspect **[A12]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

R¹ is selected from among





In another aspect [A13] the invention relates to a compound of formula (I) or a salt thereof, wherein

R^1 is 5-6 membered heteroaryl optionally substituted with C_{1-4} alkyl.

- 5 In another aspect [B1] the invention relates to a compound of formula (I) or a salt thereof, wherein

R^2 is hydrogen.

In another aspect [B2] the invention relates to a compound of formula (I) or a salt thereof, wherein

- 10 R^2 is C_{1-4} alkyl.

In another aspect [B3] the invention relates to a compound of formula (I) or a salt thereof, wherein

R^2 is methyl.

- 15 In another aspect [B4] the invention relates to a compound of formula (I) or a salt thereof, wherein

R^2 is halogen.

In another aspect [B5] the invention relates to a compound of formula (I) or a salt thereof, wherein

R^2 is selected from the group consisting of fluorine and bromine.

- 20 In another aspect [B6] the invention relates to a compound of formula (I) or a salt thereof, wherein

R^2 is fluorine.

In another aspect [B7] the invention relates to a compound of formula (I) or a salt thereof,

wherein

R² is C₃₋₅cycloalkyl.

In another aspect **[B8]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

5 **R**² is cyclopropyl.

In another aspect **[C1]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

R³ is hydrogen.

10 In another aspect **[C2]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

R³ is C₁₋₄alkyl.

In another aspect **[C3]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

R³ is methyl.

15 In another aspect **[D1]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

ring system **A** is selected from the group consisting of C₆₋₁₀aryl, 5-10 membered heteroaryl and 9-10 membered bicyclic heterocyclyl;

p denotes 1 or 2;

20 each **R**⁴ is independently selected from the group consisting of C₁₋₄alkyl, C₂₋₄alkinyl, C₁₋₄haloalkyl, hydroxy-C₁₋₄haloalkyl, C₁₋₄haloalkyl substituted with a 3-6 membered heterocyclyl, halogen and the bivalent substituent =O, while =O may only be a substituent in a non-aromatic ring.

25 In another aspect **[D2]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein


ring system **A** is selected from the group consisting of C₆₋₁₀aryl and 9-10 membered bicyclic heterocyclyl;

p denotes 1 or 2;

each **R**⁴ is independently selected from the group consisting of C₁₋₄alkyl, C₂₋₄alkynyl, C₁₋₄haloalkyl, hydroxy-C₁₋₄haloalkyl, C₁₋₄haloalkyl substituted with a 3-6 membered heterocyclyl, halogen and the bivalent substituent =O, while =O may only be a substituent
5 in a non-aromatic ring.

In another aspect **[D3]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

A together with the **p** substituents **R**⁴ has substructure



10 **R**^A is selected from the group consisting of C₁₋₄alkyl, C₁₋₄haloalkyl, hydroxy-C₁₋₄alkyl, hydroxy-C₁₋₄haloalkyl, C₁₋₄haloalkyl substituted with a 3-6 membered heterocyclyl, C₃₋₆cycloalkyl, hydroxy-C₃₋₆cycloalkyl, 3-6 membered heterocyclyl, 3-6 membered hydroxy-heterocyclyl, halogen and -SO₂-C₁₋₄alkyl;

R^B is selected from the group consisting of hydrogen and -NH₂;


15 **R**^C is selected from the group consisting of hydrogen, C₁₋₄alkyl and halogen;

or

R^A and **R**^C together with the carbon atoms they are attached form a 5-6 membered non-aromatic carbocycle, a 5-6 membered non-aromatic heterocycle or a 5-6 membered heteroaryl, wherein the 5-6 membered non-aromatic carbocycle, 5-6 membered non-
20 aromatic heterocycle and 5-6 membered heteroaryl are all optionally substituted by one or more halogen or by an oxo group.

In another aspect **[D4]** the invention relates to a compound of formula **(I)** or a salt thereof, wherein

A together with the **p** substituents **R**⁴ has substructure



;

R^A is selected from the group consisting of C₁₋₄alkyl, C₁₋₄haloalkyl, hydroxy-C₁₋₄alkyl, hydroxy-C₁₋₄haloalkyl, C₁₋₄haloalkyl substituted with a 3-6 membered heterocyclyl, C₃₋₆cycloalkyl, hydroxy-C₃₋₆cycloalkyl, 3-6 membered heterocyclyl, 3-6 membered hydroxy-heterocyclyl, halogen and -SO₂-C₁₋₄alkyl;

R^B is selected from the group consisting of hydrogen and -NH₂;


R^C is selected from the group consisting of hydrogen, C₁₋₄alkyl and halogen;

or

R^A and **R^C** together with the carbon atoms they are attached form a 5-6 membered non-aromatic carbocycle or a 5-6 membered non-aromatic heterocycle, wherein the 5-6 membered non-aromatic carbocycle and the 5-6 membered non-aromatic heterocycle are both optionally substituted by one or more halogen or by an oxo group.

In another aspect [D5] the invention relates to a compound of formula (I) or a salt thereof, wherein

A together with the **p** substituents **R⁴** has substructure



;

R^A is selected from the group consisting of C₁₋₄haloalkyl, hydroxy-C₁₋₄haloalkyl and C₁₋₄haloalkyl substituted with a 3-6 membered heterocyclyl;

R^B is hydrogen;

R^C is selected from the group consisting of hydrogen, C₁₋₄alkyl and fluorine;


or

R^A and **R^C** together with the carbon atoms they are attached form a 5-6 membered non-aromatic carbocycle, a 5-6 membered non-aromatic heterocycle or a 5-6 membered

heteroaryl, wherein the 5-6 membered non-aromatic carbocycle, 5-6 membered non-aromatic heterocycle and 5-6 membered heteroaryl are all optionally substituted by one or more fluorine or by an oxo group.

In another aspect [D6] the invention relates to a compound of formula (I) or a salt thereof,
5 wherein

A together with the p substituents R^4 has substructure



R^A is selected from the group consisting of C_{1-4} haloalkyl, hydroxy- C_{1-4} haloalkyl and C_{1-4} haloalkyl substituted with a 3-6 membered heterocyclyl;

10 R^B is hydrogen;


R^C is selected from the group consisting of hydrogen, C_{1-4} alkyl and fluorine;


or

R^A and R^C together with the carbon atoms they are attached form a 5-6 membered non-aromatic carbocycle or a 5-6 membered non-aromatic heterocycle, wherein the 5-6
15 membered non-aromatic carbocycle and the 5-6 membered non-aromatic heterocycle are both optionally substituted by one or more fluorine or by an oxo group.

In another aspect [D7] the invention relates to a compound of formula (I) or a salt thereof, wherein


A together with the p substituents R^4 are selected from among






In another aspect [D8] the invention relates to a compound of formula (I) or a salt thereof, wherein

A together with the p substituents R^4 are selected from among





All the above-mentioned structural aspects **[A1]** to **[A13]**, **[B1]** to **[B8]**, **[C1]** to **[C3]** and **[D1]** to **[D8]** are preferred embodiments of the corresponding aspects **[A0]**, **[B0]**, **[C0]** and **[D0]**, respectively. The structural aspects **[A0]** to **[A13]**, **[B0]** to **[B8]**, **[C0]** to **[C3]** and **[D0]** to **[D8]** relating to different molecular parts of the compounds **(I)** according to the invention may be combined with one another as desired in combinations **[A][B][C][D]** to obtain preferred compounds **(I)**. Each combination **[A][B][C][D]** represents and defines individual embodiments or generic subsets of compounds **(I)** according to the invention.

Preferred embodiments of the invention with structure (I) are example compounds **I-1** to **I-179** and any subset thereof.

All synthetic intermediates generically defined as well as specifically disclosed herein and their salts are also part of the invention.

All individual synthetic reaction steps as well as reaction sequences comprising these individual synthetic reaction steps, both generically defined or specifically disclosed herein, are also part of the invention.

The present invention further relates to hydrates, solvates, polymorphs, metabolites, derivatives, isomers and prodrugs of a compound of formula **(I)** (including all its embodiments).

The present invention further relates to a hydrate of a compound of formula **(I)** (including all its embodiments).

The present invention further relates to a solvate of a compound of formula **(I)** (including all its embodiments).

Compounds of formula (I) (including all its embodiments) which e.g. bear ester groups are potential prodrugs the ester being cleaved under physiological conditions and are also part of the invention.

5 The present invention further relates to a pharmaceutically acceptable salt of a compound of formula (I) (including all its embodiments).

The present invention further relates to a pharmaceutically acceptable salt of a compound of formula (I) (including all its embodiments) with anorganic or organic acids or bases.

Medical Uses – Methods of Treatment

10 The present invention is directed to SOS1 inhibitor compounds, in particular compounds of formula (I) (including all its embodiments), which are useful in the treatment and/or prevention of a disease and/or condition associated with or modulated by SOS1, especially wherein the inhibition of the interaction of SOS1 and a RAS-family protein and/or RAC1 is of therapeutic benefit, including but not limited to the treatment and/or prevention of cancer.

15 In another aspect the invention relates to a compound of formula (I) – or a pharmaceutically acceptable salt thereof – for use as a medicament.

In another aspect the invention relates to a compound of formula (I) – or a pharmaceutically acceptable salt thereof – for use in a method of treatment of the human or animal body.

20 In another aspect the invention relates to a SOS1 inhibitor compound, in particular a compound of formula (I), – or a pharmaceutically acceptable salt thereof – for use in the treatment and/or prevention of a disease and/or condition wherein the inhibition of the interaction of SOS1 and a RAS-family protein and/or RAC1 is of therapeutic benefit, including but not limited to the treatment and/or prevention of cancer.

25 In another aspect the invention relates to a SOS1 inhibitor compound, in particular a compound of formula (I), – or a pharmaceutically acceptable salt thereof – for use in the treatment and/or prevention of cancer.

30 In another aspect the invention relates to a SOS1 inhibitor compound, in particular a compound of formula (I), – or a pharmaceutically acceptable salt thereof – for use in a method of treatment and/or prevention of cancer in the human or animal body.

In another aspect the invention relates to a SOS1 inhibitor compound, in particular a

compound of formula (I), – or a pharmaceutically acceptable salt thereof – for use in a method of treatment and/or prevention of cancer in the human or animal body.

In another aspect the invention relates to a SOS1 inhibitor compound – or a pharmaceutically acceptable salt thereof – for use as hereinbefore defined wherein said
5 SOS1 inhibitor compound is administered before, after or together with at least one other pharmacologically active substance.

In another aspect the invention relates to a compound of formula (I) – or a pharmaceutically acceptable salt thereof – for use as hereinbefore defined wherein said compound is administered before, after or together with at least one other
10 pharmacologically active substance.

In another aspect the invention relates to a SOS1 inhibitor compound – or a pharmaceutically acceptable salt thereof – for use as hereinbefore defined, wherein said SOS1 inhibitor compound is administered in combination with at least one other pharmacologically active substance.

15 In another aspect the invention relates to a compound of formula (I) – or a pharmaceutically acceptable salt thereof – for use as hereinbefore defined, wherein said compound is administered in combination with at least one other pharmacologically active substance.

In another aspect the invention relates to a pharmacologically active substance prepared
20 for being administered before, after or together with a SOS1 inhibitor compound – or a pharmaceutically acceptable salt thereof – for use as hereinbefore defined for the use of the compound of formula (I).

In another aspect the invention relates to a pharmacologically active substance prepared for being administered before, after or together with a compound of formula (I) – or a
25 pharmaceutically acceptable salt thereof – for use as hereinbefore defined for the use of the compound of formula (I).

In another aspect the invention relates to a SOS1 inhibitor compound, in particular a compound of formula (I), – or a pharmaceutically acceptable salt thereof – for use in the treatment or in a method of treatment as hereinbefore defined.

30 In another aspect the invention relates to the use of a SOS1 inhibitor compound, in particular a compound of formula (I), – or a pharmaceutically acceptable salt thereof – for

preparing a pharmaceutical composition for the treatment and/or prevention of cancer.

In another aspect the invention relates to the use of a SOS1 inhibitor compound – or a pharmaceutically acceptable salt thereof – as hereinbefore defined wherein said SOS1 inhibitor compound is administered before, after or together with at least one other
5 pharmacologically active substance.

In another aspect the invention relates to the use of a compound of formula (I) – or a pharmaceutically acceptable salt thereof – as hereinbefore defined wherein said compound is administered before, after or together with at least one other pharmacologically active substance.

10 In another aspect the invention relates to the use of a SOS1 inhibitor compound, in particular a compound of formula (I), – or a pharmaceutically acceptable salt thereof – as hereinbefore defined for the treatment.

In another aspect the invention relates to a method for the treatment and/or prevention of a disease and/or condition wherein the inhibition of the interaction of SOS1 and a RAS-family protein or RAC1 is of therapeutic benefit comprising administering a therapeutically
15 effective amount of a SOS1 inhibitor compound, in particular a compound of formula (I), – or a pharmaceutically acceptable salt thereof – to a human being.

In another aspect the invention relates to a method for the treatment and/or prevention of cancer comprising administering a therapeutically effective amount of a SOS1 inhibitor
20 compound, in particular a compound of formula (I), – or a pharmaceutically acceptable salt thereof – to a human being.

In another aspect the invention relates to a method as hereinbefore defined wherein the SOS1 inhibitor compound – or a pharmaceutically acceptable salt thereof – is administered before, after or together with at least one other pharmacologically active
25 substance.

In another aspect the invention relates to a method as hereinbefore defined wherein the compound of formula (I) – or a pharmaceutically acceptable salt thereof – is administered before, after or together with at least one other pharmacologically active substance.

In another aspect the invention relates to a method as hereinbefore defined wherein the
30 SOS1 inhibitor compound – or a pharmaceutically acceptable salt thereof – is administered in combination with a therapeutically effective amount of at least one other

pharmacologically active substance.

In another aspect the invention relates to a method as hereinbefore defined wherein the compound of formula **(I)** – or a pharmaceutically acceptable salt thereof – is administered in combination with a therapeutically effective amount of at least one other
5 pharmacologically active substance.

In another aspect the invention relates to a method for the treatment as hereinbefore defined.

In another aspect the invention relates to a kit comprising

- a first pharmaceutical composition or dosage form comprising a SOS1 inhibitor
10 compound and, optionally, one or more pharmaceutically acceptable carriers, excipients and/or vehicles, and
- at least a second pharmaceutical composition or dosage form comprising another pharmacologically active substance and, optionally, one or more pharmaceutically acceptable carriers, excipients and/or vehicles.

15 In another aspect the invention relates to a kit comprising

- a first pharmaceutical composition or dosage form comprising a compound of formula **(I)** and, optionally, one or more pharmaceutically acceptable carriers, excipients and/or vehicles, and
- at least a second pharmaceutical composition or dosage form comprising another
20 pharmacologically active substance and, optionally, one or more pharmaceutically acceptable carriers, excipients and/or vehicles.

In another aspect the invention relates to a pharmaceutical composition comprising at least one (preferably one) compound of formula **(I)** – or a pharmaceutically acceptable salt thereof – and one or more pharmaceutically acceptable excipient(s).

25 In another aspect the invention relates to a pharmaceutical preparation comprising a compound of formula **(I)** – or a pharmaceutically acceptable salt thereof – and at least one (preferably one) other pharmacologically active substance.

In another aspect the pharmacologically active substance to be used together/in combination with the SOS1 inhibitor compound, in particular compound of formula **(I)**
30 (including all individual embodiments or generic subsets of compounds **(I)**), or in the medical uses, uses, methods of treatment and/or prevention as herein (above and below)

defined can be selected from any one or more of the following (preferably there is only one additional pharmacologically active substance used in all these embodiments):

1. an inhibitor of EGFR and/or of mutants thereof

- a. e.g. afatinib, erlotinib, gefitinib, lapatinib, cetuximab, panitumumab, osimertinib,
5 olmutinib, EGF-816;
- b. preferred are afatinib, osimertinib and cetuximab;
- c. most preferred is afatinib

2. an inhibitor of ErbB2 (Her2) and/or of mutants thereof

- a. e.g. afatinib, lapatinib, trastuzumab, pertuzumab;
- 10 b. preferred are afatinib and trastuzumab;
- c. most preferred is trastuzumab;

3. an inhibitor of ALK and/or of mutants thereof

- a. e.g. crizotinib, alectinib, entrectinib, brigatinib;
- b. preferred are crizotinib and alectinib;
- 15 c. most preferred is crizotinib;

4. an inhibitor of MEK and/or of mutants thereof

- a. e.g. trametinib, cobimetinib, binimetinib, selumetinib, refametinib;
- b. preferred are trametinib and cobimetinib;
- c. most preferred is trametinib;

5. an inhibitor of GDP-bound KRAS and/or of mutants thereof

- a. an irreversible inhibitor of KRAS G12C
 - i. e.g. ARS-853 (compound V-64 in WO 2014/152588), example I-272 in WO
2016/044772;
- b. a reversible inhibitor of GDP-bound KRAS and/or of mutants thereof;

6. an inhibitor of BCR-ABL and/or of mutants thereof

- a. e.g. imatinib, dasatinib, nilotinib;
- b. preferred are imatinib and nilotinib;
- 25 c. most preferred is imatinib;

7. an inhibitor of FGFR1 and/or FGFR2 and/or FGFR3 and/or of mutants thereof

- 30 a. e.g. nintedanib;

8. an inhibitor of ROS1 and/or of mutants thereof

- a. e.g. crizotinib, entrectinib, lorlatinib, ceritinib, merestinib;
- b. preferred are crizotinib and entrectinib;
- c. most preferred is crizotinib;

9. an inhibitor of c-MET and/or of mutants thereof

5 **10. an inhibitor of AXL and/or of mutants thereof**

11. an inhibitor of NTRK1 and/or of mutants thereof

12. an inhibitor of RET and/or of mutants thereof

13. a taxane

- a. e.g. paclitaxel, nab-paclitaxel, docetaxel;
- 10 b. preferred is paclitaxel;

14. a platinum-containing compound

- a. e.g. cisplatin, carboplatin, oxaliplatin;

15. an *anti*-metabolite

- a. e.g. 5-fluorouracil, capecitabine, floxuridine, cytarabine, gemcitabine, combination
- 15 of trifluridine and tipiracil (= TAS102);
- b. preferred is gemcitabine;

16. mitotic kinase inhibitor

- a. e.g. CDK4/6 inhibitor
 - i. e.g. palbociclib, ribociclib, abemaciclib;
 - 20 ii. preferred are palbociclib and abemaciclib;
 - iii. most preferred is abemaciclib;

17. an immunotherapeutic agent

- a. e.g. an immune checkpoint inhibitor
 - i. e.g. an *anti*-CTLA4 mAb, *anti*-PD1 mAb, *anti*-PD-L1 mAb, *anti*-PD-L2 mAb,
 - 25 *anti*-LAG3 mAb, *anti*-TIM3 mAb;
 - ii. preferred is an *anti*-PD1 mAb;
 - iii. e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, pidilizumab, PDR-001 (= spartalizumab);
 - iv. preferred are nivolumab, pembrolizumab and PDR-001 (= spartalizumab);
 - 30 v. most preferred is pembrolizumab;

18. an *anti*-angiogenic drug

- a. e.g. bevacizumab, nintedanib;
- b. most preferred is bevacizumab;

19. a topoisomerase inhibitor

- a. e.g. irinotecan, liposomal irinotecan, topotecan;
- 5 b. most preferred is irinotecan;

20. an inhibitor of A-Raf and/or B-Raf and/or C-Raf and/or of mutants thereof

- a. e.g. RAF-709 (= example 131 in WO 2014/151616), LY-3009120 (= example 1 in WO 2013/134243);

21. an inhibitor of ERK and/or of mutants thereof

- 10 a. e.g. ulixertinib;

22. an apoptosis regulator

- a. e.g. an inhibitor of the interaction between p53 (preferably functional p53, most preferably *wt* p53) and MDM2 (a "MDM2 inhibitor");
 - i. e.g. HDM-201, NVP-CGM097, RG-7112, MK-8242, RG-7388, SAR405838, AMG-232, DS-3032, RG-7775, APG-115;
 - 15 ii. preferred are HDM-201, RG-7388 and AMG-232
- b. e.g. a PARP inhibitor;
- c. e.g. a MCL-1 inhibitor;

23. an inhibitor of *mTOR*

- 20 a. e.g. rapamycin, temsirolimus, everolimus, ridaforolimus;

24. an epigenetic regulator

- a. e.g. a BET inhibitor
 - i. e.g. JQ-1, GSK 525762, OTX 015 (= MK8628), CPI 0610, TEN-010 (= RO6870810);
- 25 b. e.g. a CDK9 inhibitor;

25. an inhibitor of IGF1/2 and/or of IGF1-R

- a. e.g. xentuzumab (antibody 60833 in WO 2010/066868), MEDI-573 (= dusigitumab);

26. an inhibitor of RAS GEFs and/or of mutants thereof

- 30 a. e.g. an inhibitor of SOS2 and/or of mutants thereof

27. an inhibitor of PI3K and/or of mutants thereof

Within this invention it is to be understood that the combinations, compositions, kits, methods, uses or compounds for use according to this invention may envisage the simultaneous, concurrent, sequential, successive, alternate or separate administration of the active ingredients or components. It will be appreciated that the SOS1 inhibitor compound (e.g. compound of formula (I)) and the at least one other pharmacologically active substance can be administered formulated either dependently or independently, such as e.g. the SOS1 inhibitor compound (e.g. compound of formula (I)) and the at least one other pharmacologically active substance may be administered either as part of the same pharmaceutical composition/dosage form or, preferably, in separate pharmaceutical compositions/dosage forms.

In this context, "combination" or "combined" within the meaning of this invention includes, without being limited, a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed (e.g. free) combinations (including kits) and uses, such as e.g. the simultaneous, concurrent, sequential, successive, alternate or separate use of the components or ingredients. The term "fixed combination" means that the active ingredients are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient.

The administration of the SOS1 inhibitor compound (e.g. compound of formula (I)) and the at least one other pharmacologically active substance may take place by co-administering the active components or ingredients, such as e.g. by administering them simultaneously or concurrently in one single or in two or more separate formulations or dosage forms. Alternatively, the administration of the SOS1 inhibitor compound (e.g. compound of formula (I)) and the at least one other pharmacologically active substance may take place by administering the active components or ingredients sequentially or in alternation, such as e.g. in two or more separate formulations or dosage forms.

For example, simultaneous administration includes administration at substantially the same time. This form of administration may also be referred to as "concomitant" administration. Concurrent administration includes administering the active agents within the same general time period, for example on the same day(s) but not necessarily at the same time. Alternate administration includes administration of one agent during a time

period, for example over the course of a few days or a week, followed by administration of the other agent(s) during a subsequent period of time, for example over the course of a few days or a week, and then repeating the pattern for one or more cycles. Sequential or successive administration includes administration of one agent during a first time period
5 (for example over the course of a few days or a week) using one or more doses, followed by administration of the other agent(s) during a second and/or additional time period (for example over the course of a few days or a week) using one or more doses. An overlapping schedule may also be employed, which includes administration of the active agents on different days over the treatment period, not necessarily according to a regular
10 sequence. Variations on these general guidelines may also be employed, e.g. according to the agents used and the condition of the subject.

The elements of the combinations of this invention may be administered (whether dependently or independently) by methods customary to the skilled person, e.g. by oral, enterical, parenteral (e.g., intramuscular, intraperitoneal, intravenous, transdermal or
15 subcutaneous injection, or implant), nasal, vaginal, rectal, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, excipients and/or vehicles appropriate for each route of administration.

Accordingly, in one aspect of the invention the invention provides a method for the treatment and/or prevention of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a SOS1 inhibitor compound (e.g. a compound of formula (I)) and a therapeutically effective amount of at least one other pharmacologically active substance, wherein the SOS1 inhibitor compound (e.g. a compound of formula (I)) is administered simultaneously, concurrently, sequentially,
20 successively, alternately or separately with the at least one other pharmacologically active substance.
25

In another aspect the invention provides a SOS1 inhibitor compound (e.g. a compound of formula (I)) for use in the treatment and/or prevention of cancer, wherein the SOS1 inhibitor compound (e.g. a compound of formula (I)) is administered simultaneously,
30 concurrently, sequentially, successively, alternately or separately with the at least one other pharmacologically active substance.

In another aspect the invention provides a kit comprising

- a first pharmaceutical composition or dosage form comprising a SOS1 inhibitor compound (e.g. a compound of formula (I)), and, optionally, one or more pharmaceutically acceptable carriers, excipients and/or vehicles, and
- at least a second pharmaceutical composition or dosage form comprising another pharmacologically active substance, and, optionally, one or more pharmaceutically acceptable carriers, excipients and/or vehicles,

for use in the treatment and/or prevention of cancer, wherein the first pharmaceutical composition is to be administered simultaneously, concurrently, sequentially, successively, alternately or separately with the second and/or additional pharmaceutical composition or dosage form.

In a further embodiment of the invention the components (*i.e.* the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention (including all embodiments) are administered simultaneously.

In a further embodiment of the invention the components (*i.e.* the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention (including all embodiments) are administered concurrently.

In a further embodiment of the invention the components (*i.e.* the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention (including all embodiments) are administered sequentially.

In a further embodiment of the invention the components (*i.e.* the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention (including all embodiments) are administered successively.

In a further embodiment of the invention the components (*i.e.* the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention (including all embodiments) are administered alternately.

In a further embodiment of the invention the components (*i.e.* the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention (including all embodiments) are administered separately.

The “therapeutically effective amount” of the active compound(s) to be administered is the minimum amount necessary to prevent, ameliorate, or treat a disease or disorder.

The combinations of this invention may be administered at therapeutically effective single

or divided daily doses. The active components of the combination may be administered in such doses which are therapeutically effective in monotherapy, or in such doses which are lower than the doses used in monotherapy, but when combined result in a desired (joint) therapeutically effective amount.

- 5 In another aspect the disease/condition/cancer to be treated/prevented with the SOS1 inhibitor compound, SOS1 inhibitor compound for use, compound of formula (I), compound of formula (I) for use, use for preparing and method for the treatment and/or prevention as herein (above and below) defined is selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma,
10 melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukaemia, bladder cancer, urothelial cancer, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B cell lymphoma, oesophageal cancer, chronic lymphocytic leukaemia, hepatocellular cancer, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer and sarcomas.
- 15 In another aspect the disease/condition/cancer to be treated/prevented with the SOS1 inhibitor compound, SOS1 inhibitor compound for use, compound of formula (I), compound of formula (I) for use, use for preparing and method for the treatment and/or prevention as herein (above and below) defined is selected from the group consisting of pancreatic cancer, lung cancer (preferably non-small cell lung cancer (NSCLC)),
20 cholangiocarcinoma and colorectal cancer.

In another aspect the disease/condition to be treated/prevented with the SOS1 inhibitor compound, SOS1 inhibitor compound for use, compound of formula (I), compound of formula (I) for use, use for preparing and method for the treatment and/or prevention as herein (above and below) defined is a RASopathy, preferably selected from the group
25 consisting of Neurofibromatosis type 1 (NF1), Noonan Syndrome (NS), Noonan Syndrome with Multiple Lentigines (NSML) (also referred to as LEOPARD syndrome), Capillary Malformation-Arteriovenous Malformation Syndrome (CM-AVM), Costello Syndrome (CS), Cardio-Facio-Cutaneous Syndrome (CFC), Legius Syndrome (also known as NF1-like Syndrome) and Hereditary gingival fibromatosis.

- 30 In another aspect the disease/condition/cancer to be treated/prevented with the SOS1 inhibitor compound, SOS1 inhibitor compound for use, compound of formula (I), compound of formula (I) for use, use for preparing and method for the treatment and/or

prevention as herein (above and below) defined is a disease/condition/cancer defined as exhibiting one or more of the following molecular features:

1. KRAS alterations:

- a. KRAS amplification (*wt* or mutant);
- 5 b. KRAS overexpression (*wt* or mutant);
- c. KRAS mutation(s):
 - i. G12 mutations (*e.g.* G12C, G12V, G12S, G12A, G12V, G12R, G12F, G12D);
 - ii. G13 mutations (*e.g.* G13C, G13D, G13R, G13V, G13S, G13A)
 - 10 iii. T35 mutation (*e.g.* T35I);
 - iv. I36 mutation (*e.g.* I36L, I36M);
 - v. E49 mutation (*e.g.* E49K);
 - vi. Q61 mutation (*e.g.* Q61H, Q61R, Q61P, Q61E, Q61K, Q61L, Q61K);
 - vii. K117 mutation (*e.g.* K117N);
 - 15 viii. A146 mutation (*e.g.* A146T, A146V);

2. NRAS alterations:

- a. NRAS amplification (*wt* or mutant);
- b. NRAS overexpression (*wt* or mutant);
- c. NRAS mutation(s):
 - 20 i. G12 mutations (*e.g.* G12A, G12V, G12D, G12C, G12S, G12R);
 - ii. G13 mutation (*e.g.* G13V, G13D, G13R, G13S, G13C, G13A);
 - iii. Q61 mutation (*e.g.* Q61K, Q61L, Q61H, Q61P, Q61R);
 - iv. A146 mutation (*e.g.* A146T, A146V);

3. HRAS alterations:

- 25 a. HRAS amplification (*wt* or mutant);
- b. HRAS overexpression (*wt* or mutant);
- c. HRAS mutation(s):
 - i. G12 mutation (*e.g.* G12C, G12V, G12S, G12A, G12V, G12R, G12F, G12D);
 - 30 ii. G13 mutation (*e.g.* G13C, G13D, G13R, G13V, G13S, G13A);
 - iii. Q61 mutation (*e.g.* Q61K, Q61L, Q61H, Q61P, Q61R);

4. EGFR alterations:

- a. EGFR amplification (*wt* or mutant);
- b. EGFR overexpression (*wt* or mutant);
- c. EGFR mutation(s)
 - 5 i. e.g. exon 20 insertion, exon 19 deletion (Del19), G719X (e.g. G719A, G719C, G719S), T790M, C797S, T854A, L858R, L861Q, or any combination thereof;

5. ErbB2 (Her2) alterations:

- a. ErbB2 amplification;
- 10 b. ErbB2 overexpression;
- c. ErbB2 mutation(s)
 - i. e.g. R678, G309, L755, D769, V777, P780, V842, R896, c.2264_2278del (L755_T759del), c.2339_2340ins (G778_P780dup), S310;

6. c-MET alterations:

- 15 a. c-MET amplification;
- b. c-MET overexpression;
- c. c-MET mutation(s)
 - i. e.g. E168, N375, Q648, A887, E908, T1010, V1088, H1112, R1166, R1188, Y1248, Y1253, M1268, D1304, A1357, P1382;

7. AXL alterations:

- a. AXL amplification;
- b. AXL overexpression;

8. BCR-ABL alterations:

- a. chromosomal rearrangements involving the ABL gene;

9. ALK alterations:

- a. ALK amplification;
- b. ALK overexpression;
- c. ALK mutation(s)
 - 25 i. e.g. 1151Tins, L1152R, C1156Y, F1174L, L1196M, L1198F, G1202R, S1206Y, G1269A;
 - 30 d. chromosomal rearrangements involving the ALK gene;

- 10. FGFR1 alterations:**
- a. FGFR1 amplification;
 - b. FGFR1 overexpression;
- 11. FGFR2 alterations:**
- 5 a. FGFR2 amplification;
- b. FGFR2 overexpression;
- 12. FGFR3 alterations:**
- a. FGFR3 amplification;
 - b. FGFR3 overexpression;
 - 10 c. chromosomal rearrangement involving the FGFR3 gene;
- 13. NTRK1 alterations:**
- a. chromosomal rearrangements involving the NTRK1 gene;
- 14. NF1 alterations:**
- a. NF1 mutation(s);
- 15 **15. RET alterations:**
- a. RET amplification;
 - b. RET overexpression;
 - c. chromosomal rearrangements involving the RET gene
- 16. ROS1 alterations:**
- 20 a. ROS1 amplification;
- b. ROS1 overexpression;
- c. ROS1 mutation(s)
- i. *e.g.* G2032R, D2033N, L2155S;
- d. chromosomal rearrangements involving the ROS1 gene;
- 25 **17. SOS1 alterations**
- a. SOS1 amplification;
 - b. SOS1 overexpression;
 - c. SOS1 mutation(s);
- 18. RAC1 alterations**
- 30 a. RAC1 amplification;
- b. RAC1 overexpression;

- c. RAC1 mutation(s);

19. MDM2 alterations

- a. MDM2 amplification
b. MDM2 overexpression
5 c. MDM2 amplification in combination with functional p53
d. MDM2 amplification in combination with wild-type p53

20. RAS wild-type

- a. KRAS wild-type
b. HRAS wild-type
10 c. NRAS wild-type

21. B-Raf mutation(s) other than V600E

Particularly preferred, the cancer to be treated/prevented with the SOS1 inhibitor compound, SOS1 inhibitor compound for use, compound of formula (I), compound of formula (I) for use, use for preparing and method for the treatment and/or prevention as
15 herein (above and below) defined is selected from the group consisting of:

- lung adenocarcinoma harboring a KRAS mutation selected from the group consisting of G12C, G12V, G12D and G12R;
- colorectal adenocarcinoma harboring a KRAS mutation selected from the group consisting of G12D, G12V, G12C, G12R and G13D; and
20 • pancreatic adenocarcinoma harboring a KRAS mutation selected from the group consisting of G12D, G12V, G12R, G12C and Q61H.

Any disease/condition/cancer, medical use, use, method of treatment and/or prevention as disclosed or defined herein (including molecular/genetic features) may be treated/performed with any compound of formula (I) as disclosed or defined herein
25 (including all individual embodiments or generic subsets of compounds (I)).

Definitions

Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification, however, unless specified to the contrary, the following terms have the
30 meaning indicated and the following conventions are adhered to:

The use of the prefix **C_{x-y}**, wherein **x** and **y** each represent a positive integer (**x < y**),

indicates that the chain or ring structure or combination of chain and ring structure as a whole, specified and mentioned in direct association, may consist of a maximum of **y** and a minimum of **x** carbon atoms.

The indication of the number of members in groups that contain one or more heteroatom(s) (e.g. heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclalkyl) relates to the total number of atoms of all the ring members or the total of all the ring and carbon chain members.

The indication of the number of carbon atoms in groups that consist of a combination of carbon chain and carbon ring structure (e.g. cycloalkylalkyl, arylalkyl) relates to the total number of carbon atoms of all the carbon ring and carbon chain members. Obviously, a ring structure has at least three members.

In general, for groups comprising two or more subgroups (e.g. heteroarylalkyl, heterocyclalkyl, cycloalkylalkyl, arylalkyl) the last named subgroup is the radical attachment point, for example, the substituent aryl-C₁₋₆alkyl means an aryl group which is bound to a C₁₋₆alkyl group, the latter of which is bound to the core or to the group to which the substituent is attached.

In groups like HO, H₂N, (O)S, (O)₂S, NC (cyano), HOOC, F₃C or the like, the skilled artisan can see the radical attachment point(s) to the molecule from the free valences of the group itself.

Alkyl denotes monovalent, saturated hydrocarbon chains, which may be present in both straight-chain (unbranched) and branched form. If an **alkyl** is substituted, the substitution may take place independently of one another, by mono- or polysubstitution in each case, on all the hydrogen-carrying carbon atoms.

The term "C₁₋₅alkyl" includes for example H₃C-, H₃C-CH₂-, H₃C-CH₂-CH₂-, H₃C-CH(CH₃)-, H₃C-CH₂-CH₂-CH₂-, H₃C-CH₂-CH(CH₃)-, H₃C-CH(CH₃)-CH₂-, H₃C-C(CH₃)₂-, H₃C-CH₂-CH₂-CH₂-CH₂-, H₃C-CH₂-CH₂-CH(CH₃)-, H₃C-CH₂-CH(CH₃)-CH₂-, H₃C-CH(CH₃)-CH₂-CH₂-, H₃C-CH₂-C(CH₃)₂-, H₃C-C(CH₃)₂-CH₂-, H₃C-CH(CH₃)-CH(CH₃)- and H₃C-CH₂-CH(CH₂CH₃)-.

Further examples of **alkyl** are methyl (Me; -CH₃), ethyl (Et; -CH₂CH₃), 1-propyl (*n*-propyl; *n*-Pr; -CH₂CH₂CH₃), 2-propyl (*i*-Pr; *iso*-propyl; -CH(CH₃)₂), 1-butyl (*n*-butyl; *n*-Bu; -CH₂CH₂CH₂CH₃), 2-methyl-1-propyl (*iso*-butyl; *i*-Bu; -CH₂CH(CH₃)₂), 2-butyl (*sec*-butyl; *sec*-Bu; -CH(CH₃)CH₂CH₃), 2-methyl-2-propyl (*tert*-butyl; *t*-Bu; -C(CH₃)₃),

- 1-pentyl (*n*-pentyl; $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 2-pentyl ($-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{CH}_3$), 3-pentyl ($-\text{CH}(\text{CH}_2\text{CH}_3)_2$), 3-methyl-1-butyl (*iso*-pentyl; $-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$), 2-methyl-2-butyl ($-\text{C}(\text{CH}_3)_2\text{CH}_2\text{CH}_3$), 3-methyl-2-butyl ($-\text{CH}(\text{CH}_3)\text{CH}(\text{CH}_3)_2$), 2,2-dimethyl-1-propyl (*neo*-pentyl; $-\text{CH}_2\text{C}(\text{CH}_3)_3$), 2-methyl-1-butyl ($-\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$), 1-hexyl (*n*-hexyl; $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 2-hexyl ($-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 3-hexyl ($-\text{CH}(\text{CH}_2\text{CH}_3)(\text{CH}_2\text{CH}_2\text{CH}_3)$), 2-methyl-2-pentyl ($-\text{C}(\text{CH}_3)_2\text{CH}_2\text{CH}_2\text{CH}_3$), 3-methyl-2-pentyl ($-\text{CH}(\text{CH}_3)\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$), 4-methyl-2-pentyl ($-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}(\text{CH}_3)_2$), 3-methyl-3-pentyl ($-\text{C}(\text{CH}_3)(\text{CH}_2\text{CH}_3)_2$), 2-methyl-3-pentyl ($-\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}(\text{CH}_3)_2$), 2,3-dimethyl-2-butyl ($-\text{C}(\text{CH}_3)_2\text{CH}(\text{CH}_3)_2$), 3,3-dimethyl-2-butyl ($-\text{CH}(\text{CH}_3)\text{C}(\text{CH}_3)_3$), 2,3-dimethyl-1-butyl ($-\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}(\text{CH}_3)\text{CH}_3$), 2,2-dimethyl-1-butyl ($-\text{CH}_2\text{C}(\text{CH}_3)_2\text{CH}_2\text{CH}_3$), 3,3-dimethyl-1-butyl ($-\text{CH}_2\text{CH}_2\text{C}(\text{CH}_3)_3$), 2-methyl-1-pentyl ($-\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{CH}_3$), 3-methyl-1-pentyl ($-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$), 1-heptyl (*n*-heptyl), 2-methyl-1-hexyl, 3-methyl-1-hexyl, 2,2-dimethyl-1-pentyl, 2,3-dimethyl-1-pentyl, 2,4-dimethyl-1-pentyl, 3,3-dimethyl-1-pentyl, 2,2,3-trimethyl-1-butyl, 3-ethyl-1-pentyl, 1-octyl (*n*-octyl), 1-nonyl (*n*-nonyl); 1-decyl (*n*-decyl) *etc.*

By the terms propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl *etc.* without any further definition are meant saturated hydrocarbon groups with the corresponding number of carbon atoms, wherein all isomeric forms are included.

- The above definition for **alkyl** also applies if **alkyl** is a part of another (combined) group such as for example C_{x-y} **alkyl**amino or C_{x-y} **alkyl**oxy.

The term **alkylene** can also be derived from **alkyl**. **Alkylene** is bivalent, unlike **alkyl**, and requires two binding partners. Formally, the second valency is produced by removing a hydrogen atom in an **alkyl**. Corresponding groups are for example $-\text{CH}_3$ and $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_3$ and $-\text{CH}_2\text{CH}_2-$ or $>\text{CHCH}_3$ *etc.*

- The term “ C_{1-4} alkylene” includes for example $-(\text{CH}_2)-$, $-(\text{CH}_2-\text{CH}_2)-$, $-(\text{CH}(\text{CH}_3))-$, $-(\text{CH}_2-\text{CH}_2-\text{CH}_2)-$, $-(\text{C}(\text{CH}_3)_2)-$, $-(\text{CH}(\text{CH}_2\text{CH}_3))-$, $-(\text{CH}(\text{CH}_3)-\text{CH}_2)-$, $-(\text{CH}_2-\text{CH}(\text{CH}_3))-$, $-(\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2)-$, $-(\text{CH}_2-\text{CH}_2-\text{CH}(\text{CH}_3))-$, $-(\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}_2)-$, $-(\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2)-$, $-(\text{CH}_2-\text{C}(\text{CH}_3)_2)-$, $-(\text{C}(\text{CH}_3)_2-\text{CH}_2)-$, $-(\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3))-$, $-(\text{CH}_2-\text{CH}(\text{CH}_2\text{CH}_3))-$, $-(\text{CH}(\text{CH}_2\text{CH}_3)-\text{CH}_2)-$, $-(\text{CH}(\text{CH}_2\text{CH}_2\text{CH}_3))-$, $-(\text{CH}(\text{CH}(\text{CH}_3)_2))-$ and $-\text{C}(\text{CH}_3)(\text{CH}_2\text{CH}_3)-$.

Other examples of **alkylene** are methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene, pentylene,

1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene,
1,3-dimethylpropylene, hexylene *etc.*

By the generic terms propylene, butylene, pentylene, hexylene *etc.* without any further definition are meant all the conceivable isomeric forms with the corresponding number of
5 carbon atoms, *i.e.* propylene includes 1-methylethylene and butylene includes 1-methylpropylene, 2-methylpropylene, 1,1-dimethylethylene and 1,2-dimethylethylene.

The above definition for **alkylene** also applies if **alkylene** is part of another (combined) group such as for example in HO-C_{x-y}**alkylene**amino or H₂N-C_{x-y}**alkylene**oxy.

Unlike **alkyl**, **alkenyl** consists of at least two carbon atoms, wherein at least two adjacent
10 carbon atoms are joined together by a C-C double bond and a carbon atom can only be part of one C-C double bond. If in an **alkyl** as hereinbefore defined having at least two carbon atoms, two hydrogen atoms on adjacent carbon atoms are formally removed and the free valencies are saturated to form a second bond, the corresponding **alkenyl** is formed.

15 Examples of **alkenyl** are vinyl (ethenyl), prop-1-enyl, allyl (prop-2-enyl), isopropenyl, but-1-enyl, but-2-enyl, but-3-enyl, 2-methyl-prop-2-enyl, 2-methyl-prop-1-enyl, 1-methyl-prop-2-enyl, 1-methyl-prop-1-enyl, 1-methylidenepropyl, pent-1-enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, 3-methyl-but-3-enyl, 3-methyl-but-2-enyl, 3-methyl-but-1-enyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, hex-5-enyl,
20 2,3-dimethyl-but-3-enyl, 2,3-dimethyl-but-2-enyl, 2-methylidene-3-methylbutyl, 2,3-dimethyl-but-1-enyl, hexa-1,3-dienyl, hexa-1,4-dienyl, penta-1,4-dienyl, penta-1,3-dienyl, buta-1,3-dienyl, 2,3-dimethylbuta-1,3-diene *etc.*

By the generic terms propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, nonadienyl, decadienyl *etc.* without any further
25 definition are meant all the conceivable isomeric forms with the corresponding number of carbon atoms, *i.e.* propenyl includes prop-1-enyl and prop-2-enyl, butenyl includes but-1-enyl, but-2-enyl, but-3-enyl, 1-methyl-prop-1-enyl, 1-methyl-prop-2-enyl *etc.*

Alkenyl may optionally be present in the *cis* or *trans* or *E* or *Z* orientation with regard to the double bond(s).

30 The above definition for **alkenyl** also applies when **alkenyl** is part of another (combined) group such as for example in C_{x-y}**alkenyl**amino or C_{x-y}**alkenyl**oxy.

Unlike **alkylene**, **alkenylene** consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C double bond and a carbon atom can only be part of one C-C double bond. If in an **alkylene** as hereinbefore defined having at least two carbon atoms, two hydrogen atoms at adjacent carbon atoms are formally removed and the free valencies are saturated to form a second bond, the corresponding **alkenylene** is formed.

Examples of **alkenylene** are ethenylene, propenylene, 1-methylethenylene, butenylene, 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene, pentenylene, 1,1-dimethylpropenylene, 2,2-dimethylpropenylene, 1,2-dimethylpropenylene, 1,3-dimethylpropenylene, hexenylene *etc.*

By the generic terms propenylene, butenylene, pentenylene, hexenylene *etc.* without any further definition are meant all the conceivable isomeric forms with the corresponding number of carbon atoms, *i.e.* propenylene includes 1-methylethenylene and butenylene includes 1-methylpropenylene, 2-methylpropenylene, 1,1-dimethylethenylene and 1,2-dimethylethenylene.

Alkenylene may optionally be present in the *cis* or *trans* or *E* or *Z* orientation with regard to the double bond(s).

The above definition for **alkenylene** also applies when **alkenylene** is a part of another (combined) group as for example in HO-C_{x-y}**alkenylene**amino or H₂N-C_{x-y}**alkenylene**oxy.

Unlike **alkyl**, **alkynyl** consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C triple bond. If in an **alkyl** as hereinbefore defined having at least two carbon atoms, two hydrogen atoms in each case at adjacent carbon atoms are formally removed and the free valencies are saturated to form two further bonds, the corresponding **alkynyl** is formed.

Examples of **alkynyl** are ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-2-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, 3-methyl-but-1-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl *etc.*

By the generic terms propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl *etc.* without any further definition are meant all the conceivable isomeric forms with the corresponding number of carbon atoms, *i.e.* propynyl includes prop-1-ynyl and prop-2-ynyl, butynyl includes but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-1-ynyl, 1-methyl-prop-2-ynyl, *etc.*

If a hydrocarbon chain carries both at least one double bond and also at least one triple bond, by definition it belongs to the **alkynyl** subgroup.

The above definition for **alkynyl** also applies if **alkynyl** is part of another (combined) group, as for example in C_{x-y}**alkynyl**amino or C_{x-y}**alkynyl**oxy.

5 Unlike **alkylene**, **alkynylene** consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C triple bond. If in an **alkylene** as hereinbefore defined having at least two carbon atoms, two hydrogen atoms in each case at adjacent carbon atoms are formally removed and the free valencies are saturated to form two further bonds, the corresponding **alkynylene** is formed.

10 Examples of **alkynylene** are ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene, hexynylene *etc.*

By the generic terms propynylene, butynylene, pentynylene, hexynylene *etc.* without any
15 further definition are meant all the conceivable isomeric forms with the corresponding number of carbon atoms, *i.e.* propynylene includes 1-methylethynylene and butynylene includes 1-methylpropynylene, 2-methylpropynylene, 1,1-dimethylethynylene and 1,2-dimethylethynylene.

The above definition for **alkynylene** also applies if **alkynylene** is part of another
20 (combined) group, as for example in HO-C_{x-y}**alkynylene**amino or H₂N-C_{x-y}**alkynylene**oxy.

By **heteroatoms** are meant oxygen, nitrogen and sulphur atoms.

Haloalkyl (haloalkenyl, haloalkynyl) is derived from the previously defined **alkyl (alkenyl, alkynyl)** by replacing one or more hydrogen atoms of the hydrocarbon chain independently of one another by halogen atoms, which may be identical or different. If a
25 **haloalkyl (haloalkenyl, haloalkynyl)** is to be further substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon atoms.

Examples of **haloalkyl (haloalkenyl, haloalkynyl)** are -CF₃, -CHF₂, -CH₂F, -CF₂CF₃, -CHFCH₃, -CH₂CF₃, -CF₂CH₃, -CHFCH₃, -CF₂CF₂CF₃, -CF₂CH₂CH₃, -CF=CF₂,
30 -CCI=CH₂, -CBr=CH₂, -C≡C-CF₃, -CHFCH₂CH₃, -CHFCH₂CF₃ *etc.*

From the previously defined **haloalkyl (haloalkenyl, haloalkynyl)** are also derived the

terms **haloalkylene (haloalkenylene, haloalkynylene)**. Haloalkylene (haloalkenylene, haloalkynylene), unlike haloalkyl (haloalkenyl, haloalkynyl), is bivalent and requires two binding partners. Formally, the second valency is formed by removing a hydrogen atom from a haloalkyl (haloalkenyl, haloalkynyl).

- 5 Corresponding groups are for example -CH₂F and -CHF-, -CHFCH₂F and -CHFCHF- or >CFCH₂F *etc.*

The above definitions also apply if the corresponding halogen-containing groups are part of another (combined) group.

Halogen relates to fluorine, chlorine, bromine and/or iodine atoms.

- 10 **Cycloalkyl** is made up of the subgroups **monocyclic hydrocarbon rings**, **bicyclic hydrocarbon rings** and **spiro-hydrocarbon rings**. The systems are saturated. In bicyclic hydrocarbon rings two rings are joined together so that they have at least two carbon atoms in common. In spiro-hydrocarbon rings one carbon atom (spiroatom) belongs to two rings together.

- 15 If a **cycloalkyl** is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon atoms. **Cycloalkyl** itself may be linked as a substituent to the molecule via every suitable position of the ring system.


Examples of **cycloalkyl** are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,

- 20 bicyclo[2.2.0]hexyl, bicyclo[3.2.0]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[4.3.0]nonyl (octahydroindenyl), bicyclo[4.4.0]decyl (decahydronaphthyl), bicyclo[2.2.1]heptyl (norbornyl), bicyclo[4.1.0]heptyl (norcaranyl), bicyclo[3.1.1]heptyl (pinanyl), spiro[2.5]octyl, spiro[3.3]heptyl *etc.*

- The above definition for **cycloalkyl** also applies if **cycloalkyl** is part of another (combined) group as for example in C_{x-y}**cycloalkyl**amino, C_{x-y}**cycloalkyl**oxy or C_{x-y}**cycloalkyl**alkyl.

If the free valency of a **cycloalkyl** is saturated, then an **alicyclic group** is obtained.

- The term **cycloalkylene** can thus be derived from the previously defined **cycloalkyl**. **Cycloalkylene**, unlike **cycloalkyl**, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a **cycloalkyl**. Corresponding groups are for example:



The above definition for **cycloalkylene** also applies if **cycloalkylene** is part of another (combined) group as for example in $\text{HO-C}_{x-y}\text{cycloalkyleneamino}$ or $\text{H}_2\text{N-C}_{x-y}\text{cycloalkyleneoxy}$.

- 5 **Cycloalkenyl** is also made up of the subgroups **monocyclic hydrocarbon rings**, **bicyclic hydrocarbon rings** and **spiro-hydrocarbon rings**. However, the systems are unsaturated, *i.e.* there is at least one C-C double bond but no aromatic system. If in a **cycloalkyl** as hereinbefore defined two hydrogen atoms at adjacent cyclic carbon atoms are formally removed and the free valencies are saturated to form a second bond, the corresponding **cycloalkenyl** is obtained.


If a **cycloalkenyl** is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon atoms. **Cycloalkenyl** itself may be linked as a substituent to the molecule *via* every suitable position of the ring system.

- 15 Examples of **cycloalkenyl** are cycloprop-1-enyl, cycloprop-2-enyl, cyclobut-1-enyl, cyclobut-2-enyl, cyclopent-1-enyl, cyclopent-2-enyl, cyclopent-3-enyl, cyclohex-1-enyl, cyclohex-2-enyl, cyclohex-3-enyl, cyclohept-1-enyl, cyclohept-2-enyl, cyclohept-3-enyl, cyclohept-4-enyl, cyclobuta-1,3-dienyl, cyclopenta-1,4-dienyl, cyclopenta-1,3-dienyl, cyclopenta-2,4-dienyl, cyclohexa-1,3-dienyl, cyclohexa-1,5-dienyl, cyclohexa-2,4-dienyl, cyclohexa-1,4-dienyl, cyclohexa-2,5-dienyl, bicyclo[2.2.1]hepta-2,5-dienyl (norborna-2,5-dienyl), bicyclo[2.2.1]hept-2-enyl (norbornenyl), spiro[4,5]dec-2-enyl *etc.*

The above definition for **cycloalkenyl** also applies when **cycloalkenyl** is part of another (combined) group as for example in $\text{C}_{x-y}\text{cycloalkenylamino}$, $\text{C}_{x-y}\text{cycloalkenylloxy}$ or $\text{C}_{x-y}\text{cycloalkenylalkyl}$.

- 25 If the free valency of a **cycloalkenyl** is saturated, then an **unsaturated alicyclic group** is obtained.

The term **cycloalkenylene** can thus be derived from the previously defined **cycloalkenyl**. **Cycloalkenylene**, unlike **cycloalkenyl**, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a **cycloalkenyl**. Corresponding groups are for example:



The above definition for **cycloalkenylene** also applies if **cycloalkenylene** is part of another (combined) group as for example in HO-C_{x-y}**cycloalkenylene**amino or H₂N-C_{x-y}**cycloalkenylene**oxy.


- 5 **Aryl** denotes mono-, bi- or tricyclic carbocycles with at least one aromatic carbocycle. Preferably, it denotes a monocyclic group with six carbon atoms (phenyl) or a bicyclic group with nine or ten carbon atoms (two six-membered rings or one six-membered ring with a five-membered ring), wherein the second ring may also be aromatic or, however, may also be partially saturated.
- 10 If an **aryl** is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon atoms. **Aryl** itself may be linked as a substituent to the molecule *via* every suitable position of the ring system.

Examples of **aryl** are phenyl, naphthyl, indanyl (2,3-dihydroindenyl), indenyl, anthracenyl, 15 phenanthrenyl, tetrahydronaphthyl (1,2,3,4-tetrahydronaphthyl, tetralinyl), dihydronaphthyl (1,2-dihydronaphthyl), fluorenyl *etc.* Most preferred is phenyl.

The above definition of **aryl** also applies if **aryl** is part of another (combined) group as for example in **arylamino**, **aryloxy** or **arylalkyl**.

If the free valency of an **aryl** is saturated, then an **aromatic group** is obtained.

- 20 The term **arylene** can also be derived from the previously defined **aryl**. **Arylene**, unlike **aryl**, is bivalent and requires two binding partners. Formally, the second valency is formed by removing a hydrogen atom from an **aryl**. Corresponding groups are for example:



- 25 The above definition for **arylene** also applies if **arylene** is part of another (combined)

group as for example in HO-**arylene**amino or H₂N-**arylene**oxy.

Heterocyclyl denotes ring systems, which are derived from the previously defined **cycloalkyl**, **cycloalkenyl** and **aryl** by replacing one or more of the groups -CH₂- independently of one another in the hydrocarbon rings by the groups -O-, -S- or -NH- or by replacing one or more of the groups =CH- by the group =N-, wherein a total of not more than five heteroatoms may be present, at least one carbon atom must be present between two oxygen atoms and between two sulphur atoms or between an oxygen and a sulphur atom and the ring as a whole must have chemical stability. Heteroatoms may optionally be present in all the possible oxidation stages (sulphur → sulfoxide -SO-, sulphone -SO₂-; nitrogen → N-oxide). In a **heterocyclyl** there is no heteroaromatic ring, i.e. no heteroatom is part of an aromatic system.

A direct result of the derivation from **cycloalkyl**, **cycloalkenyl** and **aryl** is that **heterocyclyl** is made up of the subgroups **monocyclic heterorings**, **bicyclic heterorings**, **tricyclic heterorings** and **spiro-heterorings**, which may be present in saturated or unsaturated form.


By unsaturated is meant that there is at least one double bond in the ring system in question, but no heteroaromatic system is formed. In bicyclic heterorings two rings are linked together so that they have at least two (hetero)atoms in common. In spiro-heterorings one carbon atom (spiroatom) belongs to two rings together.


If a **heterocyclyl** is substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon and/or nitrogen atoms. **Heterocyclyl** itself may be linked as a substituent to the molecule *via* every suitable position of the ring system. Substituents on **heterocyclyl** do not count for the number of members of a **heterocyclyl**.


Examples of **heterocyclyl** are tetrahydrofuryl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, thiazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, oxiranyl, aziridinyl, azetidiny, 1,4-dioxanyl, azepanyl, diazepanyl, morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl, homopiperazinyl, homothiomorpholinyl, thiomorpholinyl-S-oxide, thiomorpholinyl-S,S-dioxide, 1,3-dioxolanyl, tetrahydropyranyl, tetrahydrothiopyranyl, [1,4]-oxazepanyl, tetrahydrothienyl, homothiomorpholinyl-S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridyl, dihydro-pyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl-S-oxide,


tetrahydrothienyl-*S,S*-dioxide, homothiomorpholinyl-*S*-oxide, 2,3-dihydroazet, 2*H*-pyrrolyl, 4*H*-pyranyl, 1,4-dihydropyridinyl, 8-aza-bicyclo[3.2.1]octyl, 8-aza-bicyclo[5.1.0]octyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 3,8-diaza-bicyclo[3.2.1]octyl, 2,5-diaza-bicyclo[2.2.1]heptyl, 1-aza-bicyclo[2.2.2]octyl, 3,8-diaza-bicyclo[3.2.1]octyl, 3,9-diaza-bicyclo[4.2.1]nonyl, 2,6-diaza-bicyclo[3.2.2]nonyl, 1,4-dioxa-spiro[4.5]decyl, 1-oxa-3,8-diaza-spiro[4.5]decyl, 2,6-diaza-spiro[3.3]heptyl, 2,7-diaza-spiro[4.4]nonyl, 2,6-diaza-spiro[3.4]octyl, 3,9-diaza-spiro[5.5]undecyl, 2,8-diaza-spiro[4,5]decyl *etc.*

Further examples are the structures illustrated below, which may be attached via each hydrogen-carrying atom (exchanged for hydrogen):










Preferably, heterocyclyls are 4 to 8 membered, monocyclic and have one or two heteroatoms independently selected from oxygen, nitrogen and sulfur.

Preferred heterocyclyls are: piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, azetidiny, tetrahydropyranyl, tetrahydrofuranyl.

The above definition of **heterocyclyl** also applies if **heterocyclyl** is part of another (combined) group as for example in **heterocyclylamino**, **heterocyclylloxy** or **heterocyclylalkyl**.

If the free valency of a **heterocyclyl** is saturated, then a **heterocyclic group** is obtained.


- 10 The term **heterocyclylene** is also derived from the previously defined **heterocyclyl**. **Heterocyclylene**, unlike **heterocyclyl**, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a **heterocyclyl**. Corresponding groups are for example:




The above definition of **heterocyclylene** also applies if **heterocyclylene** is part of another (combined) group as for example in HO-**heterocyclylene**amino or H₂N-**heterocyclylene**oxy.

- Heteroaryl** denotes monocyclic heteroaromatic rings or polycyclic rings with at least one heteroaromatic ring, which compared with the corresponding **aryl** or **cycloalkyl** (cycloalkenyl) contain, instead of one or more carbon atoms, one or more identical or different heteroatoms, selected independently of one another from among nitrogen, sulphur and oxygen, wherein the resulting group must be chemically stable. The prerequisite for the presence of **heteroaryl** is a heteroatom and a heteroaromatic system.
- If a **heteroaryl** is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon and/or nitrogen atoms. **Heteroaryl** itself may be linked as a substituent to the molecule *via* every suitable position of the ring system, both carbon and nitrogen. Substituents on **heteroaryl** do not count for the number of members of a **heteroaryl**.
- Examples of **heteroaryl** are furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyridyl-*N*-oxide, pyrrolyl-*N*-oxide, pyrimidinyl-*N*-oxide, pyridazinyl-*N*-oxide, pyrazinyl-*N*-oxide, imidazolyl-*N*-oxide, isoxazolyl-*N*-oxide, oxazolyl-*N*-oxide, thiazolyl-*N*-oxide, oxadiazolyl-*N*-oxide, thiadiazolyl-*N*-oxide, triazolyl-*N*-oxide, tetrazolyl-*N*-oxide, indolyl, isoindolyl, benzofuryl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolyl, quinolyl, quinoxalyl, cinnolyl, phthalazinyl, quinazolinyl, benzotriazinyl, indolizyl, oxazolopyridyl, imidazopyridyl, naphthyridinyl, benzoxazolyl, pyridopyridyl, pyrimidopyridyl, purinyl, pteridinyl, benzothiazolyl, imidazopyridyl, imidazothiazolyl, quinolyl-*N*-oxide, indolyl-*N*-oxide, isoquinolyl-*N*-oxide, quinazolinyl-*N*-oxide, quinoxalyl-*N*-oxide, phthalazinyl-*N*-oxide, indolizyl-*N*-oxide, indazolyl-*N*-oxide, benzothiazolyl-*N*-oxide, benzimidazolyl-*N*-oxide *etc.*

Further examples are the structures illustrated below, which may be attached *via* each hydrogen-carrying atom (exchanged for hydrogen):






Preferably, heteroaryls are 5-6 membered monocyclic or 9-10 membered bicyclic, each with 1 to 4 heteroatoms independently selected from oxygen, nitrogen and sulfur.

The above definition of **heteroaryl** also applies if **heteroaryl** is part of another (combined) group as for example in **heteroarylamino**, **heteroaryloxy** or **heteroarylalkyl**.

If the free valency of a **heteroaryl** is saturated, a **heteroaromatic group** is obtained.

The term **heteroarylene** is also derived from the previously defined **heteroaryl**. **Heteroarylene**, unlike **heteroaryl**, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a **heteroaryl**.
Corresponding groups are for example:



The above definition of **heteroarylene** also applies if **heteroarylene** is part of another (combined) group as for example in HO-**heteroaryleneamino** or H₂N-**heteroaryleneoxy**.

By **substituted** is meant that a hydrogen atom which is bound directly to the atom under consideration, is replaced by another atom or another group of atoms (**substituent**). Depending on the starting conditions (number of hydrogen atoms) mono- or polysubstitution may take place on one atom. Substitution with a particular substituent is only possible if the permitted valencies of the substituent and of the atom that is to be substituted correspond to one another and the substitution leads to a stable compound (*i.e.* to a compound which is not converted spontaneously, *e.g.* by rearrangement, cyclisation or elimination).

Bivalent substituents such as =S, =NR, =NOR, =NNRR, =NN(R)C(O)NRR, =N₂ or the like, may only be substituents on carbon atoms, whereas the bivalent substituents =O and =NR may also be a substituent on sulphur. Generally, substitution may be carried out by a bivalent substituent only at ring systems and requires replacement of two geminal hydrogen atoms, *i.e.* hydrogen atoms that are bound to the same carbon atom that is saturated prior to the substitution. Substitution by a bivalent substituent is therefore only possible at the group -CH₂- or sulphur atoms (=O group or =NR group only, one or two =O groups possible or, *e.g.*, one =O group and one =NR group, each group replacing a free

electron pair) of a ring system.

Stereochemistry/solvates/hydrates: Unless specifically indicated, throughout the specification and appended claims, a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, *E/Z* isomers, *etc.*) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates and hydrates of the free compound or solvates and hydrates of a salt of the compound.

In general, substantially pure stereoisomers can be obtained according to synthetic principles known to a person skilled in the field, e.g. by separation of corresponding mixtures, by using stereochemically pure starting materials and/or by stereoselective synthesis. It is known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis, e.g. starting from optically active starting materials and/or by using chiral reagents.

Enantiomerically pure compounds of this invention or intermediates may be prepared via asymmetric synthesis, for example by preparation and subsequent separation of appropriate diastereomeric compounds or intermediates which can be separated by known methods (e.g. by chromatographic separation or crystallization) and/or by using chiral reagents, such as chiral starting materials, chiral catalysts or chiral auxiliaries.

Further, it is known to the person skilled in the art how to prepare enantiomerically pure compounds from the corresponding racemic mixtures, such as by chromatographic separation of the corresponding racemic mixtures on chiral stationary phases, or by resolution of a racemic mixture using an appropriate resolving agent, e.g. by means of diastereomeric salt formation of the racemic compound with optically active acids or bases, subsequent resolution of the salts and release of the desired compound from the salt, or by derivatization of the corresponding racemic compounds with optically active chiral auxiliary reagents, subsequent diastereomer separation and removal of the chiral auxiliary group, or by kinetic resolution of a racemate (e.g. by enzymatic resolution); by enantioselective crystallization from a conglomerate of enantiomorphous crystals under suitable conditions, or by (fractional) crystallization from a suitable solvent in the presence of an optically active chiral auxiliary.

Salts: The phrase “**pharmaceutically acceptable**” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.

As used herein “**pharmaceutically acceptable salts**” refers to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.


For example, such salts include salts from benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl-benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid and tartaric acid.

Further pharmaceutically acceptable salts can be formed with cations from ammonia, L-arginine, calcium, 2,2'-iminobisethanol, L-lysine, magnesium, *N*-methyl-D-glucamine, potassium, sodium and tris(hydroxymethyl)-aminomethane.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.


Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention (e.g. trifluoro acetate salts), also comprise a part of the invention.

In a representation such as for example




the letter A has the function of a ring designation in order to make it easier, for example, to indicate the attachment of the ring in question to other rings.

For bivalent groups in which it is crucial to determine which adjacent groups they bind and with which valency, the corresponding binding partners are indicated in brackets where necessary for clarification purposes, as in the following representations:



5 In a representation such as for example



the asterisk designates the point of attachment of the respective group as a substituent.

Groups or substituents are frequently selected from among a number of alternative groups/substituents with a corresponding group designation (e.g. R^a , R^b etc). If such a group is used repeatedly to define a compound according to the invention in different parts of the molecule, it is pointed out that the various uses are to be regarded as totally independent of one another.

By a **therapeutically effective amount** for the purposes of this invention is meant a quantity of substance that is capable of obviating symptoms of illness or of preventing or alleviating these symptoms, or which prolong the survival of a treated patient.

RAS-family proteins are meant to include KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), NRAS (neuroblastoma RAS viral oncogene homolog) and HRAS (Harvey murine sarcoma virus oncogene) and any mutants thereof.

A **SOS1 inhibitor compound** is a compound, which binds to SOS1 and thereby prevents the SOS1 mediated nucleotide exchange and subsequently reduces the levels of RAS in its GTP bound form. More specifically, a SOS1 inhibitor compound shows a pharmacological inhibition of the binding of the catalytic site of SOS1 to RAS-family proteins. Thus, such a compound interacts with SOS1, e.g. the catalytic site on SOS1, and reduces the level of binding to the RAS-family protein in relation to said binding without addition of a SOS1 inhibitor compound. Accordingly, it is envisaged that a SOS1 inhibitor compound at least reduces the level of binding to the RAS-family protein about 5 %, 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 % or even 100 % when

compared to the binding that is achieved without the addition of said inhibitor compound. Suitable test systems to measure the binding to the catalytic site of SOS1 are disclosed herein. Said compound may be chemically synthesized (e.g. a small molecule) or microbiologically produced (e.g. a monoclonal antibody) and/or comprised in, for example, samples, e.g., cell extracts from, e.g., plants, animals or microorganisms. Preferably, the SOS1 inhibitor compound is a small molecule.

List of abbreviations

Ac	acetyl
ACN	acetonitrile
amphos	bis(di- <i>tert</i> -butyl(4-dimethylaminophenyl)phosphine)
aq.	aquatic, aqueous
ATP	adenosine triphosphate
Bn	benzyl
Boc	<i>tert</i> -butyloxycarbonyl
Bu	butyl
c	concentration
Cbz	carboxybenzyl
CH ₂ Cl ₂	dichloro methane
d	day(s)
dba	dibenzylideneacetone
TLC	thin layer chromatography
DAST	diethylamino sulfurtrifluoride
Davephos	2-dimethylamino-2'-dicyclohexylaminophosphinobiphenyl
DBA	dibenzylidene acetone
DBU	1,8-Diazabicyclo(5.4.0)undec-7-ene
DCE	dichloro ethane
DCM	dichloro methane
DEA	diethyl amine
DEAD	diethyl azodicarboxylate
DIPEA	<i>N</i> -ethyl- <i>N,N</i> -diisopropylamine (Hünig's base)
DMAP	4- <i>N,N</i> -dimethylaminopyridine
DME	1,2-dimethoxyethane
DMF	<i>N,N</i> -dimethylformamide

DMSO	dimethylsulphoxide
DPPA	diphenylphosphorylazide
dppf	1,1'-bis(diphenylphosphino)ferrocene
EDTA	ethylenediaminetetraacetic acid
EGTA	ethyleneglycoltetraacetic acid
eq	equivalent(s)
equiv.	equivalent(s)
ESI	electron spray ionization
Et	ethyl
Et ₂ O	diethyl ether
EtOAc	ethyl acetate
EtOH	ethanol
h	hour
HATU	O-(7-azabenzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyl-uronium hexafluorophosphate
HPLC	high performance liquid chromatography
IBX	2-iodoxy benzoic acid
<i>i</i>	iso
conc.	concentrated
LC	liquid chromatography
LiHMDS	lithium bis(trimethylsilyl)amide
sln.	solution
Me	methyl
MeOH	methanol
min	minutes
MPLC	medium pressure liquid chromatography
MS	mass spectrometry
MTBE	methyl <i>tert</i> -butyl ether
NBS	<i>N</i> -bromo-succinimide
NIS	<i>N</i> -iodo-succinimide
NMM	<i>N</i> -methylmorpholine
NMP	<i>N</i> -methylpyrrolidone
NP	normal phase
n.a.	not available

PBS	phosphate-buffered saline
Ph	phenyl
Pr	propyl
PTSA	<i>p</i> -toluenesulfonic acid
Py	pyridine
rac	racemic
red.	reduction
R _f (R _f)	retention factor
RP	reversed phase
RRLC	Rapid resolution liquid chromatography
rt	ambient temperature
SFC	supercritical fluid chromatography
S _N	nucleophilic substitution
TBAF	tetrabutylammonium fluoride
TBDMS	<i>tert</i> -butyldimethylsilyl
TBME	<i>tert</i> -butylmethylether
TBTU	O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium tetrafluoroborate
tBu	<i>tert</i> -butyl
TEA	triethyl amine
temp.	temperature
<i>tert</i>	tertiary
Tf	triflate
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TMS	trimethylsilyl
t _{Ret.}	retention time (HPLC)
TRIS	tris(hydroxymethyl)-aminomethane
TsOH	<i>p</i> -toluenesulphonic acid
UPLC	ultra performance liquid chromatography
UV	ultraviolet
wt	weight

Features and advantages of the present invention will become apparent from the following detailed examples which illustrate the principles of the invention by way of example

without restricting its scope:

Preparation of the compounds according to the invention

General

Unless stated otherwise, all the reactions are carried out in commercially obtainable
5 apparatus using methods that are commonly used in chemical laboratories. Starting
materials that are sensitive to air and/or moisture are stored under protective gas and
corresponding reactions and manipulations therewith are carried out under protective gas
(nitrogen or argon).

The compounds according to the invention are named in accordance with CAS rules using
10 the software Autonom (Beilstein). If a compound is to be represented both by a structural
formula and by its nomenclature, in the event of a conflict the structural formula is
decisive.

Microwave reactions are carried out in an initiator/reactor made by Biotage or in an
Explorer made by CEM or in Synthos 3000 or Monowave 3000 made by Anton Paar in
15 sealed containers (preferably 2, 5 or 20 mL), preferably with stirring.

Chromatography

The thin layer chromatography is carried out on ready-made silica gel 60 TLC plates on
glass (with fluorescence indicator F-254) made by Merck.

The **preparative high pressure chromatography (RP HPLC)** of the example
20 compounds according to the invention is carried out on Agilent or Gilson systems with
columns made by Waters (names: SunFire™ Prep C18, OBD™ 10 µm, 50 x 150 mm or
SunFire™ Prep C18 OBD™ 5 µm, 30 x 50 mm or XBridge™ Prep C18, OBD™ 10 µm,
50 x 150 mm or XBridge™ Prep C18, OBD™ 5 µm, 30 x 150 mm or XBridge™ Prep C18,
OBD™ 5 µm, 30 x 50 mm) and YMC (names: Actus-Triart Prep C18, 5 µm, 30 x 50 mm).

25 Different gradients of H₂O/acetonitrile are used to elute the compounds, while for Agilent
systems 5 % acidic modifier (20 mL HCOOH to 1 L H₂O/acetonitrile (1/1)) is added to the
water (acidic conditions). For Gilson systems the water is added 0.1 % HCOOH.

For the chromatography under basic conditions for Agilent systems H₂O/acetonitrile
gradients are used as well, while the water is made alkaline by addition of 5 % basic
30 modifier (50 g NH₄HCO₃ + 50 mL NH₃ (25 % in H₂O) to 1 L with H₂O). For Gilson systems
the water is made alkaline as follows: 5mL NH₄HCO₃ solution (158 g in 1 L H₂O) and 2 mL

NH₃ (28 % in H₂O) are replenished to 1 L with H₂O.

The **supercritical fluid chromatography (SFC)** of the intermediates and example compounds according to the invention is carried out on a JASCO SFC-system with the following columns: Chiralcel OJ (250 x 20 mm, 5 µm), Chiralpak AD (250 x 20 mm, 5 µm),
 5 Chiralpak AS (250 x 20 mm, 5 µm), Chiralpak IC (250 x 20 mm, 5 µm), Chiralpak IA (250 x 20 mm, 5 µm), Chiralcel OJ (250 x 20 mm, 5 µm), Chiralcel OD (250 x 20 mm, 5 µm), Phenomenex Lux C2 (250 x 20 mm, 5 µm).

The **analytical HPLC (reaction control)** of intermediate and final compounds is carried out using columns made by Waters (names: XBridge™ C18, 2.5 µm, 2.1 x 20 mm or
 10 XBridge™ C18, 2.5 µm, 2.1 x 30 mm or Aquity UPLC BEH C18, 1.7 µm, 2.1 x 50mm) and YMC (names: Triart C18, 3.0 µm, 2.0 x 30 mm) and Phenomenex (names: Luna C18, 5.0 µm, 2.0 x 30 mm). The analytical equipment is also equipped with a mass detector in each case.

HPLC-mass spectroscopy/UV-spectrometry

15 The retention times/MS-ESI⁺ for characterizing the example compounds according to the invention are produced using an HPLC-MS apparatus (high performance liquid chromatography with mass detector). Compounds that elute at the injection peak are given the retention time $t_{Ret.} = 0.00$.

HPLC-Methods (preparative)

20 *prep. HPLC1*

HPLC:	333 and 334 Pumps
Column:	Waters X-Bridge C18 OBD, 10 µm, 30 x 100 mm, Part.No. 186003930
Solvent:	A: 10 mM NH ₄ HCO ₃ in H ₂ O; B: Acetonitrile (HPLC grade)
25 Detection:	UV/Vis-155
Flow:	50 mL/min
Gradient:	0.00 – 1.50 min: 1.5 % B 1.50 – 7.50 min: varying 7.50 – 9.00 min: 100 % B

30 *prep. HPLC2*

HPLC:	333 and 334 Pumps
Column:	Waters Sunfire C18 OBD, 10 µm, 30 x 100 mm, Part.No.

186003971

Solvent: A: H₂O + 0.2 % HCOOH; B: Acetonitrile (HPLC grade) + 0.2 % HCOOH

Detection: UV/Vis-155

5 Flow: 50 mL/min

Gradient: 0.00 – 1.50 min: 1.5 % B
1.50 – 7.50 min: varying
7.50 – 9.00 min: 100 % B

HPLC-Methods (analytic)

10 **LCMSBAS1**

HPLC: Agilent 1100 Series

MS: Agilent LC/MSD SL

Column: Phenomenex Mercury Gemini C18, 3 µm, 2 x 20 mm, Part.No. 00M-4439-B0-CE

15 Solvent: A: 5 mM NH₄HCO₃/20 mM NH₃ in H₂O; B: acetonitrile (HPLC grade)

Detection: MS: positive and negative mode

Mass range: 120 – 900 m/z

Flow: 1.00 mL/min

20 Column temperature: 40 °C

Gradient: 0.00 – 2.50 min: 5 % B → 95 % B
2.50 – 2.80 min: 95 % B
2.81 – 3.10 min: 95 % B → 5 % B

VAB

25 HPLC: Agilent 1100/1200 Series

MS: Agilent LC/MSD SL

Column: Waters X-Bridge BEH C18, 2.5 µm, 2.1 x 30 mm XP

Solvent: A: 5 mM NH₄HCO₃/19 mM NH₃ in H₂O; B: acetonitrile (HPLC grade)

30 Detection: MS: positive and negative mode

Mass range: 100 – 1200 m/z

Flow: 1.40 mL/min

Column temperature: 45 °C

Gradient: 0.00 – 1.00 min: 5 % B → 100 % B

1.00 – 1.37 min: 100 % B

1.37 – 1.40 min: 100 % B → 5 % B

5 **RND-FA-3.5**

HPLC: Agilent Infinity-1290 Series

MS: Agilent SQD-6150 (API-ES +/- 3000 V)

MSD signal settings: Scan pos 100 – 1000, Scan neg 100 – 1000

Column: Aquity BEH C18, 2.1 x 50 mm, 1.7 µm

10 Eluent: A: 0.1 % formic acid in water; B: 0.1 % formic acid in acetonitrile

Detection signal: UV 215 nm (bandwidth 4, reference off)

Spectrum: range: 200 – 400 nm; step: 2 nm

Peak width: > 0.025 min (0.5 S)

Injection: 0.5 µL injection with needle wash at flush port

15 Flow rate: 0.8 mL/min

Column temperature: 45 °C

Gradient: 0.0 – 0.2 min: 2 % B

0.2 – 1.5 min: 2 % B → 98 % B

1.5 – 2.6 min: 98 % B

20 2.6 – 2.61 min: 98 % B → 2 % B

2.61 – 3.2 min: 2 % B

GVK_LCMS_18

HPLC: Agilent Infinity-1290 Series

MS: Agilent SQD -6130 (API-ES + 3500 V/ -3000 V)

25 MSD signal settings: Scan pos 100 – 1200, Scan neg 100 – 1200

Column: Aquity BEH C18, 2.1 x 50mm, 1.7µm

Eluent: A: 0.1% formic acid in acetonitrile; B: 0.1% formic acid in water

Detection signal: UV 215/254 nm (bandwidth 4, reference off)

Spectrum: range: 200 – 400 nm; step: 2 nm

30 Peak width: > 0.025 min (0.5 S)

Injection: 0.5 µL injection with needle wash at flush port.

Flow rate: 0.8 mL/min

Column temperature: 60 °C

Gradient: 0.0 – 0.4 min: 97 % B
 0.4 – 2.2 min: 97 % B → 2 % B
 2.2 – 2.6 min: 2 % B
 2.6 – 2.61 min: 2 % B → 97 % B
 2.61 – 3.0 min: 97 % B

5

GVK_LCMS_02

UPLC: Waters UPLC
 MS: Micromass Triple quad (ESI)
 Capillary Voltage: 3500
 Cone voltage: 25 to 50V
 Desolvation gas: 600 L/h
 Desolvation temp.: 350 °C
 MSD signal settings: Scan pos 100 – 1000, Scan neg 100 – 1000
 Column: Aquity BEH C18, 2.1 x 50 mm, 1.7 µm
 Eluent: A: 0.1 % formic acid in water; B: 0.1 % formic acid in acetonitrile
 Detection signal: UV-diode array
 Spectrum: range: 200 – 400 nm; resolution: 1.2 nm
 Sampling rate: 10 points/sec
 Injection: 0.5 µL injection with needle wash
 Flow rate: 0.4 mL/min
 Column temperature: 35 °C
 Gradient: 0.0 – 0.5 min: 5 % B
 0.5 – 2.0 min: 50 % B
 2.0 – 3.5 min: 100 % B
 3.5 – 5.0 min: 100 % B → 5 % B
 5.0 – 5.50 min: 5 % B

10

15

20

25

GVK_LCMS_31

HPLC: Agilent Infinity-1290 Series
 MS: Agilent-6130 quadrupole LCMS (ESI/APCI, multi-mode +
 3500 V/ - 3000 V)
 Charging Voltage: 2000
 Fragmenter: 50 to 70
 Corona voltage: 4 µ amp

30

	Disolvation temp.:	300 °C
	Disolvation gas:	600 L/h
	MSD signal settings:	Scan pos 100 – 1200, Scan neg 100 – 1200
	Column:	Aquity BEH C18, 2.1 x 50 mm, 1.7 µm
5	Eluent:	A: 0.1 % formic acid in acetonitrile; B: 0.1 % formic acid in water
	Detection signal:	UV 215 nm (bandwidth 4, reference off); UV 254 nm (bandwidth 4, reference off)
	Spectrum:	range: 200 – 400 nm; step: 2 nm
	Peak width:	> 0.025 min (0.5 S)
10	Injection:	0.5 µL injection with needle wash at flush port
	Flow rate:	0.8 mL/min
	Column temperature:	50 °C
	Gradient:	0.0 – 0.2 min: 2 % A
		0.2 – 2.3 min: 98 % A
15		2.3 – 3.4 min: 98 % A → 2 % A
		3.4 – 3.41 min: 2 % A
		3.41 – 3.5 min: 2 % A

GVK_LCMS_34

	HPLC:	Agilent Infinity-1290 Series
20	MS:	Agilent-6130 quadrupole LCMS (APCI-ES + 3500 V/ - 3500 V)
	Cone voltage:	25 to 50 V
	Disolvation gas:	600 L/h
	Disolvation temp.:	350 °C
	MSD signal settings:	Scan pos 100 – 1000, Scan neg 100 – 1000
25	Column:	Aquity BEH C18, 2.1 x 50 mm, 1.7 µm
	Eluent:	A: 0.1 % formic acid in water; B: 0.1 % formic acid in acetonitrile
	Detection signal:	UV 215 nm (bandwidth 4, reference off); UV 254 nm (bandwidth 16, reference off)
	Spectrum:	range: 190 – 400 nm; step: 2 nm
30	Peak width:	> 0.05 min (0.5 S)
	Injection:	0.5 µL injection with needle wash at flush port
	Flow rate:	0.8 mL/min
	Column temperature:	60 °C

Gradient: 0.0 – 0.4 min: 2 % B
 0.4 – 2.2 min: 2 % B → 98 % B
 2.2 – 2.6 min: 98 % B
 2.6 – 2.61 min: 98 % B → 2 % B
 2.61 – 3.0 min: 2 % B

5

GVK_LCMS_35

UPLC: Waters Acquity UPLC H-Class System

MS: Waters SQ Detector 2 (ESI);

Capillary voltage: 3.50 kV

10 Cone voltage: 50 V

Disolvation gas: 750 L/h

Disolvation temp.: 350 °C

MSD signal settings: Scan pos 100 – 1200, Scan neg 100 – 1200

Column: Aquity BEH C18, 2.1 x 50 mm, 1.7 µm

15 Eluent: A: 0.05 % formic acid in acetonitrile; B: 0.05 % formic acid in water

Detection signal: UV-diode array

Spectrum: range: 200 – 400 nm; resolution: 1.2 nm

Sampling rate: 10Points/sec

20 Injection: 0.5 µL injection with pre-inject wash 15 sec & post-inject wash 20 sec

Flow rate: 0.6 mL/min

Column temperature: 35 °C

Gradient: 0.0 – 0.3 min: 97 % B

25 0.3 – 2.2 min: 97 % B → 2 % B

2.2 – 3.30 min: 2 % B

3.30 – 4.50 min: 2 % B → 97 % B

4.51 – 5.50 min: 97 % B

GVK_LCMS_21

30 LC: Agilent Infinity 1290 series

MS: Agilent 6130 Quadrupole lcms(SQ)

MSD signal settings: Scan pos/neg 80-1200

Column: Aquity BEH C18 2.1 x 50 mm, 1.7 µm

	Eluent:	A: water + 0.1 % formic acid; B: acetonitrile (HPLC grade) + 0.1 % formic acid
	Detection signal:	UV 215/254 nm (bandwidth 4, reference off)
	Spectrum:	range: 200 – 400 nm; step: 2.0 nm
5	Peak width:	> 0.01 min (0.2 s)
	Injection:	0.5 µL standard injection
	Flow:	0.8 mL/min
	Column temperature:	60 °C
	Gradient:	0.0 – 0.2 min: 3 % B
10		0.2 – 1.5 min: 3% B → 95 % B
		1.5 – 2.5 min: 95 % B
		2.5 – 2.6min: 95% B → 3 % B
		2.6 – 3.2 min: 3 % B

GVK_LCMS_22

15	HPLC:	Agilent Infinity-1290 Series
	MS:	Agilent SQD-6150 (API-ES +/- 3000 V)
	MSD signal settings:	Scan pos 100 – 1000, Scan neg 100 – 1000
	Column:	Aquity BEH C18, 2.1 x 50 mm, 1.7 µm
	Eluent:	A: 0.1 % formic acid in water; B: 0.1 % formic acid in acetonitrile
20	Detection signal:	UV 215 nm (bandwidth 4, reference off)
	Spectrum:	range: 200 – 400 nm; step: 2 nm
	Peak width:	> 0.025 min (0.5 S)
	Injection:	0.5 µL injection with needle wash at flush port
	Flow rate:	0.8 mL/min
25	Column temperature:	45 °C
	Gradient:	0.0 – 0.2 min: 2 % B
		0.2 – 1.5 min: 2 % B → 98 % B
		1.5 – 2.6 min: 98 % B
		2.6 – 2.61 min: 98 % B → 2 % B
30		2.61 – 3.2 min: 2 % B

D_LC_SSTD

HPLC:	Agilent 1100/1200 (binary Pump 1)
Column:	(Waters) XBridge BEH C18, 30 x 3.0 mm; 2.5 µm

Eluent: A: 0.2 % formic acid in water; B: acetonitrile
 Detection signal: UV 254 nm (bandwidth 4, reference 550 nm, bandwidth 100)
 Spectrum: range: 190 – 400 nm; step: 2 nm
 Peak width: > 0.01 min
 5 Injection: 1.0 µL
 Flow rate: 2.30 mL/min
 Column temperature: 50 °C
 Gradient: 0.1 – 1.4 min: 97 % A → 100 % B
 1.4 – 1.6 min: 100 % B
 10 1.6 – 1.8 min: 100 % B → 97 % A

D_LC_BSTD

HPLC: Agilent 1100/1200 (binary Pump 1)
 Column: (Waters) XBridge BEH C18, 30 x 3.0 mm; 2.5 µm
 Eluent: A: 0.2 % ammonia (25 %) in water; B: acetonitrile
 15 Detection signal: UV 254 nm (bandwidth 4, reference 550 nm, bandwidth 100)
 Spectrum: range: 190 – 400 nm; step: 2 nm
 Peak width: > 0.01 min
 Injection: 1.0 µL
 Flow rate: 2.00 mL/min
 20 Column temperature: 50 °C
 Gradient: 0.1 – 1.4 min: 97 % A → 100 % B
 1.4 – 1.6 min: 100 % B
 1.6 – 1.8 min: 100 % B → 97 % A

GVK_LCMS_19

25 RRLC: Agilent RRLC
 MS: Agilent SQD
 Capillary voltage: 3.50 kV
 Cone voltage: 25 to 50 V
 Desolvation gas: 600 L/h
 30 Desolvation temp.: 350 °C
 Column: XBridge C18, 4.6 x 75 mm, 3.5 µm
 Eluent: A: 10 mM ammonium acetate; B: acetonitrile
 Flow rate: 2.0 mL/min

Column temperature: 35 °C

Gradient: [Time in min / % of B]: 0/10, 0.2/10, 2.5/75, 3.0/100, 4.8/100, 5.0/10


GVK_LCMS_41

- 5 UPLC: Waters Acquity-UPLC
MS: SQ Detector-2
Capillary voltage: 3.50 kV
Cone voltage: 50 V
Disolvation gas: 750 L/h
10 Disolvation temp.: 350 °C
Column: AQUITY UPLC BEH C18 1.7 µm, 2.1 x 50 mm
Eluent: A: 0.07 % in acetonitrile; B: 0.07 % formic acid in water
Flow rate: 0.6 mL/min
Column temperature: 35 °C
15 Gradient: [Time in min / % of B]: 0/97, 0.3/97, 2.2/2, 3.3/2, 4.5/2, 4.51/97

The compounds according to the invention and intermediates are prepared by the methods of synthesis described hereinafter in which the substituents of the general formulae have the meanings given hereinbefore. These methods are intended as an illustration of the invention without restricting its subject matter and the scope of the compounds claimed to these examples. Where the preparation of starting compounds is not described, they are commercially obtainable or their synthesis is described in the prior art or they may be prepared analogously to known prior art compounds or methods described herein, *i.e.* it is within the skills of an organic chemist to synthesize these compounds. Substances described in the literature can be prepared according to the published methods of synthesis.

General reaction scheme and summary of the syntheses routes towards compounds (I) according to the invention

Scheme 1:



Compounds (**I**) according to the invention can be prepared stepwise with syntheses routes depicted in scheme 1.

Acetal **A-2** can be prepared *via* acetalization of the corresponding aldehyde **A-1**.

A-7 can be prepared *via* different routes:

- 5 One approach starts with nucleophilic aromatic substitution of **A-2** with a substituted or unsubstituted malonic ester to provide intermediate **A-3** (introduction of R^2). Decarboxylation of intermediate **A-3** leads to **A-4**, which is converted with building block **B-5** (see below) in a nucleophilic aromatic substitution. Saponification of the resulting ester **A-5** and subsequent amidation with building block **C-1** (introduction of R^1) provides
10 intermediate **A-7** in a single step.


- In an alternative approach compound **A-2** is converted with a substituted or unsubstituted malonic ester (introduction of R^2) and then treated with building block **B-5** (see below) to furnish compound **A-5** in a single step. Saponification of the resulting ester **A-5** and subsequent amidation with building block **C-1** (introduction of R^1) provides intermediate
15 **A-7**.

- Another route begins with nucleophilic aromatic substitution of **A-2** with a substituted or unsubstituted malonic ester (introduction of R^2) followed by nucleophilic aromatic substitution with building block **B-5** (see below) to provide compound **A-6** in a single step. Direct conversion of **A-6** into **A-7** can be achieved by saponification of diester **A-6**, *in situ*
20 decarboxylation and subsequent amidation with building block **C-1** (introduction of R^1) in a single step.

Final compounds (**I**) can be prepared by deprotection of acetal **A-7** and cyclization. Compounds (**I**) can be further derivatized in optional steps (especially in R^1 and R^2) not depicted in scheme 1 to obtain further/additional compounds (**I**).

- 25 Thus, one aspect of the invention is the manufacture of a compound (**I**) as herein defined comprising ring closure of a compound **A-7** as herein defined; optionally further comprising reacting a compound **A-5** as herein defined with an amine **C-1** as herein defined; optionally further comprising reacting a compound **A-4** as herein defined with a compound **B-5** as herein defined; optionally further comprising reacting a compound **A-3**
30 as herein defined to obtain the compound **A-4** as herein defined; optionally further comprising reacting a compound **A-2** as herein defined to obtain the compound **A-3** as herein defined, optionally further comprising reacting a compound **A-1** as herein defined to obtain the compound **A-2** as herein defined.

Scheme 2:




Alternatively, compounds **(I)** according to the invention may be prepared stepwise with the synthetic route depicted in scheme 2.

Starting from β -oxo diesters **E-1** the corresponding α,β -dioxo esters **E-3** can be prepared via intermediates **E-2** obtained by reaction with DMF-acetale. Ring closure with amines **C-1** leads to the hydroxy pyridon ring **E-4**. Palladium catalyzed cross coupling after transfer of the hydroxy group to the corresponding sulfonate (e.g. tosylate, triflate etc., **E-5**) with amides yields pyridon amides **E-6**, which allow for second ring closure to obtain the desired bicyclic pyridopyrimidine-dione scaffold (**E-7**). **E-7** thus obtained can be

activated (with e.g. hexachlorocyclotriphosphazene, SOCl_2 , POCl_3 or the like) to be reacted with building block **B-5** to reach final compounds (**I**) according to the invention (which can also be derivatized in additional steps).

Thus, one aspect of the invention is the manufacture of a compound (**I**) as herein defined comprising activating a compound **E-7** as herein defined with an agent selected from hexachlorocyclotriphosphazene, SOCl_2 and POCl_3 and reacting activated **E-7** with a compound **B-5** as herein defined; optionally further comprising reacting a compound **E-6** as herein defined to obtain the compound **E-7** as herein defined; optionally further comprising reacting a compound **E-5** as herein defined with an amide $\text{R}^3\text{-CONH}_2$ as hererin defined; optionally further comprising reacting a compound **E-4** as herein defined to obtain the compound **E-5** as herein defined; optionally further comprising reacting a compound **E-3** as herein defined with an amine **C-1** as herein defined; optionally further comprising reacting a compound **E-2** as herein defined to obtain the compound **E-3** as herein defined; optionally further comprising reacting a compound **E-1** as herein defined to obtain the compound **E-2** as herein defined.

Scheme 3:



Building blocks **B-5** can be prepared stepwise, starting with a synthesis depicted in scheme 3.


(Hetero)aryl ethylamine systems **B-5** can be prepared from (hetero)aryl bromides **B-1**, which are converted via a metal catalyzed cross coupling into the corresponding acetyl (hetero)aryls **B-2**. The formation of chiral sulfinamides **B-3** is followed by stereoselective reduction to provide **B-4**. Finally cleavage of the sulfinamide provides the desired chiral (hetero)aryl ethylamine **B-5**.

Alternatively, acetyl (hetero)aryls **B-2** can be reduced enantioselectively to the corresponding alcohols **B-6** which are then transformed to azides **B-7** and can in turn be hydrogenated to obtain chiral building blocks **B-5**.

Thus, one aspect of the invention is the manufacture of a compound **B-5** as herein defined comprising reducing a compound **B-7** as herein defined; optionally further comprising reacting a compound **B-6** as herein defined to obtain the compound **B-7** as herein defined; optionally further comprising reducing a compound **B-2** as herein defined to obtain the compound **B-6** as herein defined.

Synthesis of intermediates A-2

Experimental procedure for the synthesis of **A-2a**





To a stirred solution of **A-1a** (150.00 g, 785.28 mmol, 1.0 equiv.) in benzene (1500 mL) ethylene glycol (48.69 g, 785.28 mmol, 1.0 equiv.) and a catalytic amount of *p*-toluenesulphonic acid (13.51 g, 78.53 mmol, 0.1 equiv.) are added. The reaction mixture is refluxed until full conversion of the starting material is observed. The solvent is evaporated under reduced pressure, the residue diluted with DCM and washed with an aqueous sodiumbicarbonate solution. Organic layers are combined, dried (Na_2SO_4) and concentrated under reduced pressure. Further purification by flash column chromatography (eluent: 10 % ethyl acetate in hexane) yields the desired product **A-2a**.

The following intermediates **A-2** (table 1) are available in an analogous manner starting from different pyrimidines **A-1**. The crude product **A-2** is purified by chromatography if


necessary.

Table 1:

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-2a		1.719	235	GVK_LCMS_22
A-2b		n.a.	n.a.	-

Synthesis of intermediates A-3



5 Experimental procedure for the synthesis of A-3a




A-2a (80.00 g, 340.33 mmol, 1.0 equiv.) is dissolved in DMSO (400 mL) and treated with cesium carbonate (220.53 g, 680.66 mmol, 2.0 equiv.) and dimethyl malonate (49.42 g, 374.36 mmol, 1.1 equiv.). The resulting mixture is heated to 80 °C for 10 h. After full conversion of the starting material the reaction mixture is diluted with ethyl acetate and poured on ice cold water. The aqueous layer is extracted with ethyl acetate. The organic layers are combined and washed with an aqueous solution of 0.1 N formic acid. The organic layer is dried (Na₂SO₄) and concentrated under reduced pressure. Further purification by flash column chromatography (eluent: 30 % ethyl acetate in hexane) yields the desired product **A-3a**.


The following intermediates **A-3** (table 2) are available in an analogous manner starting from different pyrimidines **A-2**. The crude product **A-3** is purified by chromatography if necessary.

Table 2:

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-3a		2.133	331	GVK_LCMS_34
A-3b		1.537	317	GVK_LCMS_34

Experimental procedure for the synthesis of A-3c





- 5 A stirred solution of 2-fluoro-malonic acid dimethyl ester (72.30 g, 481.99 mmol, 1.1 equiv.) in anhydrous DMF (300 mL) is cooled to 5 °C and treated portionwise with sodium hydride (20.16 g, 876.35 mmol, 2.0 equiv.). After stirring at room temperature for 10 minutes **A-2a** (103.00 g, 438.17 mmol, 1.0 equiv.) dissolved in DMF (50 mL) is added and the resulting mixture stirred for additional 2 h. After full conversion the reaction
- 10 mixture is poured on ice cold water and the aqueous layer extracted with ethylacetate. The organic layers are combined, dried (Na₂SO₄) and concentrated under reduced pressure. Further purification by flash column chromatography (eluent: 15 % ethyl acetate in hexane) yields the desired product **A-3c** (HPLC method: GVK_LCMS_31; t_{ret} = 1.756 min; [M+H]⁺ = 350).





Synthesis of intermediates A-5Experimental procedure for the synthesis of A-5a





- 5 **A-4a** (3135 mg, 11.50 mmol, 1.5 equiv.) and **B-5a** (1450 mg, 7.67 mmol, 1.0 equiv.) are dissolved in anhydrous DMSO (10 mL) and DIPEA is added (2670 μ L, 15.33 mmol, 2.0 equiv.). The reaction mixture is stirred at 80 °C for 6 h until complete conversion of **B-5a** is achieved. The reaction mixture is filtered and the filtrate purified by basic reversed phase chromatography (gradient elution: 25 % to 65 % acetonitrile in water) to furnish the desired product **A-5a**.
- 10 The following intermediates **A-5** (table 4) are available in an analogous manner starting from different pyrimidines **A-4** and amines **B-5**. The crude product **A-5** is purified by chromatography if necessary.

Table 4:





#	structure	t_{ret} [min]	$[M+H]^+$	HPLC method
A-5a		0.949	426.2	VAB


#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-5b		0.973	422.1	VAB
A-5c		1.002	426.2	VAB
A-5d		1.014	444.2	VAB
A-5e		1.143	440.3	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-5f		0.966	422.3	VAB
A-5g		1.027	440.3	VAB
A-5h		0.992	434.3	VAB
A-5i		0.863	456.2	VAB


#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-5j		0.903	412	VAB
A-5k		0.967	412	VAB
A-5l		0.944	426.0	VAB
A-5m		0.936	420.2	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-5n		0.874	470.1	VAB
A-5o		0.991	444.2	VAB
A-5p		1.028	458.1	VAB
A-5q		0.953	502.3	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-5r		1.017	496.3	VAB
A-5s		0.944	436.3	VAB
A-5t		0.971	416.1	VAB
A-5u		n.a.	n.a.	-

Experimental procedure for the synthesis of **A-5v**

A solution of **A-2b** (500 mg, 2.262 mmol, 1.0 equiv.) in anhydrous DMSO (4.0 mL) is treated with 2-fluoro-malonic acid dimethyl ester (281 μ L, 2.262 mmol, 1.0 equiv.) and sodium carbonate (360 mg, 3.393 mmol, 1.5 equiv.). The resulting mixture is stirred at room temperature for 4 d until full conversion of the starting material is observed. Triethylamine (627 μ L, 4.524 mmol, 2.0 equiv.) and **B-5a** (642 mg, 3.393 mmol, 1.5 equiv.) are added and the reaction mixture stirred at 80 °C for additional 16 h. After complete conversion the reaction is quenched with an aqueous NaHCO_3 solution and the aqueous layer extracted with DCM. The organic layers are combined, dried (Na_2SO_4) and concentrated under reduced pressure. Further purification by basic reversed phase chromatography (gradient elution: 15 % to 85 % acetonitrile in water) yields the desired product **A-5v** (HPLC method: VAB, $t_{\text{ret}} = 0.945$ min; $[\text{M}+\text{H}]^+ = 430.3$).



Synthesis of intermediates A-615 Experimental procedure for the synthesis of **A-6a**


A-2a (50 mg, 0.213 mmol, 1.0 equiv.) is dissolved in DMSO (0.5 mL) and treated with 2-fluoro-malonic acid dimethyl ester (27 μ L, 0.221 mmol, 1.0 equiv.) and potassium carbonate (58.8 mg, 0.425 mmol, 2.0 equiv.). The resulting mixture is stirred at 100 °C for

5 min until full conversion of the starting material is observed. Triethylamine (89 μ L, 0.639 mmol, 3.0 equiv.) and **B-5a** (60.2 mg, 0.318 mmol, 1.5 equiv.) are added and the reaction mixture stirred at 60 °C for additional 3 h. The reaction mixture is filtered and the filtrate purified by basic reversed phase chromatography (gradient elution: 35 % to 75 %
 5 acetonitrile in water) to furnish the desired product **A-6a**.

The following intermediates **A-6** (table 5) are available in an analogous manner starting from different pyrimidines **A-5**. The crude product **A-6** is purified by chromatography if necessary.

Table 5:




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-6a		1.109	530.2	VAB
A-6b		1.087	572.2	VAB





Synthesis of intermediates A-7Experimental procedure for the synthesis of **A-7a**





- A-5a** (200.0 mg, 0.470 mmol, 1.0 equiv.) is dissolved in DMSO (2 mL) and ACN (1 mL).
- 5 An aqueous sodium hydroxide solution (20 %, 313 μL , 1.881 mmol, 4 equiv.) is added and the resulting mixture stirred for 30 min until complete conversion of the starting material is observed. Triethylamine (130 μL , 0.933 mmol, 2.0 equiv.), 1-methyl-cyclopropylamine hydrochloride (62.8 mg, 0.583 mmol, 1.3 equiv.) and HATU (266.3 mg, 0.700 mmol, 1.5 equiv.) are added and the resulting mixture stirred for 20 min until complete
- 10 conversion is observed. Water is added and the mixture diluted with DCM. The aqueous layer is extracted with DCM, the organic layers are combined and dried with magnesium sulfate. The resulting crude product **A-7a** can be used without further purification in the next step.




- The following intermediates **A-7** (table 6) are available in an analogous manner starting
- 15 from different pyrimidines **A-5** and coupling with various amines **C-1** or their corresponding salts. The crude product **A-7** is purified by chromatography if necessary.




Table 6:




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7a		0.957	465.2	VAB
A-7b		0.903	483.2	VAB
A-7c		0.968	501.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7d		0.983	519.2	VAB
A-7e		0.992	479.3	VAB
A-7f		0.911	495.2	VAB
A-7g		0.896	528.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7h		1.011	527.2	VAB
A-7i		1.022	545.3	VAB
A-7j		1.002	507.2	VAB
A-7k		1.004	479.1	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7l		0.937	483.2	VAB
A-7m		0.962	501.2	VAB
A-7n		0.986	515.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7o		0.991	477.2	VAB
A-7p		0.988	495.2	VAB
A-7q		0.907	562.3	VAB





#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7r		0.978	549.2	VAB
A-7s		0.978	549.2	VAB
A-7t		0.978	549.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7u		0.942	495.2	VAB
A-7v		1.059	505.3	VAB
A-7w		1.080	519.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7x		1.024	537.3	VAB
A-7y		0.911	535.3	VAB
A-7z		0.963	461.3	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7aa		0.975	497.1	VAB
A-7ab		0.983	461.3	VAB
A-7ac		1.013	475.4	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7ad		0.936	491.1	VAB
A-7ae		0.950	572.3	VAB
A-7af		0.962	586.3	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7ag		0.906	516.2	VAB
A-7ah		0.988	465.2	VAB
A-7ai		0.864	451.3	VAB
A-7aj		1.171	453.2	VAB





#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7ak		1.059	467.3	VAB
A-7al		1.061	479.1	VAB
A-7am		1.036	495.0	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7an		1.098	493.3	VAB
A-7ao		1.051	529.3	VAB
A-7ap		0.996	495.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7aq		1.334	509.1	VAB
A-7ar		1.309	509.1	VAB
A-7as		0.966	522.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7at		1.154	505.1	VAB
A-7au		0.935	520.3	VAB
A-7av		1.003	493.3	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7aw		1.023	499.3	VAB
A-7ax		1.090	499.3	VAB
A-7ay		1.062	513.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7az		1.190	589.3	VAB
A-7ba		1.026	479.1	VAB
A-7bb		1.010	497.3	VAB
A-7bc		1.053	533.3	VAB





#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7bd		1.157	507.4	VAB
A-7be		1.044	479.3	VAB
A-7bf		1.069	493.3	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7bg		0.919	495.2	VAB
A-7bh		0.932	495.2	VAB
A-7bi		1.010	497.3	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7bj		1.061	529.3	VAB
A-7bk		1.007	563.2	VAB
A-7bl		1.001	509.1	VAB





#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7bm		1.198	509.3	VAB
A-7bn		1.127	585.3	VAB
A-7bo		0.978	534.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7bp		0.954	461.3	VAB
A-7bq		0.995	491.3	VAB
A-7br		0.986	545.3	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7bs		0.974	479.1	VAB
A-7bt		0.964	497.3	VAB
A-7bu		0.982	515.2	VAB
A-7bv		1.014	533.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7bw		1.003	509.1	VAB
A-7bx		0.964	473.3	VAB
A-7by		0.990	509.3	VAB
A-7bz		1.007	485.3	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7ca		0.904	514.3	VAB
A-7cb		0.973	535.3	VAB
A-7cc		0.991	549.2	VAB




#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7cd		0.906	451.3	VAB
A-7ce		0.896	469.3	VAB
A-7cf		0.909	487.3	VAB
A-7cg		0.952	505.3	VAB





#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7ch		0.936	463.3	VAB
A-7ci		0.906	487	VAB
A-7cj		0.906	487	VAB





#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7ck		0.889	469.3	VAB
A-7cl		0.956	463.3	VAB
A-7cm		0.940	481.1	VAB





#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7cn		0.990	523.3	VAB
A-7co		0.845	477.2	VAB
A-7cp		0.937	451	VAB





#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7cq		0.938	465	VAB
A-7cr		0.917	483.2	VAB
A-7cs		0.978	495	VAB
A-7ct		0.925	459.2	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7cu		0.967	471.2	VAB
A-7cv		1.022	499.3	VAB
A-7cw		0.915	539.3	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7cx		0.976	483.2	VAB
A-7cy		1.011	497.3	VAB
A-7cz		1.008	515.3	VAB
A-7da		0.980	539.3	VAB


#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7db		0.949	541.3	VAB
A-7dc		0.961	577.3	VAB
A-7dd		0.973	553.3	VAB
A-7de		0.969	571.3	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7df		1.016	553.3	VAB
A-7dg		1.033	589.3	VAB
A-7dh		0.953	505.3	VAB
A-7di		1.032	501.2	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7dj		1.018	519.2	VAB
A-7dk		0.970	497.3	VAB
A-7dl		0.935	475.3	VAB
A-7dm		0.962	511.1	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7dn		0.973	491.1	VAB
A-7do		n.a.	n.a.	-

Experimental procedure for the synthesis of **A-7dp**








- 5 **A-6a** (16.0 mg, 0.032 mmol, 1.0 equiv.) is dissolved in DMSO (1.5 mL). An aqueous sodium hydroxide solution (20 %, 16 μ L, 0.096 mmol, 3.0 equiv.) is added and the resulting mixture stirred for 30 min until complete conversion of the starting material is observed. Triethylamine (8.5 μ L, 0.061 mmol, 2.0 equiv.), 1-fluoromethylcyclopropylamine hydrochloride (4.8 mg, 0.038 mmol, 1.3 equiv.) and HATU (17.3 mg,

0.045 mmol, 1.5 equiv.) are added and the resulting mixture stirred for 20 min until complete conversion is observed. Water is added and the mixture diluted with DCM. The aqueous layer is extracted with DCM, the organic layers are combined and dried with magnesium sulfate. The resulting crude product **A-7dp** can be used without further purification in the next step.

The following intermediates **A-7** (table 7) are available in an analogous manner starting from different pyrimidines **A-6** and coupling with various amines **C-1** or their corresponding salts. The crude product **A-7** is purified by chromatography if necessary.

Table 7:


#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7dp		0.966	501.2	VAB
A-7dq		0.998	519.2	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7dr		0.977	519.2	VAB
A-7ds		0.979	501.4	VAB
A-7dt		1.001	567.2	VAB

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
A-7du		1.014	553.3	VAB
A-7dv		1.028	589.3	VAB

Synthesis of intermediates B-1




Experimental procedure for the synthesis of D-2a



- 5 To a stirred solution of **D-1a** (20.00 g, 172.24 mmol, 1.0 equiv.) in DCM (200 mL) is added EDCI (49.35 g, 258.37 mmol, 1.5 equiv.), triethylamine (26.14 g, 258.37 mmol, 1.5 equiv.), DMAP (0.21 g, 1.72 mmol, 0.01 equiv.) and *N,O*-dimethylhydroxylamine hydrochloride (25.20 g, 258.37 mmol, 1.5 equiv.) at 0 °C. The reaction mixture is warmed to room temperature and stirred for 16 h. After complete conversion of the starting material 1N HCl
- 10 is added to the reaction mixture. The aqueous layer is extracted with EtOAc, the combined organic layers are washed with saturated aqueous NaHCO₃, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by flash column chromatography (5 % ethyl acetate in hexane) yielding the desired product **D-2a**.


The following intermediates **D-2** (table 8) are available in an analogous manner starting from different acids **D-1**. The crude product **D-2** is purified by chromatography if necessary.

Table 8:

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
D-2a		1.034	160	GVK_LCMS_18
D-2b		1.045	160	GVK_LCMS_18
D-2c		1.059	160	GVK_LCMS_18


5

Experimental procedure for the synthesis of **D-3a**



To a stirred solution of **D-2a** (150 mg, 0.942 mmol, 1.0 equiv.) in THF (5 mL) is slowly added 3-bromophenylmagnesium bromide (0.5 N, 2.26 mL, 1.130 mmol, 1.2 equiv) at -15 °C. The reaction mixture is warmed to room temperature and stirred for 3 h. After complete conversion of the starting material, water is added. The aqueous layer is extracted with EtOAc, the organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by flash column chromatography (eluent: 10 % ethyl acetate in hexane) yielding the desired product **D-3a**.

15 Experimental procedure for the synthesis of **D-3b**






A stirred solution of 1,3-dibromo-2-fluoro-benzene (15.95 g, 62.82 mmol, 1.0 equiv.) in anhydrous THF (100 mL) is cooled to -78 °C. n-Butyllithium (1.6 N, 47.1 mL, 75.36 mmol,


1.2 equiv.) is added dropwise and the resulting mixture is stirred for 30 min at -78 °C. **D-2b** (10.00 g, 62.82 mmol, 1.0 equiv.) dissolved in THF (40 mL) is slowly added. After complete conversion, saturated aqueous ammonium chloride is added. The aqueous layer is extracted with EtOAc, the organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by chromatography on silica gel (gradient elution: 10 % to 20 % ethyl acetate in petroleum ether) yielding the desired product **D-3b**.

The following intermediates **D-3** (table 9) are available in an analogous manner starting from different amides **D-2**. The crude product **D-3** is purified by chromatography if necessary.

Table 9:

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
D-3a		n.a.	n.a.	-
D-3b		1.762	273	GVK_LCMS_34
D-3c		1.756	273	GVK_LCMS_34

Experimental procedure for the synthesis of **B-1a**








To a stirred solution of **D-3d** (150 g, 738.89 mmol, 1.0 equiv.) in DCM (1.5 L) is slowly added diethylaminosulfur trifluoride (178.64 g, 1108.33 mmol, 1.5 equiv) at 0 °C. The reaction mixture is warmed to room temperature and stirred for 16 h. After complete conversion of the starting material, ice water is added. The aqueous layer is extracted with


EtOAc, the organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product **B-1a** is used without further purification in the next step.

The following intermediates **B-1** (table 10) are available in an analogous manner starting from different bromobenzenes **D-3**. The crude product **B-1** is purified by chromatography if necessary.

Table 10:

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-1a		n.a.	n.a.	-
B-1b		1.66	n.a.	GVK_LCMS_34
B-1c		1.974	278	GVK_LCMS_31
B-1d		n.a.	n.a.	-
B-1e		n.a.	n.a.	-

Experimental procedure for the synthesis of **D-5a**




10

To a stirred solution of ethyl bromodifluoroacetate (126.50 g, 623 mmol, 2.5 equiv.) in


DMSO (225 mL) is added copper powder (39.26 g, 623 mmol, 2.5 equiv) at room temperature. After 1 h **B-1f** (75.00 g, 249.26 mmol, 1.0 equiv) is added and the resulting mixture heated to 70 °C and stirred for additional 3 h. After complete conversion of the starting material, ice water and EtOAc is added. Insolubles are removed by filtration and the aqueous layer is extracted with EtOAc. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by column chromatography (gradient elution: 0 % to 10 % ethyl acetate in petroleum ether) yielding the desired product **D-4a**.

Experimental procedure for the synthesis of **B-1g**



To a stirred solution of **D-4a** (100.00 g, 336.62 mmol, 1.0 equiv.) in anhydrous toluene (1 L) is slowly added methylmagnesium bromide (1 N, 1.34 L, 1340 mmol, 4.0 equiv) at 0 °C. The resulting mixture is stirred for 1 h at room temperature. After complete conversion of the starting material, saturated aqueous ammonium chloride is added and the aqueous layer is extracted with EtOAc. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by chromatography (25 % ethyl acetate in hexane) yielding the desired product **B-1g**.


Experimental procedure for the synthesis of **D-5a**



B-1h (480.00 g, 2274 mmol, 1.0 equiv.) and ethane-1,2-dithiol (213.78 g, 2274 mmol, 1.0 equiv.) are dissolved in toluene (5 L), TsOH (78.24 g, 454.9 mmol, 0.2 equiv.) is added at room temperature and the resulting mixture heated to reflux for 24 h. After complete conversion of the starting material, a 10 % aqueous NaOH solution is added and the aqueous layer is extracted with EtOAc. The organic layers are combined, washed with water and brine, dried over Na₂SO₄ and concentrated under reduced pressure. The crude


product is purified by chromatography (gradient elution: 0 % to 10 % ethyl acetate in petroleum ether) yielding the desired product **D-5a**.

Experimental procedure for the synthesis of **B-1i**




- 5 To a stirred solution of 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (793.8 g, 2785 mmol, 4.0 equiv.) in DCM (1.5 L) is added HF-pyridine (70 %, 800 mL, 30800 mmol, 44 equiv.) at -70 °C. To this mixture **D-5a** (200.00 g, 696.28 mmol, 1.0 equiv.) dissolved in DCM (0.5 L) is added dropwise. The temperature is kept below -60 °C for 4 h and then the resulting mixture is stirred for additional 16 h at room temperature. After complete
- 10 conversion of the starting material, a 2 N aqueous NaOH solution and a 30 % aqueous NaHSO₃ solution are added. The organic layer is washed with water and brine, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by column chromatography on silica gel (gradient elution: 0 % to 3 % ethyl acetate in petroleum ether) yielding the desired product **B-1i**.


- 15 Experimental procedure for the synthesis of **B-1j**



- B-1i** (140.00 g, 448.79 mmol, 1.0 equiv.) is dissolved in DCM (1.5 L) and DBU (102.32 g, 673.19 mmol, 1.5 equiv.) is added at 0 °C. The resulting mixture is stirred for 6 h at room temperature. After complete conversion of the starting material, the mixture is diluted with
- 20 DCM, washed with 0.5 N aqueous HCl, water and brine, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by chromatography (gradient elution: 0 % to 10 % ethyl acetate in petroleum ether) yielding the desired product **B-1j**.

Experimental procedure for the synthesis of B-1k

To a stirred solution of **B-1j** (130.00 g, 562.68 mmol, 1.0 equiv.) and 2-nitrobenzenesulfonyl chloride (124.35 g, 562.68 mmol, 1.0 equiv.) in acetonitrile (1.3 L) are slowly added K_3PO_4 (23.86 g, 112.54 mmol, 0.2 equiv) and hydrazine hydrate (56.27 g, 1125.36 mmol, 2.0 equiv) at 0 °C. The resulting mixture is stirred for 24 h at room temperature. After complete conversion of the starting material, water is added and the aqueous layer is extracted with EtOAc. The organic layers are combined, washed with water and brine, dried over Na_2SO_4 and concentrated under reduced pressure. The crude product is purified by column chromatography on silica gel (gradient elution: 0 % to 5 % ethyl acetate in petroleum ether) yielding the desired product **B-1k**.









Synthesis of intermediates B-2Experimental procedure for the synthesis of B-2a


B-1a (125.0 g, 555.54 mmol, 1.0 equiv.) is dissolved in anhydrous 1,4-dioxane (1.2 L). Triethylamine (140.27 mL, 1388.85 mmol, 2.5 equiv.) and tributyl(1-ethoxyvinyl)tin (240.66 g, 666.65 mmol, 1.2 equiv.) are added and the resulting solution is purged with argon for 15 min. Bis(triphenylphosphine)palladium(II)chloride (3.90 g, 5.6 mmol, 0.01 equiv.) is added and the reaction mixture heated to 100 °C in an autoclave for 16 h. After complete conversion of the starting material, the reaction mixture is cooled to room temperature and treated with 1 N HCl and stirred for additional 16 h. The aqueous layer is extracted with EtOAc, the combined organic layers are dried over Na_2SO_4 , filtered and the solvent is removed under reduced pressure. The crude product **B-2a** is used without further purification in the next step.

The following intermediates **B-2** (table 11) are available in an analogous manner starting from different bromobenzenes **B-1**. The crude product **B-2** is purified by chromatography


if necessary.

Table 11:


#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-2a		n.a.	n.a.	-
B-2b		1.665	185	GVK_LCMS_18
B-2c		2.023	241	GVK_LCMS_31
B-2d		n.a.	n.a.	-
B-2e		n.a.	n.a.	-
B-2f		1.95	247	GVK_LCMS_35
B-2g		2.04	197	GVK_LCMS_31
B-2h		1.699	185	GVK_LCMS_18

Experimental procedure for the synthesis of D-6a


To a stirred solution of **B-2i** (80.00 g, 368.60 mmol, 1.0 equiv.) in THF (800 mL) are added TMS-acetylene (54.31 g, 552.94 mmol, 1.5 equiv.), triethylamine (111.69 g, 1105.84 mmol, 3.0 equiv.), CuI (4.034 g, 36.86 mmol, 0.1 equiv.) and Pd(PPh₃)₂Cl₂ (25.88 g, 36.87 mmol, 0.1 equiv.) at room temperature. The resulting mixture is heated to reflux for 16 h. After complete conversion of the starting material, ice water and EtOAc are added and the aqueous layer is extracted with EtOAc. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by flash column chromatography (gradient elution: 0 % to 10 % ethyl acetate in hexane) yielding the desired product **D-6a**.

Experimental procedure for the synthesis of B-2j


To a stirred solution of **D-6a** (60.00 g, 256.04 mmol, 1.0 equiv.) in DCM (1.2 L) and methanol (1.2 L) is added potassium carbonate (353.87 g, 2560.38 mmol, 10.0 equiv.) at room temperature. The resulting mixture is stirred for 2 h. After complete conversion of the starting material, ice water is added and the aqueous layer is extracted with DCM. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by flash column chromatography (gradient elution: 20 % ethyl acetate in hexane) yielding the desired product **B-2j**.

Experimental procedure for the synthesis of B-2k

B-2j (98.00 g, 604.34 mmol, 1.0 equiv.) is dissolved in 1,1,1,3,3,3-hexafluoro propanol (500 mL) in a teflon flask. HF-pyridine (70 %, 250 mL, 9625 mmol, 16 equiv.) is added and the flask is sealed. The resulting mixture is stirred for 3 d at room temperature. After complete conversion of the starting material, ice water and EtOAc are added and the aqueous layer is extracted with EtOAc. The organic layers are combined, washed with a saturated aqueous NaHCO₃ solution and brine, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by flash column chromatography (gradient elution: 0 % to 20 % ethyl acetate in hexane) yielding the desired product **B-2k**.

Experimental procedure for the synthesis of D-8a

To a stirred solution of **D-7a** (120.00 g, 479.98 mmol, 1.0 equiv.) in THF (1.2 L) is added methylmagnesiumbromide (1 N, 720 mL, 720.00 mmol, 1.5 equiv) dropwise at -78 °C. The resulting mixture is stirred for 3 h at same temperature. After complete conversion of the starting material, a saturated aqueous ammonium chloride solution is added and the aqueous layer is extracted with EtOAc. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by chromatography on silica gel (gradient elution: 0 % to 10 % ethyl acetate in petroleum ether) yielding the desired product **D-8a**.

Experimental procedure for the synthesis of B-2l

To a stirred solution of **D-8a** (24.00 g, 90.21 mmol, 1.0 equiv.) in acetonitrile (240 mL) is added tetrapropylammonium perruthenate (3.166 g, 9.01 mmol, 0.1 equiv.) and

5

Experimental procedure for the synthesis of **D-9a**



10

Experimental procedure for the synthesis of **B-2m**




20

water and EtOAc are added and the aqueous layer is extracted with EtOAc. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by flash column chromatography yielding the desired product **B-2m**.

5 **Synthesis of intermediates B-3**

Experimental procedure for the synthesis of **B-3a**















B-2a (170.00 g, 903.53 mmol; 1.0 equiv.) is dissolved in THF (1.7 L). (*R*)-(+)-2-methyl-2-propanesulfonamide (164.13 g; 1355.33 mmol; 1.5 equiv.) and titanium tetraethoxide (618.03 g, 2710.66 mmol; 3.0 equiv.) are added at room temperature and the resulting reaction mixture is heated to 80 °C for 16 h. After complete conversion of the starting material, ice water and EtOAc are added and the aqueous layer is extracted with EtOAc. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product **B-3a** is used without further purification in the next step.


15 The following intermediates **B-3** and **D-10** (table 12) are available in an analogous manner starting from different acetophenones **B-2** and **D-9**. The crude product is purified by chromatography if necessary.

Table 12:

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-3a		n.a.	n.a.	-


#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-3b		1.896	288	GVK_LCMS_22
B-3c		1.898	344	GVK_LCMS_18
B-3d		1.897	362	GVK_LCMS_34
B-3e		1.916	362	GVK_LCMS_34
B-3f		1.750	350	GVK_LCMS_18
B-3g		1.877	300	GVK_LCMS_18

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-3h		n.a.	n.a.	-
B-3i		n.a.	n.a.	-
B-3j		2.036	292	GVK_LCMS_22
B-3k		2.32	310	GVK_LCMS_34
B-3l		1.502	306	GVK_LCMS_21
B-3m		n.a.	n.a.	-

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
D-11a		1.926	364	GVK_LCMS_18

Synthesis of intermediates B-4


Experimental procedure for the synthesis of B-4a









5 A solution of **B-3a** (170.00 g, 583.53 mmol; 1.0 equiv.) is dissolved in THF (1.7 L) and cooled to 0 °C. Sodium borohydride (21.59 g; 583.51 mmol; 1.0 equiv.) is added and the resulting reaction mixture stirred at room temperature for 6 h. After complete conversion of the starting material, ice water and EtOAc are added and the aqueous layer is extracted with EtOAc. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by chromatography (gradient elution: 33 % ethyl acetate in petroleum ether) yielding the desired product **B-4a**.


The following intermediates **B-4** (table 13) are available in an analogous manner starting from different sulfinamides **B-3**. The crude product **B-4** is purified by chromatography if necessary.

15 **Table 13:**


#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-4a		1.763	294	GVK_LCMS_18

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-4b		n.a.	n.a.	-
B-4c		1.841	346	GVK_LCMS_18
B-4d		1.854	364	GVK_LCMS_18
B-4e		1.86	364	GVK_LCMS_34
B-4f		2.1	352	GVK_LCMS_35
B-4g		1.842	302	GVK_LCMS_18


#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-4h		n.a.	n.a.	-
B-4i		1.85	364	GVK_LCMS_34
B-4j		1.77	294	GVK_LCMS_34
B-4k		2.27	312	GVK_LCMS_35
B-4l		1.48	308	GVK_LCMS_21
B-4m		1.99	3.08	GVK_LCMS_41

Experimental procedure for the synthesis of B-4n

A solution of **D-11a** (26.00 g, 71.55 mmol; 1.0 equiv.) is dissolved in THF (260 mL) and water (5 mL) cooled to -78 °C. Sodium borohydride (8.156 g; 214.63 mmol; 3.0 equiv.) is added and the resulting reaction mixture is warmed to room temperature and stirred for 4 h. After complete conversion of the starting material, ice water and EtOAc are added and the aqueous layer is extracted with EtOAc. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by reversed phase chromatography yielding the desired product **B-4n**.

Experimental procedure for the synthesis of B-4o

To a stirred solution of **B-4n** (5.00 g, 15.46 mmol, 1.0 equiv.) in THF (50 mL) are added cesium carbonate (15.12 g, 46.38 mmol, 3.0 equiv.) and 18-crown-6 (2.04 g, 7.73 mmol, 0.5 equiv.) at rt. The resulting mixture is heated to 80 °C for 16 h. After complete conversion of the starting material, water and EtOAc are added and the aqueous layer is extracted with EtOAc. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by flash column chromatography (80 % EtOAc in hexane) and reverse phase chromatography to yield the desired product **B-4o**.

Experimental procedure for the synthesis of **B-4p**





To a stirred solution of **B-4n** (1.00 g, 3.09 mmol, 1.0 equiv.) in THF (10 mL) is added potassium *tert*-butoxide (0.52 g, 4.64 mmol, 1.5 equiv.) and 18-crown-6 (2.04 g, 7.73 mmol, 0.5 equiv.) at rt. The resulting mixture is warmed to 80 °C for 16 h. After complete conversion of the starting material, water and EtOAc are added and the aqueous layer is extracted with EtOAc. The organic layers are combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by HPLC to yield the desired product **B-4p**.


10 **Synthesis of intermediates B-6**Experimental procedure for the synthesis of **B-6a**

Acetophenone **B-2n** (5.00 g, 24.3 mmol, 1.0 equiv.) is dissolved in toluene (15 mL) and 2-methyltetrahydrofuran (5.0 mL). Sodium *tert*-amylate (281 µL, 50 % in toluene, 1.21 mmol, 5 mol%) is added and the reaction mixture is purged with Ar atmosphere. (*R*)-RUCY-Xyl-BINAP (58.0 mg, 49.0 µmol, 0.2 mol%) is added to the reaction mixture. The reaction mixture is charged with hydrogen atmosphere (3 bar) and stirred at room temperature for 19 h until complete conversion of **B-2n** is achieved. The reaction is diluted with EtOAc (50 mL) and washed with water (1 × 50 mL), aqueous HCl (1 × 10 mL, 1.0 M) and water (1 × 50 mL). The organic layer is dried over Na₂SO₄, filtered and concentrated *in vacuo* to furnish the desired product.

The following intermediates **B-6** (table 14) are available in an analogous manner starting from different acetophenones **B-2**. The crude product is purified by chromatography if necessary.

Table 14:

#	structure	t _{ret} [min]	m/z	HPLC method
B-6a		1.283	[M+H] ⁺ : 191.1	D_LC_SSTD
B-6b		1.254	[M] ⁺ : 204.2	D_LC_SSTD
B-6c		1.281	[M] ⁺ : 208.2	D_LC_SSTD
B-6d		1.095	[M-H] ⁻ : 203.1	D_LC_SSTD

Synthesis of intermediates B-5Experimental procedure for the synthesis of B-5a








5






A solution of **B-4a** (13.20 g, 45.00 mmol; 1.0 equiv.) in 1,4-dioxane (100 mL) is cooled to 0 °C and treated with 4 N HCl in 1,4-dioxane (50.00 mL, 200.00 mmol, 4.4 equiv.). The reaction mixture is stirred for 3 h. After complete conversion of the starting material, the reaction mixture is concentrated under reduced pressure, the precipitate filtered and washed with diethyl ether to obtain the desired product **B-5a** as HCl salt.


10

The following benzyl amines **B-5** (table 15) are available in an analogous manner starting from different sulfinamides **B-4**. The crude product **B-5** is purified by chromatography if necessary and isolated as HCl salt.


Table 15:

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-5a		1.18	190	GVK_LCMS_34
B-5b		1.33	186	GVK_LCMS_22
B-5c		1.12	242	GVK_LCMS_31
B-5d		1.396	260	GVK_LCMS_31
B-5e		1.381	260	GVK_LCMS_31
B-5f		1.63	248	GVK_LCMS_02
B-5g		1.31	198	GVK_LCMS_31

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-5h		1.22	186	GVK_LCMS_31
B-5i		1.355	204	GVK_LCMS_31
B-5j		1.11	220	GVK_LCMS_31
B-5k		1.370	190	GVK_LCMS_31
B-5l		1.48	208	GVK_LCMS_35
B-5m		0.963	204	GVK_LCMS_21
B-5n		1.49	204	GVK_LCMS_41
B-5o		1.592	200	GVK_LCMS_19

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-5p		1.609	180	GVK_LCMS_19








Experimental procedure for the synthesis of **B-5k** (alternative)




- Alcohol **B-6a** (2.00 g, 9.61 mmol, 1.0 equiv.) is dissolved in anhydrous toluene (20 mL).
- 5 Diazabicycloundecene (1.73 mL, 11.5 mmol, 1.2 equiv.) and diphenylphosphonic azide (2.28 mL, 10.6 mmol, 1.1 equiv.) are added subsequently. The reaction mixture is stirred at 40 °C for 18 h until complete conversion of **B-6a** is achieved. The reaction mixture is cooled to room temperature and the organic layer is washed with aqueous Na₂CO₃ solution (2 × 10 mL). Azide **B-7a** thus obtained is not isolated but directly converted in the
- 10 next step.
- Pd/C (200 mg, 10% w/w, 10% Pd) is added to the organic layer. The reaction mixture is charged with a H₂ atmosphere (10 bar) and is stirred for 24 h until complete conversion of **B-7a** is achieved. The reaction is filtered and the volatiles are removed *in vacuo*. The residue is dissolved in methyl *tert*-butyl ether (30 mL) and treated with HCl in dioxane
- 15 (4.8 mL, 4 M). The white precipitate is filter, washed with methyl *tert*-butyl ether (20 mL) and further dried *in vacuo* to furnish the desired product **B-5k**. The crude product is purified by chromatography if necessary.

The following intermediates **B-5** (table 16) are available in an analogues manner starting from different alcohols **B-6** via azides **B-7**.


Table 16:

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-7a		n.a.	n.a.	n.a.
B-7b		n.a.	n.a.	n.a.
B-7c		n.a.	n.a.	n.a.
B-7d		n.a.	n.a.	n.a.
B-5k		1.290	190.0	D_LC_BSTD
B-5i		1.294	204.0	D_LC_BSTD
B-5l		1.311	208.0	D_LC_BSTD

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
B-5m		0.829	204.2	D_LC_SSTD


Synthesis of intermediates C-1

Experimental procedure for the synthesis of D-13a




- 5 To a stirred solution of **D-12a** (6.50 g, 35.093 mmol, 1.0 equiv.) in DCM (100 mL) is added diethylaminosulfur trifluoride (8.48 g, 52.67 mmol, 1.5 equiv) dropwise at 0 °C. The reaction mixture is slowly warmed to room temperature and stirred for 16 h. After complete conversion of the starting material, a saturated aqueous NaHCO₃ solution is added. The aqueous layer is extracted with DCM, the organic layers are combined, dried
- 10 over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by chromatography on silica gel (gradient elution: 0 % to 12 % ethyl acetate in petroleum ether) yielding the desired product **D-13a**.


Experimental procedure for the synthesis of C-1a




- 15 To a stirred solution of **D-13a** (2.40 g, 11.582 mmol, 1.0 equiv.) in 1,4-dioxane (5.0 mL) is added 4 N HCl in 1,4-dioxane (10 mL, 40.00 mmol, 3.5 equiv) at 0 °C. The reaction mixture is warmed to room temperature and stirred for 16 h. After complete conversion of the starting material the reaction mixture is concentrated under reduced pressure. *N*-Pentane is added to the crude product. The solid material is filtered and washed with
- 20 *n*-pentane to yield the desired product **C-1a** as HCl salt.

Experimental procedure for the synthesis of D-15a:


Amino acid **D-14a** (2.00 g, 19.7 mmol, 1.0 equiv.) and phthalic anhydride (2.92 g, 19.7 mmol, 1.0 equiv.) are suspended in acetic acid (20 mL). The reaction mixture is set to reflux and the obtained solution is stirred at this temperature for 3 h. The reaction mixture is cooled to 0 °C while the product **D-15a** crystallizes. Water (20 mL) is added and the reaction mixture is stirred at this temperature for 1 h. The precipitate is filtered, washed with water and further dried *in vacuo* to furnish the desired product. The crude product is further purified by chromatography if necessary ($t_{\text{ret}} = 1.03$ min; $[M-H]^+ = 230.0$; HPLC method D_LC_SSTD).

Experimental procedure for the synthesis of D-16a:


Acid **D-15a** (2.00 g, 8.6 mmol, 1.0 equiv.) is suspended in toluene (10 mL) and *N,N*-dimethylformamide (0.1 mL). Thionyl chloride (1.08 g, 9.1 mmol, 1.05 equiv.) is added at room temperature, then the reaction mixture is set to reflux and the obtained solution is stirred at this temperature for 3 h until complete conversion of **D-15a** is achieved (quench with benzylamine). The reaction mixture is cooled to room temperature while the product **D-16a** crystallizes. Heptane (10 mL) is added and the reaction mixture is cooled further to 5 °C and stirred at this temperature for 1 h. The precipitate is filtered, washed with water and further dried *in vacuo* to furnish the desired product. The crude product is further purified by chromatography if necessary ($t_{\text{ret}} = 1.27$ min; $[M+H]^+ = 246/247/248$; HPLC method D_LC_SSTD as benzylamide after quench with benzylamine; ^1H NMR (400 MHz, CDCl_3) δ ppm 1.70-1.85 (m, 2 H), 2.10-2.31 (m, 2 H), 7.64-8.11 (m, 4 H).

Experimental procedure for the synthesis of D-17a:


- Acyl chloride **D-16a** (2.00 g, 8.0 mmol, 1.0 equiv.) and 10% Pd/C (dry, 100 mg, 5% w/w) are suspended in tetrahydrofuran (12 mL) and 2,6-lutidine (1.03 g, 9.6 mmol, 1.2 equiv.).
- 5 The reaction mixture is hydrogenated at 3 bar and 30 °C. After 20 h additional catalyst is added (25 mg) and the hydrogenation is continued for additional 24 h. After this time the reaction mixture is filtered and the filtrate is evaporated. The residual is partitioned between toluene and an aqueous solution of NaHCO₃. The organic phase is separated and washed again with the NaHCO₃ solution and finally with a citric acid solution. The
- 10 organic layer is dried (Na₂SO₄) and concentrated under reduced pressure. The crude product is further purified by chromatography if necessary ($t_{\text{ret}} = 1.26$ min; $[M+H]^+ = 216$; HPLC method D_LC_BSTD).

Experimental procedure for the synthesis of D-18a:


- 15 Aldehyde **D-17a** (2.00 g, 9.3 mmol, 1.0 equiv.) is dissolved in dichloromethane (12 mL) and a 50 % toluene solution of bis(2-methoxyethyl)aminosulfur trifluoride (9.90 g, 22.3 mmol, 2.4 equiv.) is added slowly at room temperature. After two days of stirring the reaction mixture is cautiously treated with an aqueous solution of NaHCO₃ and with additional dichloromethane (15 mL). The organic layer is dried (Na₂SO₄) and concentrated
- 20 under reduced pressure. The crude product **D-18a** is further purified by chromatography or crystallization if necessary ($t_{\text{ret}} = 1.24$ min; $[M+H]^+ = 238$; HPLC method D_LC_SSTD). (Potential alternative fluorinating agents to be used for the conversion of **D-17a** are for example (diethylamino)difluorosulfonium tetrafluoroborate and sulfur tetrafluoride)

Experimental procedure for the synthesis of **C-1a**:

Imide **D-18a** (15.0 g, 63.2 mmol, 1.0 equiv.) is suspended in N-(2-hydroxyethyl)ethylenediamine (45 mL) and the mixture heated to 80 °C. After 2 h at this temperature the reaction mixture is cooled to 40 °C and methanol (30 mL) is added. The mixture is heated again to 80 °C and product **C-1a** is distilled off at 60-70 °C and atmospheric pressure as a methanol solution. The addition of methanol and the distillation step is repeated twice. The product **C-1a** can be directly used in the next step as a methanol solution (¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) = 0.44-0.81 (m, 4 H), 5.64 (t, *J* = 57.1 Hz, 1 H). Methanol protons at δ (ppm) = 3.18 (d, 3H), 4.08 (q, 1H) not reported).

Experimental procedure for the synthesis of **D-20a**

To a stirred solution of **D-19a** (5.00 g, 58.08 mmol, 1.0 equiv.) in DCM (50 mL) are added (S)-(-)-1-phenylethylamine (6.21 g, 58.08 mmol, 1.0 equiv) and magnesium sulfate (13.94 g, 116.16 mmol, 2.0 equiv.). The reaction mixture is stirred at room temperature for 16 h. After complete conversion of the starting material, insolubles are removed by filtration and the filtrate concentrated under reduced pressure. The crude product **D-20a** is used without further purification in the next step.


Experimental procedure for the synthesis of **D-21a** and **D-21b**

To a stirred solution of **D-20a** (8.00 g, 42.27 mmol, 1.0 equiv.) in acetonitrile (80 mL) and

DMF (8 mL) are added potassium hydrogen fluoride (2.64 g, 33.85 mmol, 0.8 equiv) and trifluoroacetic acid (5.30 g, 46.49 mmol, 1.1 equiv) at 0 °C. The reaction mixture is stirred for 10 min, then trimethyl-trifluoromethyl-silane (9.02 g, 63.43 mmol, 1.5 equiv.) is added and the resulting mixture warmed to room temperature and stirred for additional 16 h.

5 After complete conversion of the starting material, water and ethyl acetate are added, the aqueous layer extracted with ethyl acetate and the combined organic layers washed with brine and dried over Na₂SO₄ and concentrated under reduced pressure. The crude product is purified by SFC yielding the desired products **D-21a** and **D-21b**.

Experimental procedure for the synthesis of **C-1b**



D-21a (2.00 g, 7.714 mmol, 1.0 equiv.) is dissolved in 3 N HCl in methanol (6.00 mL, 18.00 mmol, 2.3 equiv.) and stirred for 5 min at room temperature. The solvent is removed under reduced pressure and the resulting solid material dissolved in methanol (20 mL). Palladium on alumina (10 wt-%, 200.00 mg, 0.188 mmol, 0.025 equiv.) is added and the


15 resulting mixture is stirred for 16 h at room temperature. After complete conversion, insolubles are removed by filtration and the filtrate is concentrated under reduced pressure. Diethyl ether is added to the crude product. The solid material is filtered and washed with diethyl ether to yield the desired product **C-1b** as HCl salt.

The following amines **C-1** (table 17) are available in an analogous manner starting from

20 different intermediates **D-21**. The crude product **C-1** is purified by chromatography if necessary and isolated as HCl salt.

Table 17:

#	structure	t _{ret} [min]	[M+H] ⁺	HPLC method
C-1b		n.a.	n.a.	-
C-1c		n.a.	n.a.	-


Experimental procedure for the synthesis of **D-23a**

To a stirred solution of **D-22a** (330 mg, 1.293 mmol, 1.0 equiv.) in THF (1.0 mL) are added triethylamine (99 %, 544 μ L, 3.875 mmol, 3.0 equiv) and TBTU (518.8 g, 1.616 mmol, 1.3 equiv.). The reaction mixture is stirred at room temperature for 15 min, then dimethylamine hydrochloride (110.7 mg, 1.358 mmol, 1.1 equiv.) is added. The resulting mixture is stirred for additional 2 h. After complete conversion of the starting material, water and DCM are added and the aqueous layer is extracted with DCM. The organic layers are combined, dried over MgSO_4 and concentrated under reduced pressure. The crude product **D-23a** is used without further purification in the next step.

The following amides **D-23** (table 18) are available in an analogous manner starting from different acids **D-22**. The crude product **D-23** is purified by chromatography if necessary.

Table 18:

#	structure	t_{ret} [min]	$[\text{M}+\text{H}]^+$	HPLC method
D-23a		0.816	283	VAB
D-23b		0.853	297	VAB



15 Experimental procedure for the synthesis of **C-1d**

D-23a (360 mg, 1.275 mmol, 1.0 equiv.) is dissolved in DCM (5.0 mL) and treated with

4 N HCl in 1,4-dioxane (2.55 mL, 10.200 mmol, 8.0 equiv.). The reaction mixture is stirred for 18 h. After complete conversion of the starting material, the solvents are partially removed under reduced pressure. The solid material is filtered and dried to yield the desired product **C-1d** as HCl salt.


- 5 The following amides **C-1** (table 19) are available in an analogous manner starting from different intermediates **D-23**. The crude product **C-1** is purified by chromatography if necessary and isolated as HCl salt.

Table 19:


#	structure	t_{ret} [min]	$[M+H]^+$	HPLC method
C-1d		n.a.	n.a.	-
C-1e		n.a.	n.a.	-

10 **Synthesis of intermediates E-3**


Experimental procedure for the synthesis of **E-3a**:




- At 0 °C dimethyl 3-oxopentanedioate **E-1a** (10.0 g, 57.4 mmol, 1.0 equiv.) is combined with *N,N*-dimethylformamide dimethyl acetal (7.60 mL, 57.4 mmol, 1.0 equiv.) in 2-methyltetrahydrofuran (75 mL). After stirring 3 h at 0–4 °C the reaction mixture is warmed to room temperature and aqueous hydrochloric acid (4 N, 26 mL) is slowly added (intermediate **E-2a** is not isolated). After stirring 3 h at room temperature the organic layer is separated, washed with water and then brine and concentrated under reduced pressure. The crude product **E-3a** is further purified by distillation or chromatography if necessary ($t_{\text{ret}} = 0.99/1.04$ min; $[M+H]^+ = 203$; HPLC method D_LC_SSTD).

Synthesis of intermediates E-6Experimental procedure for the synthesis of **E-6a**:


Tosylate **E-5a** (4.00 g, 9.78 mmol, 1.0 equiv.), acetamide (686 mg, 11.6 mmol, 1.0 equiv.),
 5 K_3PO_4 (2.26 g, 10.6 mmol, 1.1 equiv.), palladium(π -cinnamyl) chloride dimer (75.2 mg, 145 μ mol, 1.5 mol%) and Xantphos (168 mg, 290 μ mol, 3.0 mol%) are suspended in dioxane (20 mL). The reaction mixture is purged with Ar atmosphere and stirred at reflux for 2 h until complete conversion is achieved. At 50 °C conc. HCl (36 %, 83 μ L, 968 mmol, 0.1 equiv.) and water (40 mL) is added. The reaction is further cooled and stirred at room
 10 temperature for 2 h. The precipitate is filtered, washed with water and further dried *in vacuo* to furnish the desired product. The crude product **E-6a** is purified by chromatography if necessary (t_{ret} = 1.123 min; $[M+H]^+$ = 301.0; HPLC method D_LC_SSTD).

Synthesis of intermediates E-715 Experimental procedure for the synthesis of **E-7a**:

Acetamide **E-6a** (2.50 g, 8.33 mmol, 1.0 equiv.) is suspended in methanolic NH_3 (7 M, 20 mL) and stirred at room temperature for 5 days until complete conversion of **E-6a** is achieved. The solvent is removed *in vacuo* and the solid residue is dissolved in methanol
 20 (10 mL). Aqueous NaOH solution (1 M, 10 mL) is added to the reaction mixture and the reaction is stirred at 50 °C for 20 min. The reaction mixture is filtered, the residual solids are washed with methanol (5 mL) and the filtrate is neutralized using aqueous HCl (1 M, ca. 10 mL). The precipitate is filtered, washed with water and acetonitrile and further dried *in vacuo* to furnish the desired product. The crude product **E-7a** is purified by
 25 chromatography if necessary (t_{ret} = 0.885 min; $[M+H]^+$ = 268.0; HPLC method

D_LC_SSTD). **Synthesis of compounds (I) according to the invention**Experimental procedure for the synthesis of I-1





A-7a (272.0 mg, 0.586 mmol, 1.0 equiv.) is dissolved in 2-propanol (0.5 mL). An aqueous
 5 5 N HCl solution (586 μ L, 2.928 mmol, 5.0 equiv.) is added and the resulting mixture
 stirred for 1 hour at 50 °C until complete conversion of the starting material is observed.
 The reaction mixture is basified with aqueous ammonia, filtered and the filtrate purified by
 basic reversed phase chromatography (gradient elution: 20 % to 60 % acetonitrile in
 water) to furnish the desired product.






Experimental procedure for the synthesis of I-97






E-7a (1.00 g, 3.74 mmol, 1.0 equiv.) is suspended in MeCN (20 mL). K_3PO_4 (2.00 g,
 9.42 mmol, 2.5 equiv.) and hexachlorocyclotriphosphazene (1.30 g, 3.74 mmol,
 1.0 equiv.) is added and the reaction mixture is stirred at room temperature for 1 h. The
 15 phenethylamine hydrochloride **B-5k** (930 mg, 4.12 mmol, 1.1 equiv.) is added and the
 reaction mixture is stirred for further 1 h. Aqueous NH_3 solution (25 %, 2.0 mL) and after
 1 h a sat. K_2CO_3 solution (20 mL) are added. The biphasic reaction mixture is stirred at
 room temperature for 16 h and the organic layer is concentrated *in vacuo*. The crude
 product **I-97** is purified by chromatography if necessary.






The following compounds **I** (table 20) are available in an analogous manner starting from different acetals **A-7** or starting from different building blocks **E-7** and **B-5**. The crude products are purified by chromatography if necessary.






Table 20:






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-1		1.16 403	LCMSBAS1	5
I-2		1.16 421	LCMSBAS1	4
I-3		1.20 439	LCMSBAS1	5
I-4		1.22 457	LCMSBAS1	8






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-5		1.20 417	LCMSBAS1	12
I-6		1.15 433	LCMSBAS1	6
I-7		1.13 466	LCMSBAS1	8
I-8		1.27 465	LCMSBAS1	16
I-9		1.28 483	LCMSBAS1	30






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-10		1.25 445	LCMSBAS1	11
I-11		1.22 417	LCMSBAS1	5
I-12		1.16 421	LCMSBAS1	7
I-13		1.20 439	LCMSBAS1	11
I-14		1.24 453	LCMSBAS1	21






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-15		1.21 415	LCMSBAS1	8
I-16		1.22 433	LCMSBAS1	12
I-17		1.13 500	LCMSBAS1	5
I-18		1.06 433	LCMSBAS1	5
I-19		1.28 443	LCMSBAS1	2






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-20		1.18 399	LCMSBAS1	3
I-21		1.22 435	LCMSBAS1	3
I-22		1.19 399	LCMSBAS1	6
I-23		1.23 413	LCMSBAS1	4
I-24		1.20 510	LCMSBAS1	10






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-25		1.22 403	LCMSBAS1	13
I-26		1.13 389	LCMSBAS1	37
I-27		1.17 391	LCMSBAS1	38
I-28		1.23 417	LCMSBAS1	27
I-29		1.27 431	LCMSBAS1	24






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-30		1.27 467	LCMSBAS1	39
I-31		1.13 433	LCMSBAS1	11
I-32		1.13 449	LCMSBAS1	12
I-33		1.14 437	LCMSBAS1	38
I-34		1.14 437	LCMSBAS1	39






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-35		1.14 451	LCMSBAS1	9
I-36		1.26 527	LCMSBAS1	40
I-37		1.27 417	LCMSBAS1	5
I-38		1.29 435	LCMSBAS1	4
I-39		1.35 471	LCMSBAS1	18






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-40		1.17 445	LCMSBAS1	9
I-41		1.30 417	LCMSBAS1	14
I-42		1.33 431	LCMSBAS1	9
I-43		1.19 433	LCMSBAS1	5
I-44		1.18 433	LCMSBAS1	12






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-45		1.28 435	LCMSBAS1	11
I-46		1.35 467	LCMSBAS1	31
I-47		1.31 501	LCMSBAS1	33
I-48		1.27 501	LCMSBAS1	27
I-49		1.19 447	LCMSBAS1	6






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-50		1.19 399	LCMSBAS1	9
I-51		1.25 429	LCMSBAS1	31
I-52		1.21 417	LCMSBAS1	4
I-53		1.21 435	LCMSBAS1	4
I-54		1.24 453	LCMSBAS1	5






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-55		1.28 471	LCMSBAS1	13
I-56		1.27 447	LCMSBAS1	15
I-57		1.21 411	LCMSBAS1	2
I-58		1.24 447	LCMSBAS1	2
I-59		1.25 423	LCMSBAS1	3






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-60		1.14 452	LCMSBAS1	2
I-61		1.15 473	LCMSBAS1	1
I-62		1.10 389	LCMSBAS1	7
I-63		1.10 407	LCMSBAS1	7
I-64		1.14 425	LCMSBAS1	8

#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-65		1.16 443	LCMSBAS1	10
I-66		1.14 401	LCMSBAS1	15
I-67		1.12 425	LCMSBAS1	
I-68		1.12 425	LCMSBAS1	
I-69		1.10 407	LCMSBAS1	6






#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-70		1.15 401	LCMSBAS1	7
I-71		1.16 419	LCMSBAS1	7
I-72		1.16 473	LCMSBAS1	11
I-73		1.22 461	LCMSBAS1	3
I-74		1.04 415	LCMSBAS1	





#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-75		1.16 389	LCMSBAS1	15
I-76		1.15 403	LCMSBAS1	7
I-77		1.15 421	LCMSBAS1	6
I-78		1.21 433	LCMSBAS1	9
I-79		0.840 477.2	VAB	


#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-80		1.18 421	LCMSBAS1	9
I-81		1.18 439	LCMSBAS1	6
I-82		1.21 457	LCMSBAS1	5
I-83		1.20 457	LCMSBAS1	15
I-84		1.17 439	LCMSBAS1	8

#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-85		1.22 505	LCMSBAS1	9
I-86		0.41 435	LCMSBAS1	6
I-87		1.23 453	LCMSBAS1	4
I-88		1.06 479	LCMSBAS1	2
I-89		1.16 515	LCMSBAS1	2

#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-90		1.12 491	LCMSBAS1	4
I-91		1.13 509	LCMSBAS1	4
I-92		1.22 473	LCMSBAS1	4
I-93		1.27 509	LCMSBAS1	3
I-94		1.19 491	LCMSBAS1	5

#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-95		1.22 527	LCMSBAS1	5
I-96		1.15 443	LCMSBAS1	7
I-97		0.924 439.3	VAB	14
I-98		0.955 457.3	VAB	8
I-99		0.903 435.2	VAB	7



#	structure	t_{ret} [min], [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-100		0.912 453.2	VAB	30
I-101		0.864 413.1	VAB	4
I-102		0.884 449.1	VAB	4
I-103		0.901 429.2	VAB	5





Experimental procedure for the synthesis of **I-104** and **I-105**


A-7ct (90 mg, 0.196 mmol, 1.0 equiv.) is dissolved in 2-propanol (0.5 mL). An aqueous 2 N HCl solution (500 μ L, 1.000 mmol, 5.1 equiv.) is added and the resulting mixture stirred for 3 h at 50 °C until complete conversion of the starting material is observed. The reaction mixture is basified with aqueous ammonia, filtered and the filtrate purified by basic reversed phase chromatography (gradient elution: 15 % to 85 % acetonitrile in water) to furnish the desired products.

The following compounds **I** (table 21) are available in an analogous manner starting from different pyrimidines **A-7**. The crude products are purified by chromatography if necessary.

Table 21:

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-104		1.15 397	LCMSBAS1	4
I-105		0.94 375	LCMSBAS1	25

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-106		1.20 409	LCMSBAS1	4
I-107		1.00 387	LCMSBAS1	17
I-108		1.27 435	LCMSBAS1	4
I-109		1.09 415	LCMSBAS1	6






Experimental procedure for the synthesis of **I-110**






A-7ak (56.0 mg, 0.120 mmol, 1.0 equiv.) is dissolved in 2-propanol (0.5 mL). An aqueous 2 N HCl solution (500 μ L, 1.000 mmol, 8.3 equiv.) is added and the resulting mixture stirred for 1 h at 50 $^{\circ}$ C until complete conversion of the starting material is observed. An aqueous 2 M NaOH (500 μ L, 1.000 mmol, 8.3 equiv.) is added and the resulting mixture stirred for an additional hour at room temperature until complete conversion of the intermediate is observed. The reaction mixture is filtered and the filtrate purified by basic reversed phase chromatography (gradient elution: 30 % to 70 % acetonitrile in water) to furnish the desired product.






The following compounds **I** (table 22) are available in an analogous manner starting from different pyrimidines **A-7**. For the preparation of some compounds also other bases like aqueous ammonia have been used instead of aqueous NaOH. The crude products are purified by chromatography if necessary.






Table 22:

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-110		1.22 405	LCMSBAS1	25


#	structure	t _{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-111		1.14 433	LCMSBAS1	9
I-112		1.17 447	LCMSBAS1	13
I-113		1.21 447	LCMSBAS1	39
I-114		1.21 460	LCMSBAS1	26
I-115		1.30 443	LCMSBAS1	10

#	structure	t _{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-116		1.18 458	LCMSBAS1	4
I-117		1.22 487	LCMSBAS1	9
I-118		1.22 487	LCMSBAS1	20
I-119		1.22 487	LCMSBAS1	5
I-120		1.33 457	LCMSBAS1	6

#	structure	t _{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-121		1.28 475	LCMSBAS1	5
I-122		1.14 473	LCMSBAS1	3
I-123		1.16 429	LCMSBAS1	3
I-124		1.21 524	LCMSBAS1	2
I-125		1.37 486	LCMSBAS1	2

#	structure	t _{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-126		1.25 447	LCMSBAS1	5
I-127		1.31 523	LCMSBAS1	23
I-128		1.24 472	LCMSBAS1	2
I-129		1.24 483	LCMSBAS1	18
I-130		1.20 487	LCMSBAS1	1



Experimental procedure for the synthesis of **I-131**













I-1 (179.0 mg, 0.445 mmol, 1.0 equiv.) is dissolved in acetonitrile (1.5 mL). A solution of NBS (80.8 mg, 0.454 mmol, 1.0 equiv.) in acetonitrile (0.5 mL) is added dropwise and the resulting mixture stirred for 1 h at room temperature until complete conversion of the starting material is observed. The reaction mixture is diluted with DCM and washed with water. Organic layers are combined, dried (MgSO₄) and concentrated under reduced pressure to provide the desired product **I-131**.






The following compounds **I** (table 23) are available in an analogous manner starting from different compounds **I**. The crude products are purified by chromatography if necessary.






Table 23:

#	structure	t _{ret} [min] [M+H] ⁺	HPLC method
I-131		1.24 481	LCMSBAS1
I-132		0.92 551/553	VAB

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method
I-133		0.94 477/479	VAB
I-134		0.90 532/534	VAB
I-135		0.96 550/552	VAB
I-136		0.89 530/532	VAB
I-137		0.856 467.1/469	VAB


#	structure	t_{ret} [min] [M+H] ⁺	HPLC method
I-138		0.858 485/487	VAB
I-139		0.887 503/505.1	VAB
I-140		0.913 521/523	VAB
I-141		0.872 503/505	VAB
I-142		0.872 503/505	VAB

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method
I-143		0.890 479/481	VAB
I-144		0.805 485/487	VAB
I-145		0.900 479/481	VAB
I-146		0.914 497/499	VAB
I-147		0.950 539/541	VAB

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method
I-148		0.849 493/495	VAB
I-149		1.21 467	LCMSBAS1
I-150		0.897 481/483	VAB
I-151		0.912 499/501	VAB
I-152		0.940 511/513	VAB

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method
I-153		0.976 515/517	VAB
I-154		0.886 555/557	VAB





Experimental procedure for the synthesis of I-155













I-131 (23.0 mg, 0.048 mmol, 1.0 equiv.) is dissolved in dioxane (0.75 mL) and water (0.25 mL). Cesium carbonate (90 %, 26.0 mg, 0.072 mmol, 1.5 equiv.), bis(diphenylphosphino)ferrocene]dichloropalladium(II) (complex with DCM) (3.9 mg, 0.005 mmol, 0.1 equiv.) and trimethylboroxine (99 %, 7.5 μ L, 0.054 mmol, 1.1 equiv.) are added. The flask is flushed with argon and the reaction mixture stirred for 16 h at 100 °C until full conversion of the starting material is observed. The reaction mixture is diluted with DCM and washed with aqueous NaHCO₃. Organic layers are combined, dried (MgSO₄) and concentrated under reduced pressure. Purification by basic reversed phase chromatography (gradient elution: 25 % to 85 % acetonitrile in water) furnishes the desired product.






The following compounds I (table 24) are available in an analogous manner starting from different compounds I. The crude products are purified by chromatography if necessary.






Table 24:


#	structure	t_{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-155		1.25 417	LCMSBAS1	5
I-156		1.22 487	LCMSBAS1	4
I-157		1.28 413	LCMSBAS1	5
I-158		1.23 468	LCMSBAS1	2

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-159		1.37 488	LCMSBAS1	3
I-160		1.21 466	LCMSBAS1	2
I-161		1.16 403	LCMSBAS1	12
I-162		1.16 421	LCMSBAS1	7
I-163		1.20 439	LCMSBAS1	15

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-164		1.23 457	LCMSBAS1	13
I-165		1.17 439	LCMSBAS1	17
I-166		1.18 439	LCMSBAS1	26
I-167		1.20 415	LCMSBAS1	36
I-168		1.16 421	LCMSBAS1	9

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-169		1.21 415	LCMSBAS1	12
I-170		1.22 433	LCMSBAS1	12
I-171		1.31 475	LCMSBAS1	6
I-172		1.11 429	LCMSBAS1	14
I-173		1.22 403	LCMSBAS1	18

#	structure	t_{ret} [min] [M+H] ⁺	HPLC method	IC ₅₀ [nM]
I-174		1.21 417	LCMSBAS1	9
I-175		1.21 435	LCMSBAS1	13
I-176		1.28 447	LCMSBAS1	10
I-177		1.34 451	LCMSBAS1	2
I-178		1.18 491	LCMSBAS1	5

Experimental procedure for the synthesis of I-179

I-137 (50.0 mg, 0.107 mmol, 1.0 equiv.) is dissolved in dioxane (0.8 mL) and water (0.2 mL). Potassium carbonate (90 %, 33.0 mg, 0.214 mmol, 2.0 equiv.),
 5 bis(diphenylphosphino)ferrocene]dichloropalladium(II) (complex with DCM) (9.0 mg, 0.011 mmol, 0.1 equiv.) and cyclopropylboronic acid (14.0 mg, 0.161 mmol, 1.5 equiv.) are added. The flask is flushed with argon and the reaction mixture stirred for 4 h at 100 °C until full conversion of the starting material is observed. The reaction mixture is diluted with DCM and washed with aqueous NaHCO₃. Organic layers are combined, dried
 10 (MgSO₄) and concentrated under reduced pressure. Purification by basic reversed phase chromatography (gradient elution: 25 % to 85 % acetonitrile in water) furnishes the desired product (HPLC method: LCMSBAS1, $t_{\text{ret.}}$ = 1.27 min; $[M+H]^+$ = 429; IC₅₀ = 11 nM).

The following Examples describe the biological activity of the compounds according to the invention, without restricting the invention to these Examples.

15 Compounds of formula (I) are characterized by their many possible applications in the therapeutic field.

KRAS::SOS1 AlphaScreen Binding Assay

This assay can be used to examine the potency with which compounds inhibit the protein-protein interaction between SOS1 and KRAS G12D. This demonstrates the molecular
 20 mode of action of compounds. Low IC₅₀ values are indicative of high potency of the SOS1 inhibitor compound in this assay setting:

Reagents:

- GST-tagged SOS1 (564_1049_GST_TEV_ECO) produced in-house
- GST-TEV-SOS1 (564 -1049) is purchased from Viva Biotech Ltd.
- 25 • 6xHis-Tev-K-RasG12D(1-169)Avi is purchased from Xtal BioStructures, Inc. (Lot#

X129-110)

- GDP (Sigma Cat No G7127)
- AlphaLISA Glutathione Acceptor Beads (PerkinElmer, Cat No AL109)
- AlphaScreen Streptavidin Donor Beads (PerkinElmer Cat No 6760002)
- 5 • Assay plates: Proxiplate-384 PLUS, white (PerkinElmer, Cat No 6008289)

Assay buffer:

- 1 x PBS
- 0.1 % BSA
- 100 μ M EDTA or without EDTA (IC_{50} s in the tables are measured without EDTA
- 10 unless they are marked with an asterisk)
- 0.05 % Tween 20

KRAS::SOS1 GDP mix:

10 nM (final assay concentration) KRAS G12D, 10 μ M (final assay concentration) GDP and 5 nM (final assay concentration) GST-SOS1 are mixed in assay buffer prior to use and kept at room temperature.

15

Bead mix:

AlphaLISA Glutathione Acceptor Beads and AlphaScreen Streptavidin Donor Beads are mixed in assay buffer at a concentration of 10 μ g/mL (final assay concentration) each prior to use and kept at room temperature.

20 Assay protocol:

Compounds are diluted to a final start concentration of 100 μ M and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Access Labcyte Workstation with a Labcyte Echo 550 or 555 acoustic dispenser. For compound a start concentration of 100 μ M, 150 nL of compound solution is transferred per well in 11 concentrations in duplicate with serial 1:5 dilutions.

25

The assay is run using a fully automated robotic system in a darkened room below 100 Lux. 10 μ L of KRAS::SOS1 GDP mix is added into columns 1-24 to the 150 nL of compound solution (final dilution in the assay 1:100, final DMSO concentration 1 %).

After a 30 minute incubation time 5 μ L of bead mix is added into columns 1-23. Plates are kept at room temperature in a darkened incubator. After a further 60 minute incubation, the signal is measured using a PerkinElmer Envision HTS Multilabel Reader using the

30

AlphaScreen specifications from PerkinElmer. Each plate contains the following controls:

- diluted DMSO + KRAS::SOS1 GDP mix + bead mix
- diluted DMSO + KRAS::SOS1 GDP mix

Result calculation:

- 5 IC₅₀ values are calculated and analyzed using a 4 parametric logistic model.

Tables of example compounds disclosed herein contain IC₅₀ values determined using the above assay.

Cell Proliferation Assays

- 10 Cell proliferation assays are used to examine the potency with which compounds inhibit the SOS1-mediated proliferation, growth and apoptosis of cancer cell lines *in vitro*. This demonstrates the molecular mode of action of compounds. Low IC₅₀ values are indicative of high potency of the SOS1 inhibitor compounds in this assay setting. In particular, it is observed that SOS1 inhibitor compounds demonstrate a potent inhibitory effect on the proliferation of KRAS mutant human cancer cell lines and not on BRAF V600E mutant
- 15 cancer cell lines or non-addicted KRAS wild-type human cancer cell lines. This confirms the molecular mode of action of the SOS1 inhibitor compounds as selectively targeting cancer cells dependent on RAS-family protein function.

Cell proliferation assays are performed in three-dimensional (3D) anchorage-independent soft-agar conditions with the following human cell lines:

- 20 NCI-H358: human non-small cell lung cancer (NSCLC) with a KRAS G12C mutation;
PC-9: human non-small cell lung cancer (NSCLC) with wild-type KRAS and an EGFR del 19 mutation;
NCI-H1792: human non-small cell lung cancer (NSCLC) with a KRAS G12C mutation;
SW900: human non-small cell lung cancer (NSCLC) with a KRAS G12V mutation;
- 25 A-549: human non-small cell lung cancer (NSCLC) with a KRAS G12S mutation;
NCI-H2122: human non-small cell lung cancer (NSCLC) with a KRAS G12C mutation;
NCI-H520: human non-small cell lung cancer (NSCLC) with wild-type KRAS; MIA PaCa-2: human pancreatic cancer cell (PAC) with a KRAS G12C mutation;
DLD-1: human colon cancer with a KRAS G13D mutation;
- 30 A-375: human melanoma cancer with wildtype KRAS but a BRAFV600E mutation, which is used as a cell line being non-responsive following treatment with a SOS1 inhibitor compound;

All cell lines but PC-9 can be purchased from the American Type Culture Collection (ATCC). PC-9 can be purchased from the European Collection of Authenticated Cell Cultures (ECACC).

Materials used:

- 5 96-well Ultra low binding plates from Corning (CLS2474-24EA);
4 % Agarose Gel 1 x liquid 40 mL from Gibco (18300-012);
RPMI-1640 Medium (ATCC® 30-2001™);
Leibovitz's L-15 (Gibco, Cat# 11415);
F-12K (ATCC, Catalog No. 30-2004);
10 DMEM (Lonza BE12-604F); Fetal Bovine Serum (FBS) from HyClone (SH30071.03);
Alamar Blue from Invitrogen (DAL1100CSTM1)

Cell Culture:

- NCI-H358 cells (ATCC HTB-182), DLD-1 cells (ATCC CCL-221), NCI-H520 cells (ATCC HTB-182), PC-9 cells (ECACC 90071810), NCI-H1792 cells (ATCC CRL-5895) and NCI-
15 H2122 cells (ATCC CRL-5985) are grown in cell culture flasks (175 cm²) using RPMI medium. SW900 cells (ATCC HTB-59) are grown in Leibovitz's L-15 medium, A-549 cells (ATCC CCL-185) are grown in F12K medium, MIA PaCa-2 cells (ATCC CRL-1420) and A-375 (ATCC-CRL-1619) are grown in DMEM medium. Cell culture medium for all listed cell lines is supplemented with 10 % FBS. Cultures are incubated at 37 °C and 5 % CO₂ in
20 a humidified atmosphere, with medium change or subcultivation performed 2-3 times a week. SW900 cells are cultured without addition of CO₂.

Assay conditions:

The assay set-up is composed of the following:

- A bottom layer consisting of 90 µL medium including 1.2 % agarose
- 25 • A cell-layer consisting of 60 µL medium including 0.3 % agarose
- A top-layer consisting of 30 µL medium including the test compounds (without agarose)

- For preparation of the bottom layer, 4 % agarose (microwave-heated) is mixed with culture medium (incl. 2 % FBS for all cell lines but SW900, for SW900 10 % FCS was
30 used to achieve cellular growth) to a final dilution of 1.2 % agarose in medium. Each well is filled with 90 µL of the bottom layer suspension and cooled to room temperature for 1 h. For the cell-layer, cells are trypsinized, counted and plated in 60 µL culture medium (2 % FBS) including 0.3 % agarose (1500 cells per well). After cooling to room temperature for

1 h, plates are incubated overnight at 37 °C and 5 % CO₂ in a humidified atmosphere. The next day the compounds (30 µL of serial dilutions) are added in triplicates. The concentration of the test compounds covers a range between 10 micromolar and 0.13 nanomolar minimum. Compounds (Stock: 10 mM in 100 % DMSO) are diluted in medium. Cells are incubated at 37 °C and 5 % CO₂ in a humidified atmosphere for 14 days.

Detection:

20 µL/well of AlamarBlue suspension is added per well and incubated 4-24 hours in the incubator. Fluorescence intensity is determined using a fluorescence reader (2030 VICTOR X5, Perkin Elmer). The excitation wavelength is 544/15 nm, emission 590 nm. In monotherapy data is fitted by iterative calculation using a sigmoidal curve analysis program (GraphPAD Prism) with variable hill slope to ascertain IC₅₀ values.

ERK Phosphorylation Assay

ERK phosphorylation assays are used to examine the potency with which compounds inhibit the SOS1-mediated signal transduction in a KRAS mutant human cancer cell line *in vitro*. This demonstrates the molecular mode of action of compounds by interfering with the RAS-family protein signal transduction cascade. Low IC₅₀ values are indicative of high potency of the SOS1 inhibitor compounds in this assay setting. It is observed that SOS1 inhibitor compounds demonstrate an inhibitory effect on ERK phosphorylation in a KRAS mutant human cancer cell line, thus confirming the molecular mode of action of the SOS1 inhibitor compounds on RAS-family protein signal transduction.

ERK phosphorylation assays are performed using the following human cell lines:

DLD-1 (ATCC CCL-221): human colon cancer with a KRAS G13D mutation;

Materials used:

RPMLI-1640 Medium (ATCC® 30-2001™)

Fetal Bovine Serum (FBS) from HyClone (SH30071.03)

Non-essential amino acids from Thermo Fischer Scientific (11140035)

Pyruvate from Thermo Fischer Scientific (11360039)

Glutamax from Thermo Fischer Scientific (35050061)

384 plates from Greiner Bio-One (781182)

Proxiplate™ 384 from PerkinElmer Inc. (6008280)

AlphaLISA SureFire Ultra p-ERK1/2 (Thr202/Tyr204) Assay Kit (ALSU-PERK-A500)

EGF from Sigma (E4127)

Acceptor Mix: Protein A Acceptor Beads from PerkinElmer (6760137M)

Donor Mix: AlphaScreen Streptavidin-coated Donor Beads from PerkinElmer (6760002)

Trametinib

Staurosporine from Sigma Aldrich (S6942)

5 *Assay setup:*

DLD-1 cells (ATCC CCL-221) are seeded at 50,000 cells per well in /60 μ L of RPMI with 10 % FBS, non-essential amino acids, pyruvate and glutamax in Greiner TC 384 plates. The cells are incubated for 1 h at room temperature and then incubated overnight in an incubator at 37 °C and 5 % CO₂ in a humidified atmosphere. 60 nL compound solution (10 mM DMSO stock solution) is then added using a Labcyte Echo 550 device. After a 1 h incubation in the aforementioned incubator, 3 μ L Epidermal Growth Factor (EGF, final concentration 50 ng/mL) is added. 10 minutes later the medium is removed, and the cells lysed by addition of 20 μ L of 1.6-fold lysis buffer from the AlphaLISA SureFire Ultra pERK1/2 (Thr202/Tyr204) Assay Kit with added protease inhibitors, 100 nM trametinib + 100 nM staurosporine. After 20 minutes of incubation at room temperature with shaking, 6 μ L of each lysate sample is transferred to a 384-well Proxiplate and analyzed for pERK (Thr202/Tyr204) with the AlphaLISA SureFire Ultra pERK1/2 (Thr202/Tyr204) Assay Kit. 3 μ L Acceptor Mix and 3 μ L Donor Mix are added under subdued light and incubated for 2 h at room temperature in the dark, before the signal is measured on a Perkin Elmer Envision plate reader using 384 AlphaScreen settings for Proxiplates. Data are fitted by iterative calculation with variable hill slope. The sigmoidal curve slope is fitted using a default fitting curve to ascertain IC₅₀ values.

Table 25 shows data obtained with the disclosed assay for a selection of compounds (I) according to the invention.

25 **Table 25:**

#	pERK [nM]
I-21	113
I-23	111
I-37	61
I-38	33
I-39	62
I-45	47

#	pERK [nM]
I-49	81
I-52	96
I-53	74
I-57	63
I-58	89
I-59	113

#	pERK [nM]
I-61	95
I-73	88
I-87	100
I-97	81
I-101	79
I-102	67

#	pERK [nM]
I-103	70
I-104	87
I-106	113
I-108	77
I-119	70

#	pERK [nM]
I-121	93
I-123	118
I-124	85
I-126	51
I-130	38

#	pERK [nM]
I-156	57
I-157	104
I-171	93
I-176	120
I-177	91

Metabolic (microsomal) stability assay:

The metabolic degradation of the test compound is assayed at 37 °C with pooled liver microsomes (mouse (MLM), rat (RLM) or human (HLM)). The final incubation volume of 74 µL per time point contains TRIS buffer (pH 7.5; 0.1 M), magnesium chloride (6.5 mM), microsomal protein (0.5 mg/mL for mouse/rat, 1 mg/mL for human specimens) and the test compound at a final concentration of 1 µM. Following a short preincubation period at 37 °C, the reactions are initiated by addition of 8 µL beta-nicotinamide adenine dinucleotide phosphate, reduced form (NADPH, 10 mM) and terminated by transferring an aliquot into solvent after different time points. Additionally, the NADPH-independent degradation is monitored in incubations without NADPH, terminated at the last time point by addition of acetonitrile. The quenched incubations are pelleted by centrifugation (1811 g, 5 min). An aliquot of the supernatant is assayed by LC-MS/MS for the amount of parent compound.

In vitro intrinsic clearance ($CL_{int,in vitro}$) is calculated from the time course of the disappearance of the test drug during the microsomal incubation. Each plot is fitted to the first-order elimination rate constant as $C(t) = C_0 \cdot \exp(-k_e \cdot t)$, where $C(t)$ and C_0 are the concentration of unchanged test drug at incubation time t and that at preincubation and k_e is the disappearance rate constant of the unchanged drug. Subsequently, $CL_{int,in vitro}$ ($\mu\text{L min}^{-1} \cdot \text{amount protein}$) values are converted to $CL_{int,in vitro}$ ($\text{mL min}^{-1} \cdot \text{kg}^{-1}$) for the whole body. $CL_{int,in vitro}$ data are scaled up using physiological parameters. For better across species comparison the predicted clearance is expressed as percent of the liver blood flow [% QH] in the individual species. In general, high stability (corresponding to low % QH) of the compounds across species is desired.

Table 26 shows metabolic stability data obtained with the disclosed assay for a selection of compounds (I) according to the invention.

Table 26:

#	MLM [%QH]	RLM [%QH]	HLM [%QH]
I-3	51	<23	<24
I-4	46	<23	<24
I-10	41	40	<24
I-13	<24	52	<24
I-14	26	56	27
I-25	<24	<23	<24
I-27	88	<23	<24
I-47	<24	29	24
I-50	<24	<23	<24
I-51	<24	49	<24
I-54	55	<23	<24
I-69	<24	40	<24
I-71	<24	<23	<24
I-78	<24	<23	<24
I-80	50	<23	<24
I-81	64	<23	<24
I-83	<24	42	<24
I-84	<24	29	<24
I-85	55	<23	24
I-86	33	<23	<24
I-88	<24	<23	24
I-90	<24	<23	<24
I-96	30	<23	<24
I-97	<24	<23	<24
I-98	<24	<23	<24
I-101	59	<23	36
I-128	<24	<23	29
I-161	44	<23	31
I-165	54	<23	<24
I-166	48	38	24
I-169	64	44	<24

#	MLM [%QH]	RLM [%QH]	HLM [%QH]
I-170	51	37	<24
I-172	53	<23	<24

Time dependent inhibition of CYP3A4 assay (TDI 3A4):

The time dependent inhibition towards CYP3A4 is assayed in human liver microsomes (0.02 mg/mL) with midazolam (15 μ M) as a substrate. The test compounds are preincubated in presence of NADPH with human liver microsomes (0.2 mg/mL) at a concentration of 25 μ M for 0 min and 30 min. After preincubation, the incubate is diluted 1:10 and the substrate midazolam is added for the main incubation (15 min). The main incubation is quenched with acetonitrile and the formation of hydroxy-midazolam is quantified via LC/MS-MS. The formation of hydroxy-midazolam from the 30 min preincubation relative to the formation from the 0 min preincubation is used as a readout.

Values of less than 100 % mean that the substrate midazolam is metabolized to a lower extend upon 30 min preincubation compared to 0 min preincubation. In general low effects upon 30 min preincubation are desired (corresponding to values close to 100 %)

Table 27 shows data obtained with the disclosed assay for a selection of compounds (I) according to the invention.

Table 27:

#	TDI 3A4 [%]	#	TDI 3A4 [%]	#	TDI 3A4 [%]
I-20	93	I-75	86	I-126	88
I-22	87	I-80	86	I-127	97
I-25	90	I-81	85	I-128	98
I-49	92	I-87	81	I-163	82
I-50	82	I-89	83	I-166	87
I-53	84	I-98	85	I-169	84
I-54	84	I-123	87	I-170	82
I-57	87	I-125	93	I-173	84

Determination of off-target liabilities

There are certain targets (44) which are considered to be all strongly associated with *in vivo* adverse drug reactions as referenced in the publication *Reducing safety-related drug attrition: the use of in vitro pharmacological profiling*, Nature Review Drug Discovery 11,

909-922 (December 2012). This paper was a collaborative effort between several large pharmaceutical company safety pharmacology groups with the aim of establishing a core panel of *in vitro* pharmacology assays. Eurofins Cerep (France) commercially offers measurement on its SafetyScreen44TM Panel (comprising these off-targets) for a rational first step in preliminary safety assessments. Compounds (I) according to the invention may be assayed against this panel to investigate off-target liability.

Therapeutic Use

Due to their biological properties the compounds of the invention, their tautomers, racemates, enantiomers, diastereomers, mixtures thereof and the salts of all the above-mentioned forms may be suitable for treating diseases characterised by excessive or abnormal cell proliferation such as cancer.

For example, the following cancers, tumors and other proliferative diseases may be treated with compounds of the invention, without being restricted thereto:

Cancers/tumors/carcinomas of the head and neck: e.g. tumors/carcinomas/cancers of the nasal cavity, paranasal sinuses, nasopharynx, oral cavity (including lip, gum, alveolar ridge, retromolar trigone, floor of mouth, tongue, hard palate, buccal mucosa), oropharynx (including base of tongue, tonsil, tonsillar pillar, soft palate, tonsillar fossa, pharyngeal wall), middle ear, larynx (including supraglottis, glottis, subglottis, vocal cords), hypopharynx, salivary glands (including minor salivary glands);

cancers/tumors/carcinomas of the lung: e.g. non-small cell lung cancer (NSCLC) (squamous cell carcinoma, spindle cell carcinoma, adenocarcinoma, large cell carcinoma, clear cell carcinoma, bronchioalveolar), small cell lung cancer (SCLC) (oat cell cancer, intermediate cell cancer, combined oat cell cancer);

neoplasms of the mediastinum: e.g. neurogenic tumors (including neurofibroma, neurilemoma, malignant schwannoma, neurosarcoma, ganglioneuroblastoma, ganglioneuroma, neuroblastoma, pheochromocytoma, paraganglioma), germ cell tumors (including seminoma, teratoma, non-seminoma), thymic tumors (including thymoma, thymolipoma, thymic carcinoma, thymic carcinoid), mesenchymal tumors (including fibroma, fibrosarcoma, lipoma, liposarcoma, myxoma, mesothelioma, leiomyoma, leiomyosarcoma, rhabdomyosarcoma, xanthogranuloma, mesenchymoma, hemangioma, hemangioendothelioma, hemangiopericytoma, lymphangioma, lymphangiopericytoma, lymphangiomyoma);

- cancers/tumors/carcinomas of the gastrointestinal (GI) tract: *e.g.* tumors/carcinomas/cancers of the esophagus, stomach (gastric cancer), pancreas, liver and biliary tree (including hepatocellular carcinoma (HCC), *e.g.* childhood HCC, fibrolamellar HCC, combined HCC, spindle cell HCC, clear cell HCC, giant cell HCC, carcinosarcoma HCC, sclerosing HCC; hepatoblastoma; cholangiocarcinoma; cholangiocellular carcinoma; hepatic cystadenocarcinoma; angiosarcoma, hemangioendothelioma, leiomyosarcoma, malignant schwannoma, fibrosarcoma, Klatzkin tumor), gall bladder, extrahepatic bile ducts, small intestine (including duodenum, jejunum, ileum), large intestine (including cecum, colon, rectum, anus; colorectal cancer, gastrointestinal stroma tumor (GIST)),
- 5 genitourinary system (including kidney, *e.g.* renal pelvis, renal cell carcinoma (RCC), nephroblastoma (Wilms' tumor), hypernephroma, Grawitz tumor; ureter; urinary bladder, *e.g.* urachal cancer, urothelial cancer; urethra, *e.g.* distal, bulbomembranous, prostatic; prostate (androgen dependent, androgen independent, castration resistant, hormone independent, hormone refractory), penis);
- 10 cancers/tumors/carcinomas of the testis: *e.g.* seminomas, non-seminomas,
- Gynecologic cancers/tumors/carcinomas: *e.g.* tumors/carcinomas/cancers of the ovary, fallopian tube, peritoneum, cervix, vulva, vagina, uterine body (including endometrium, fundus);
- cancers/tumors/carcinomas of the breast: *e.g.* mammary carcinoma (infiltrating ductal, colloid, lobular invasive, tubular, adenocystic, papillary, medullary, mucinous), hormone receptor positive breast cancer (estrogen receptor positive breast cancer, progesterone receptor positive breast cancer), Her2 positive breast cancer, triple negative breast cancer, Paget's disease of the breast;
- 20 cancers/tumors/carcinomas of the endocrine system: *e.g.* tumors/carcinomas/cancers of the endocrine glands, thyroid gland (thyroid carcinomas/tumors; papillary, follicular, anaplastic, medullary), parathyroid gland (parathyroid carcinoma/tumor), adrenal cortex (adrenal cortical carcinoma/tumors), pituitary gland (including prolactinoma, craniopharyngioma), thymus, adrenal glands, pineal gland, carotid body, islet cell tumors, paraganglion, pancreatic endocrine tumors (PET; non-functional PET, PPoma, gastrinoma, insulinoma, VIPoma, glucagonoma, somatostatinoma, GRFoma, ACTHoma),
- 30 carcinoid tumors;
- sarcomas of the soft tissues: *e.g.* fibrosarcoma, fibrous histiocytoma, liposarcoma,

- leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, lymphangiosarcoma, Kaposi's sarcoma, glomus tumor, hemangiopericytoma, synovial sarcoma, giant cell tumor of tendon sheath, solitary fibrous tumor of pleura and peritoneum, diffuse mesothelioma, malignant peripheral nerve sheath tumor (MPNST), granular cell tumor, clear cell
- 5 sarcoma, melanocytic schwannoma, plexosarcoma, neuroblastoma, ganglioneuroblastoma, neuroepithelioma, extraskeletal Ewing's sarcoma, paraganglioma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, mesenchymoma, alveolar soft part sarcoma, epithelioid sarcoma, extrarenal rhabdoid tumor, desmoplastic small cell tumor;
- 10 sarcomas of the bone: e.g. myeloma, reticulum cell sarcoma, chondrosarcoma (including central, peripheral, clear cell, mesenchymal chondrosarcoma), osteosarcoma (including parosteal, periosteal, high-grade surface, small cell, radiation-induced osteosarcoma, Paget's sarcoma), Ewing's tumor, malignant giant cell tumor, adamantinoma, (fibrous) histiocytoma, fibrosarcoma, chordoma, small round cell sarcoma, hemangioendothelioma,
- 15 hemangiopericytoma, osteochondroma, osteoid osteoma, osteoblastoma, eosinophilic granuloma, chondroblastoma;
- mesothelioma: e.g. pleural mesothelioma, peritoneal mesothelioma;
- cancers of the skin: e.g. basal cell carcinoma, squamous cell carcinoma, Merkel's cell carcinoma, melanoma (including cutaneous, superficial spreading, lentigo maligna, acral
- 20 lentiginous, nodular, intraocular melanoma), actinic keratosis, eyelid cancer;
- neoplasms of the central nervous system and brain: e.g. astrocytoma (cerebral, cerebellar, diffuse, fibrillary, anaplastic, pilocytic, protoplasmic, gemistocytary), glioblastoma, gliomas, oligodendrogliomas, oligoastrocytomas, ependymomas, ependymoblastomas, choroid plexus tumors, medulloblastomas, meningiomas,
- 25 schwannomas, hemangioblastomas, hemangiomas, hemangiopericytomas, neuromas, ganglioneuromas, neuroblastomas, retinoblastomas, neurinomas (e.g. acoustic), spinal axis tumors;
- lymphomas and leukemias: e.g. B-cell non-Hodgkin lymphomas (NHL) (including small lymphocytic lymphoma (SLL), lymphoplasmacytoid lymphoma (LPL), mantle cell
- 30 lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL)), T-cell non-Hodgkin lymphomas (including anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma

- (CTCL), peripheral T-cell lymphoma (PTCL)), lymphoblastic T-cell lymphoma (T-LBL), adult T-cell lymphoma, lymphoblastic B-cell lymphoma (B-LBL), immunocytoma, chronic B-cell lymphocytic leukemia (B-CLL), chronic T-cell lymphocytic leukemia (T-CLL) B-cell small lymphocytic lymphoma (B-SLL), cutaneous T-cell lymphoma (CTLC), primary
 5 central nervous system lymphoma (PCNSL), immunoblastoma, Hodgkin's disease (HD) (including nodular lymphocyte predominance HD (NLPHD), nodular sclerosis HD (NSHD), mixed-cellularity HD (MCHD), lymphocyte-rich classic HD, lymphocyte-depleted HD (LDHD)), large granular lymphocyte leukemia (LGL), chronic myelogenous leukemia (CML), acute myelogenous/myeloid leukemia (AML), acute lymphatic/lymphoblastic
 10 leukemia (ALL), acute promyelocytic leukemia (APL), chronic lymphocytic/lymphatic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia, chronic myelogenous/myeloid leukemia (CML), myeloma, plasmacytoma, multiple myeloma (MM), plasmacytoma, myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML);
- 15 cancers of unknown primary site (CUP);

All cancers/tumors/carcinomas mentioned above which are characterized by their specific location/origin in the body are meant to include both the primary tumors and the metastatic tumors derived therefrom.

- All cancers/tumors/carcinomas mentioned above may be further differentiated by their
 20 histopathological classification:

- Epithelial cancers, e.g. squamous cell carcinoma (SCC) (carcinoma *in situ*, superficially invasive, verrucous carcinoma, pseudosarcoma, anaplastic, transitional cell, lymphoepithelial), adenocarcinoma (AC) (well-differentiated, mucinous, papillary, pleomorphic giant cell, ductal, small cell, signet-ring cell, spindle cell, clear cell, oat cell,
 25 colloid, adenosquamous, mucoepidermoid, adenoid cystic), mucinous cystadenocarcinoma, acinar cell carcinoma, large cell carcinoma, small cell carcinoma, neuroendocrine tumors (small cell carcinoma, paraganglioma, carcinoid); oncocytic carcinoma;
- Nonepithelial cancers, e.g. sarcomas (fibrosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, hemangiosarcoma, giant cell sarcoma, lymphosarcoma, fibrous histiocytoma, liposarcoma, angiosarcoma, lymphangiosarcoma, neurofibrosarcoma), lymphoma, melanoma, germ cell tumors, hematological neoplasms,
- 30

mixed and undifferentiated carcinomas;

The compounds of the invention may be used in therapeutic regimens in the context of first line, second line, or any further line treatments.

The compounds of the invention may be used for the prevention, short-term or long-term
5 treatment of the above-mentioned diseases, optionally also in combination with radiotherapy and/or surgery.

Of course, the above also includes the use of the compounds of the invention in various methods of treating the above diseases by administering a therapeutically effective dose to a patient in need thereof, as well as the use of these compounds for the manufacture of
10 medicaments for the treatment of such diseases, as well as pharmaceutical compositions including such compounds of the invention, as well as the preparation and/or manufacture of medicaments including such compounds of the invention, and the like.

Combinations with other active substances

The compounds of the invention may be used on their own or in combination with one or
15 several other pharmacologically active substances such as state-of-the-art or standard-of-care compounds, such as *e.g.* cell proliferation inhibitors, *anti*-angiogenic substances, steroids or immune modulators/checkpoint inhibitors, and the like.

Pharmacologically active substances which may be administered in combination with the compounds according to the invention, include, without being restricted thereto,
20 hormones, hormone analogues and antihormones (*e.g.* tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, aminoglutethimide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors (*e.g.* anastrozole, letrozole, liarozole, vorozole, exemestane, atamestane), LHRH agonists and antagonists (*e.g.*
25 goserelin acetate, luprolide), inhibitors of growth factors and/or of their corresponding receptors (growth factors such as for example platelet derived growth factor (PDGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insuline-like growth factors (IGF), human epidermal growth factor (HER, *e.g.* HER2, HER3, HER4) and hepatocyte growth factor (HGF) and/or their
30 corresponding receptors), inhibitors are for example (*anti*-)growth factor antibodies, (*anti*-)growth factor receptor antibodies and tyrosine kinase inhibitors, such as for example cetuximab, gefitinib, afatinib, nintedanib, imatinib, lapatinib, bosutinib, bevacizumab and

trastuzumab); antimetabolites (e.g. antifolates such as methotrexate, raltitrexed, pyrimidine analogues such as 5-fluorouracil (5-FU), ribonucleoside and deoxyribonucleoside analogues, capecitabine and gemcitabine, purine and adenosine analogues such as mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine (ara C), fludarabine); antitumour antibiotics (e.g. anthracyclins such as doxorubicin, doxil (pegylated liposomal doxorubicin hydrochloride, myocet (non-pegylated liposomal doxorubicin), daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin, dactinomycin, plicamycin, streptozocin); platinum derivatives (e.g. cisplatin, oxaliplatin, carboplatin); alkylation agents (e.g. estramustin, meclorethamine, melphalan, chlorambucil, busulphan, dacarbazine, cyclophosphamide, ifosfamide, temozolomide, nitrosoureas such as for example carmustin and lomustin, thiotepa); antimitotic agents (e.g. Vinca alkaloids such as for example vinblastine, vindesine, vinorelbine and vincristine; and taxanes such as paclitaxel, docetaxel); angiogenesis inhibitors (e.g. tasquinimod), tubuline inhibitors; DNA synthesis inhibitors, PARP inhibitors, topoisomerase inhibitors (e.g. epipodophyllotoxins such as for example etoposide and etopophos, teniposide, amsacrin, topotecan, irinotecan, mitoxantrone), serine/threonine kinase inhibitors (e.g. PDK 1 inhibitors, Raf inhibitors, A-Raf inhibitors, B-Raf inhibitors, C-Raf inhibitors, mTOR inhibitors, mTORC1/2 inhibitors, PI3K inhibitors, PI3K α inhibitors, dual mTOR/PI3K inhibitors, STK 33 inhibitors, AKT inhibitors, PLK 1 inhibitors, inhibitors of CDKs, Aurora kinase inhibitors), tyrosine kinase inhibitors (e.g. PTK2/FAK inhibitors), protein protein interaction inhibitors (e.g. IAP activator, Mcl-1, MDM2/MDMX), MEK inhibitors, ERK inhibitors, FLT3 inhibitors, BRD4 inhibitors, IGF-1R inhibitors, TRAILR2 agonists, Bcl-xL inhibitors, Bcl-2 inhibitors, Bcl-2/Bcl-xL inhibitors, ErbB receptor inhibitors, BCR-ABL inhibitors, ABL inhibitors, Src inhibitors, rapamycin analogs (e.g. everolimus, temsirolimus, ridaforolimus, sirolimus), androgen synthesis inhibitors, androgen receptor inhibitors, DNMT inhibitors, HDAC inhibitors, ANG1/2 inhibitors, CYP17 inhibitors, radiopharmaceuticals, proteasome inhibitors, immunotherapeutic agents such as immune checkpoint inhibitors (e.g. CTLA4, PD1, PD-L1, PD-L2, LAG3, and TIM3 binding molecules/immunoglobulins, such as e.g. ipilimumab, nivolumab, pembrolizumab), ADCC (antibody-dependent cell-mediated cytotoxicity) enhancers (e.g. anti-CD33 antibodies, anti-CD37 antibodies, anti-CD20 antibodies), t-cell engagers (e.g. bi-specific T-cell engagers (BiTEs[®]) like e.g. CD3 x BCMA, CD3 x CD33, CD3 x CD19), PSMA x CD3), tumor vaccines and various chemotherapeutic agents such as amifostin, anagrelid, clodronat, filgrastin, interferon, interferon alpha, leucovorin, procarbazine, levamisole,

mesna, mitotane, pamidronate and porfimer.

When two or more substances or principles are to be used as part of a combined treatment regimen, they can be administered *via* the same route of administration or *via* different routes of administration, at essentially the same time (*i.e.* simultaneously, concurrently) or at different times (*e.g.* sequentially, successively, alternately, consecutively, or according to any other sort of alternating regime).

When the substances or principles are to be administered simultaneously *via* the same route of administration, they may be administered as different pharmaceutical formulations or compositions or as part of a combined pharmaceutical formulation or composition. Also, when two or more active substances or principles are to be used as part of a combined treatment regimen, each of the substances or principles may be administered in the same amount and according to the same regimen as used when the compound or principle is used on its own, and such combined use may or may not lead to a synergistic effect. However, when the combined use of the two or more active substances or principles leads to a synergistic effect, it may also be possible to reduce the amount of one, more or all of the substances or principles to be administered, while still achieving the desired therapeutic action. This may for example be useful for avoiding, limiting or reducing any unwanted side-effects that are associated with the use of one or more of the substances or principles when they are used in their usual amounts, while still obtaining the desired pharmacological or therapeutic effect.

Of course, the above includes the preparation and methods of preparing, the compounds of the invention for the combined use with the above combination partners. Also included are the preparation, and methods of preparing, the above-mentioned combination partners for the combined use with the compounds of the invention.

Furthermore, the invention also encompasses kits comprising at least one compound of the invention and one or more other components selected from the group consisting of other drugs used for the treatment of the diseases and disorders as described above, and devices as described below.

Formulations

Suitable preparations for administering the compounds of the invention will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions – particularly solutions for injection (*s.c.*, *i.v.*,

i.m.) and infusion (injectables) – elixirs, syrups, sachets, emulsions, inhalatives or dispersible powders. The content of the pharmaceutically active compound(s) should be in the range from 0.1 to 90 wt.-%, preferably 0.5 to 50 wt.-% of the composition as a whole, *i.e.* in amounts which are sufficient to achieve the dosage range specified below. The
5 doses specified may, if necessary, be given several times a day.

Suitable tablets may be obtained, for example, by mixing the active substance(s) of the invention with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants. The tablets may also comprise several layers.

10 Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the
15 excipients mentioned above for the tablets.

Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, *e.g.* a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium
20 carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.

Solutions for injection and infusion are prepared in the usual way, *e.g.* with the addition of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or
25 dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles.

Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as
30 lactose or sorbitol and packing them into gelatine capsules.

Suitable suppositories may be made for example by mixing with carriers provided for this purpose such as neutral fats or polyethyleneglycol or the derivatives thereof.

Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).

The preparations are administered by the usual methods, preferably by oral or transdermal route, most preferably by oral route. For oral administration the tablets may of course contain, apart from the above-mentioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like. Moreover, lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tableting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.

For parenteral use, solutions of the active substances with suitable liquid carriers may be used.

The dosage range of the compounds of formula (I) applicable per day is usually from 1 mg to 2000 mg, preferably from 150 to 1000 mg.

The dosage for intravenous use is from 1 mg to 1000 mg with different infusion rates, preferably between 5 mg and 500 mg with different infusion rates.

However, it may sometimes be necessary to depart from the amounts specified, depending on the body weight, age, the route of administration, severity of the disease, the individual response to the drug, the nature of its formulation and the time or interval over which the drug is administered (continuous or intermittent treatment with one or multiple doses per day). Thus, in some cases it may be sufficient to use less than the minimum dose given above, whereas in other cases the upper limit may have to be exceeded. When administering large amounts it may be advisable to divide them up into a number of smaller doses spread over the day.

The formulation examples which follow illustrate the present invention without restricting

its scope:

Examples of pharmaceutical formulations

	A)	<u>Tablets</u>	<u>per tablet</u>
		active substance according to formula (I)	100 mg
5		lactose	140 mg
		corn starch	240 mg
		polyvinylpyrrolidone	15 mg
		magnesium stearate	5 mg
10			500 mg

The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.

	B)	<u>Tablets</u>	<u>per tablet</u>
		active substance according to formula (I))	80 mg
		lactose	55 mg
		corn starch	190 mg
20		microcrystalline cellulose	35 mg
		polyvinylpyrrolidone	15 mg
		sodiumcarboxymethyl starch	23 mg
		magnesium stearate	2 mg
25			400 mg

The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodiumcarboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.

	C)	<u>Tablets</u>	<u>per tablet</u>
		active substance according to formula (I)	25 mg
		lactose	50 mg

microcrystalline cellulose	24 mg
magnesium stearate	1 mg
	100 mg

- 5 The active substance, lactose and cellulose are mixed together. The mixture is screened, then either moistened with water, kneaded, wet-granulated and dried or dry-granulated or directly final blend with the magnesium stearate and compressed to tablets of suitable shape and size. When wet-granulated, additional lactose or cellulose and magnesium stearate is added and the mixture is compressed to produce tablets of suitable shape and size.
- 10

D) Ampoule solution

active substance according to formulae (I)	50 mg
sodium chloride	50 mg
water for inj.	5 mL

- 15 The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.

20